a LANGE medical book
Clinical Neurology sixth edition
MICHAEL J. AMINOFF, MD, DSc, FRCP Professor and Executive Vice-Chair Department of Neurology School of Medicine University of California, San Francisco
DAVID A. GREENBERG, MD, PhD Professor and Vice-President for Special Research Programs Buck Institute for Age Research Novato, California
ROGER P. SIMON, MD Robert Stone Dow Chair of Neurology Director of Neurobiology Research Legacy Health Systems Portland, Oregon
Lange Medical Books/McGraw-Hill Medical Publishing Division New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto
Copyright © 2005, 2002 by The McGraw-Hill Companies, Inc. All rights reserved. Manufactured in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher. 0-07-150196-7 The material in this eBook also appears in the print version of this title: 0-07-142360-5. All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps. McGraw-Hill eBooks are available at special quantity discounts to use as premiums and sales promotions, or for use in corporate training programs. For more information, please contact George Hoare, Special Sales, at
[email protected] or (212) 904-4069. TERMS OF USE This is a copyrighted work and The McGraw-Hill Companies, Inc. (“McGraw-Hill”) and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill’s prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms. THE WORK IS PROVIDED “AS IS.” McGRAW-HILL AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise. DOI: 10.1036/0071423605
To Our Families
This page intentionally left blank
For more information about this title, click here
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii Chapter 1: Disorders of Cognitive Function. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Chapter 2: Headache & Facial Pain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Chapter 3: Disorders of Equilibrium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 Chapter 4: Disturbances of Vision . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 Chapter 5: Motor Deficits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152 Chapter 6: Disorders of Somatic Sensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200 Chapter 7: Movement Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233 Chapter 8: Seizures & Syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263 Chapter 9: Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 Chapter 10: Coma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320 Chapter 11: Neurologic Investigations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 Appendices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359 A: The Neurologic Examination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359 B: A Brief Examination of the Nervous System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370 C: Clinical Examination of Common Isolated Peripheral Nerve Disorders. . . . . . . . . . . . . . . . . . . 372 Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379 Frequently Used Neurologic Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Inside Front Cover
v
This page intentionally left blank
Preface The warm and generous acceptance of earlier editions of this book and the advances that have occurred in the neurosciences in the last few years have prompted the preparation of this sixth edition of Clinical Neurology. We have again provided a problem-based approach to neurology based on our experience in teaching medical students and house staff, primarily in the clinics and wards of the hospitals and clinics of the University of California, San Francisco. The chapters are focused on clinical problems because that is the manner in which patients typically come to medical attention, but this is followed in each chapter by a description of specific diseases and syndromes. The cornerstone of neurologic diagnosis remains a careful history and neurologic examination, and these continue to be emphasized in this new edition. Nevertheless, technologic advances, especially in neuroimaging, have facilitated the evaluation of patients presenting with neurologic disorders, and the application of these and other investigative techniques is discussed in greater detail than in earlier editions. The sections on treatment have been updated and expanded to reflect advances in the field. In addition, we have attempted to incorporate the latest developments in molecular biology and genetics, especially when these are of clinical relevance in advancing
concepts concerning the pathogenesis or treatment of disease. With the last edition, Key Concepts were introduced at the beginning of each chapter. Certain major concepts were presented with numbered icons that then appeared later in the text to indicate where these specific points were discussed. We have retained this approach in this edition also, and hope that readers continue to find it useful. We are grateful to our families for giving us the time to see this new edition to fruition. We also thank those of our colleagues who gave us help and advice us as we updated the text, and especially Lydia Bayne, Chadwick Christine, Jim Corbett, Paul Garcia, Hubert Leonard, Catherine Lomen-Hoerth, and Norman So. The staff at McGraw-Hill has again been very helpful in seeing this book through the production process, and we greatly appreciate their unfailing assistance. Michael J. Aminoff David A. Greenberg Roger P. Simon February 2005
vii Copyright © 2005, 2002 by The McGraw-Hill Companies, Inc. Click here for terms of use.
This page intentionally left blank
Professional
Want to learn more? We hope you enjoy this McGraw-Hill eBook! If you’d like more information about this book, its author, or related books and websites, please click here.
Disorders of Cognitive Function
1
CONTENTS I. Approach to diagnosis, 3 History, 3 General physical examination, 4 Neurologic examinations, 6 Laboratory investigations, 10 II. Acute confusional states, 11 Drugs, 11 Ethanol intoxication, 11 Ethanol withdrawal, 11 Sedative drug intoxication, 13 Sedative drug withdrawal, 14 Opioids, 14 Anticholinergic drugs, 15 Phencyclidine, 15 Endocrine disturbances, 15 Hypothyroidism, 15 Hyperthyroidism, 15 Hypoglycemia, 15 Hyperglycemia, 16 Hypoadrenalism, 16 Hyperadrenalism, 17 Electrolyte disorders, 17 Hyponatremia, 17 Hypercalcemia, 17 Hypocalcemia, 17 Nutritional disorders, 18 Wernicke encephalopathy, 18 Vitamin B12 deficiency, 18 Organ system failure, 19 Hepatic encephalopathy, 19 Reye syndrome, 19
Uremia, 20 Pulmonary encephalopathy, 20 Organ transplantation, 20 Meningitis, encephalitis, & sepsis, 20 Bacterial meningitis, 20 Tuberculous meningitis, 24 Syphilitic meningitis, 25 Lyme disease, 26 Viral meningitis & encephalitis, 26 Herpes simplex virus (HSV) encephalitis, 29 Acquired immunodeficiency syndrome (AIDS), 31 Fungal meningitis, 32 Parasitic infections, 34 Leptomeningeal metastases, 38 Sepsis, 39 Vascular disorders, 39 Hypertensive encephalopathy, 39 Subarachnoid hemorrhage, 41 Vertebrobasilar ischemia, 41 Right (nondominant) hemispheric infarction, 41 Systemic lupus erythematosus, 41 Disseminated intravascular coagulation, 41 Thrombotic thrombocytopenic purpura, 42
Head trauma, 43 Concussion, 43 Intracranial hemorrhage, 43 Seizures, 43 Postictal state, 43 Complex partial seizures, 43 Psychiatric disorders, 43 III. Dementia, 44 Approach to diagnosis, 44 Differential diagnosis, 46 Cerebral disorders without extrapyramidal features, 46 Alzheimer disease, 46 Frontotemporal dementia, 51 Creutzfeldt-Jakob disease, 51 Normal-pressure hydrocephalus, 52 Cerebral disorders with extrapyramidal features, 55 Dementia with Lewy bodies, 55 Corticobasal ganglionic degeneration, 56 Huntington disease, 56 Progressive supranuclear palsy, 56 Systemic disorders, 56 Cancer, 56 Infection, 56 Metabolic disorders, 59 Organ failure, 60
(continued on next page)
1 Copyright © 2005, 2002 by The McGraw-Hill Companies, Inc. Click here for terms of use.
2 / CHAPTER 1
(continued from previous page) Trauma, 61 Vascular disorders, 61 Pseudodementia, 62 IV. Amnestic syndromes, 62 Acute amnesia, 63 Head trauma, 63 Hypoxia or ischemia, 63
Bilateral posterior cerebral artery occlusion, 64 Transient global amnesia, 64 Alcoholic blackouts, 65 Wernicke encephalopathy, 65 Dissociative (psychogenic) amnesia, 65
Chronic amnesia, 65 Alcoholic Korsakoff amnestic syndrome, 65 Postencephalitic amnesia, 66 Brain tumor, 66 Paraneoplastic limbic encephalitis, 66
KEY CONCEPTS Disorders of consciousness include disorders in which the level of consciousness (arousal or wakefulness) is impaired, such as acute confusional states and coma, and those in which the level of consciousness is normal but the content of consciousness is altered, such as dementia and amnestic disorders.
Certain causes of acute confusional state must be identified urgently because they may lead rapidly to severe structural brain damage or death, and prompt treatment can prevent these complications: hypoglycemia, bacterial meningitis, subarachnoid hemorrhage, and traumatic intracranial hemorrhage.
An acute confusional state can be most readily distinguished from dementia by the time course of the impairment: acute confusional states are acute or subacute in onset, typically developing over hours to days, whereas dementia is a chronic disorder that evolves over months or years.
The most common causes of dementia are Alzheimer disease, dementia with Lewy bodies, and vascular dementia; reversible causes of dementia are rare, but are important to diagnose.
Consciousness is awareness of the internal or external world, and disorders of consciousness can affect either the level of consciousness or the content of consciousness.
Disturbances of the Level of Consciousness Abnormalities of the level of consciousness are characterized by impaired arousal or wakefulness, and they result from acute lesions of the ascending reticular activating system (Figure 1–1) or both cerebral hemispheres. The most severe degree of depressed consciousness is coma, in which the patient is unresponsive and unarousable. Less severe depression of consciousness results in an acute confusional state or delirium, in which the patient responds to at least some stimuli in a purposeful manner but is sleepy, disoriented, and inattentive. In some acute confusional states, agitation predominates or alternates with drowsiness, and may be accompanied by autonomic changes (fever, tachycardia, hypertension, sweating, pallor, or
flushing), hallucinations, and motor abnormalities (tremor, asterixis, or myoclonus).
Disturbances of the Content of Consciousness Many pathologic conditions can impair the content of consciousness without altering the level of consciousness. Examples include isolated disorders of language or memory due to focal brain lesions and widespread deterioration of mental function (dementia) from more diffuse, chronic pathologic processes. Dementia differs from acute confusional states in several respects (Table 1–1), and distinguishing between these two syndromes is the pivotal step in evaluating a patient with altered consciousness. The time course of the disorder—acute or subacute in acute confusional states and chronic in dementia—is the single most helpful differentiating feature. Confusional states, dementia, and circumscribed
DISORDERS OF COGNITIVE FUNCTION / 3 Cerebral hemisphere Thalamus
sional states are acute to subacute in onset, whereas dementias are chronic disorders. In an acute confusional state, the observations of others may be the only historical information available. When dementia is suspected, it is useful to have access to a relative or close acquaintance who can furnish details about the patient’s previous level of functioning; the time when dysfunction became evident; and the nature of any changes in personality, behavior, mood, intellect, judgment, memory, or facility with language. Associated problems such as gait disorders, incontinence, and headaches also should be explored.
Prior Medical History
Brainstem reticular activating system
Figure 1–1. Brainstem reticular activating system and its ascending projections to the thalamus and cerebral hemispheres.
memory disorders are discussed in this chapter. Coma is discussed in Chapter 10.
I. APPROACH TO DIAGNOSIS Evaluation of the patient with a suspected disorder of consciousness is aimed first at characterizing the nature of the disorder (eg, acute confusional state, coma, dementia, amnestic syndrome) and second at determining the cause. The approach used is outlined below.
HISTORY History of Present Illness The history should establish the time course of the disorder and provide clues to its nature and cause. Confu-
A. CARDIOVASCULAR SYSTEM A history of stroke, hypertension, vasculitis, or cardiac disease may suggest a vascular cause of a confusional state or multiinfarct dementia. B. DIABETES Cognitive disturbance in diabetic patients may result from a hyperosmolar nonketotic state or insulin-induced hypoglycemia. C. SEIZURE DISORDER A history of epilepsy suggests ongoing seizures, a postictal state, or head trauma in a confused patient. D. HEAD TRAUMA Recent head trauma suggests intracranial hemorrhage. Remote head trauma may produce amnestic syndrome or chronic subdural hematoma with dementia. E. ALCOHOLISM Alcoholism predisposes patients to acute confusional states from intoxication, withdrawal, postictal state, head trauma, hepatic encephalopathy, and Wernicke encephalopathy. Chronic memory disturbance in an alcoholic is likely due to Korsakoff syndrome. F. DRUG HISTORY A confusional state can result from overdose with insulin, sedative-hypnotics, opioids, antidepressants, antipsychotic agents, or hallucinogens, or from sedative
Table 1–1. Differences between acute confusional states and dementia. Acute Confusional State
Dementia
Level of consciousness
Impaired
Not impaired, except occasionally late in course
Course
Acute to subacute; fluctuating
Chronic; steadily progressive
Autonomic hyperactivity
Often present
Absent
Prognosis
Usually reversible
Usually irreversible
4 / CHAPTER 1 drug withdrawal. Elderly patients may be more sensitive to the cognitive side effects of drugs that are well tolerated by younger patients. G. PSYCHIATRIC HISTORY A history of psychiatric illness may suggest overdose with psychotherapeutic drugs such as benzodiazepines, antidepressants, or antipsychotic agents; a previously undiagnosed medical disorder capable of producing organic psychosis (hypothyroidism, vitamin B12 deficiency); or a functional disorder masquerading as an acute confusional state or dementia. H. OTHER Individuals who engage in unprotected sexual intercourse, intravenous drug users, recipients of contaminated blood or clotting factor transfusions, the sexual partners of all these persons, and infants of infected mothers are at particular risk for developing acquired immunodeficiency syndrome (AIDS).
Family History The family history can point to a heredodegenerative disorder, such as Huntington disease, as the cause of dementia.
GENERAL PHYSICAL EXAMINATION A general physical examination helps to classify the disorder as either an acute confusional state or dementia and may suggest a systemic disease as its cause (Tables 1–2 and 1–3).
Vital Signs & General Appearance Fever, tachycardia, hypertension, and sweating occur in many confusional states, but meningitis or sepsis must receive early consideration in the febrile patient. Hypertension should raise the possibility of hypertensive encephalopathy, intracranial hemorrhage, renal disease, or Cushing syndrome. Hypothermia occurs with expo-
Table 1–2. Clinical features helpful in the differential diagnosis of acute confusional states. Feature Headache Vital signs Fever
Hypothermia
Most Suggestive of Head trauma, meningitis, subarachnoid hemorrhage Infectious meningitis, anticholinergic intoxication, withdrawal from ethanol or sedative drugs, sepsis Intoxication with ethanol or sedative drugs, hepatic encephalopathy, hypoglycemia, hypothyroidism, sepsis
Hypertension
Anticholinergic intoxication,withdrawal from ethanol or sedative drugs,hypertensive encephalopathy,subarachnoid hemorrhage,sympathomimetic intoxication
Tachycardia
Anticholinergic intoxication, withdrawal from ethanol or sedative drugs, thyrotoxicosis, sepsis
Bradycardia
Hypothyroidism
Hyperventilation
Hepatic encephalopathy, hyperglycemia, sepsis
Hypoventilation
Intoxication with ethanol or sedative drugs, opioid intoxication, pulmonary encephalopathy
General examination Meningismus Meningitis, subarachnoid hemorrhage Skin rash
Meningococcal meningitis
Feature Tetany Cranial nerves Papilledema
Most Suggestive of Hypocalcemia Hypertensive encephalopathy, intracranial mass
Dilated pupils
Head trauma, anticholinergic intoxication, withdrawal from ethanol or sedative drugs, sympathomimetic intoxication
Constricted pupils
Opioid intoxication
Nystagmus/ ophthalmoplegia
Intoxication with ethanol, sedative drugs, or phencyclidine, vertebrobasilar ischemia,Wernicke encephalopathy
Motor Tremor
Withdrawal from ethanol or sedative drugs, sympathomimetic intoxication, thyrotoxicosis
Asterixis
Metabolic encephalopathy
Hemiparesis
Cerebral infarction, head trauma, hyperglycemia, hypoglycemia
Other Seizures
Ataxia
Withdrawal from ethanol or sedative drugs, head trauma, hyperglycemia, hypoglycemia Intoxication with ethanol or sedative drugs,Wernicke encephalopathy
DISORDERS OF COGNITIVE FUNCTION / 5 Table 1–3. Clinical features helpful in the differential diagnosis of dementia. Feature History Unprotected sexual intercourse, intravenous drug abuse, hemophilia, or blood transfusions
Most Suggestive of AIDS dementia complex
Family history
Huntington disease,Wilson disease
Headache
Brain tumor, chronic subdural hematoma
Vital signs Hypothermia
Hypothyroidism
Hypertension
Multiinfarct dementia
Hypotension
Hypothyroidism
Bradycardia
Hypothyroidism
General examination Meningismus
Acquired hepatocerebral degeneration
Kayser-Fleischer rings
Wilson disease
Ophthalmoplegia
Progressive supranuclear palsy
Pseudobulbar palsy
Multiinfarct dementia, progressive supranuclear palsy
Motor Tremor
Acquired hepatocerebral degeneration
Myoclonus
Creutzfeldt-Jakob disease, AIDS dementia complex
Rigidity
Dementia with Lewy bodies, corticobasal ganglionic degeneration, acquired hepatocerebral degeneration, Creutzfeldt-Jakob disease, progressive supranuclear palsy,Wilson disease
Chorea
Huntington disease,Wilson disease
Other Gait apraxia Polyneuropathy with hyporeflexia
sure to cold, ethanol or sedative drug intoxication, hypoglycemia, hepatic encephalopathy, Wernicke encephalopathy, hypothyroidism, or shock. In most dementias, the patient does not appear acutely ill unless a systemic disorder is also present.
Head & Neck
Jaundice suggests hepatic disease, and lemon-yellow coloration of the skin may occur in vitamin B12 deficiency. Coarse dry skin, dry brittle hair, and subcutaneous edema are characteristic of hypothyroidism. Petechiae are seen in meningococcemia, and petechiae or ecchymoses may reflect coagulopathy caused by liver disease, disseminated intravascular coagulation, or thrombotic thrombocytopenia purpura. Hot, dry skin is characteristic of intoxication with anticholinergic drugs. Cushing syndrome may be associated with acne. Hyperpigmentation of the skin may be evidence of Addison disease. Needle tracks associated with intravenous drug use suggest drug overdose, AIDS, or infective endocarditis.
Dementia with Lewy bodies, corticobasal ganglionic degeneration, acquired hepatocerebral degeneration, Wilson disease, AIDS dementia complex
Asterixis
Brain tumor, chronic subdural hematoma
Skin & Mucous Membranes
Most Suggestive of
Argyll Robertson Neurosyphilis pupils
Chronic meningitis
Jaundice
Cranial nerves Papilledema
Feature
Normal pressure hydrocephalus Neurosyphilis, vitamin B12 deficiency, AIDS dementia complex
Examination of the head may reveal signs of trauma, such as scalp lacerations or contusions, postauricular hematoma (Battle sign), periorbital hematoma (raccoon eyes), hemotympanum, or cerebrospinal fluid (CSF) otorrhea or rhinorrhea. Percussion of the skull over a subdural hematoma may cause pain. Meningeal signs, such as neck stiffness on passive flexion, thigh flexion upon flexion of the neck (Brudzinski sign), or resistance to passive extension of the knee with the hip flexed (Kernig sign), are seen in meningitis and subarachnoid hemorrhage.
Chest & Abdomen Cardiac murmurs may be associated with infective endocarditis and its neurologic sequelae. Abdominal examination may reveal a source of systemic infection or suggest liver disease. Rectal examination may provide evidence of gastrointestinal bleeding, which often precipitates hepatic encephalopathy.
6 / CHAPTER 1
NEUROLOGIC EXAMINATIONS Mental Status Examination Evaluation of mental status (Table 1–4) helps to classify a disorder as a confusional state, dementia, a circumscribed cognitive disturbance (aphasia, amnesia), or a psychiatric illness. The mental status examination is most useful if performed in a standardized fashion, and complex functions can be adequately evaluated only when the basic processes upon which they depend are preserved. Thus, memory, language, calculation, or abstraction cannot be assessed reliably in a patient who is poorly arousable or inattentive. The Minimental Status Examination (Table 1–5) is often used as a rapid bedside screening test for dementia. In performing the mental status examination, the level of consciousness and attention are evaluated first. If these are impaired, an acute confusional state exists, Table 1–4. Comprehensive mental status examination. Level of consciousness Attention and concentration Language and speech Comprehension Repetition Fluency Naming Reading Writing Calculation Speech Mood and behavior Content of thought Hallucinations Delusions Abstraction Judgment Memory Immediate recall Recent memory Remote memory Integrative sensory function Astereognosis Agraphesthesia Two-point discrimination Allesthesia Extinction Unilateral neglect and anosognosia Disorders of spatial thought Integrative motor function Apraxia
Table 1–5. Minimental status examination. Item
Points1
Orientation Time (1 point each for year, season, month, date, and day of the week)
5
Place (1 point each for state, county, city, building, and floor or room)
5
Registration Repeat names of three objects (1 point per object)
3
Attention and calculation Serial 7s or spell “world” backward (1 point per subtraction or letter)
5
Recall Recall names of three objects repeated previously (1 point per object)
3
Language Name pencil and watch (1 point each)
2
Repeat “no ifs, ands, or buts”
1
Follow three-step command (1 point per step)
3
Read and follow:“close your eyes”
1
Write a complete sentence
1
Construction Copy two intersecting pentagons
1
Total
30
1 A total score of <24 should generally lead to more detailed investigation of the possibility of dementia, although norms vary to some extent with age and education. Adapted from Greenberg DA: Dementia. In: Geriatrics. Lonergan ET (editor), Appleton & Lange,
and it may be difficult or impossible to conduct the remainder of the mental status examination. If the level of consciousness and attention are adequate, more complex cortical functions are examined next to determine whether there is global cortical dysfunction, which indicates dementia. A. LEVEL OF CONSCIOUSNESS The level of consciousness is described in terms of the patient’s apparent state of wakefulness and response to stimuli. Impairment of the level of consciousness should always be documented by a written description of the patient’s responses to specific stimuli rather than by the use of nonspecific and imprecise terms such as “lethargy,” “stupor,” or “semicoma.” 1. Normal—The patient with a normal level of consciousness appears awake and alert, with eyes open at rest. Unless there is deafness or a language disorder,
DISORDERS OF COGNITIVE FUNCTION / 7 verbal stimulation results in appropriate verbal responses. 2. Impaired—Mild impairment of consciousness may be manifested by sleepiness from which the patient is easily aroused when spoken to. As consciousness is further impaired, the intensity of stimulation required for arousal increases, the duration of arousal declines, and the responses elicited become less purposeful. B. ATTENTION Attention is the ability to focus on a particular sensory stimulus to the exclusion of others; concentration is sustained attention. These processes are grossly impaired in acute confusional states, usually less impaired in dementia, and unaffected by focal brain lesions. Attention can be tested by asking the patient to repeat a series of digits or to indicate when a given letter appears in a random series. A normal person can repeat five to seven digits correctly and identify a letter in a series without error. C. LANGUAGE AND SPEECH The essential elements of language are comprehension, repetition, fluency, naming, reading, and writing, all of which should be tested when a language disorder (aphasia) is suspected. Calculation disorders (acalculia) are probably closely related to aphasia. Speech, the motor activity that is the final step in the expression of lan-
guage, is mediated by the lower cranial nerves and their supranuclear connections. Dysarthria, a disorder of articulation, is sometimes difficult to distinguish from aphasia, but it always spares oral and written language comprehension and written expression. Aphasia may be a feature of diffuse cortical disease, as it is in certain dementias, but language impairment with otherwise normal cognitive function should suggest a focal lesion in the dominant hemisphere. A disorder of comprehension (receptive, or Wernicke, aphasia) commonly leads to a false impression of a confusional state or psychiatric disturbance. There are a variety of aphasic syndromes, each characterized by a particular pattern of language impairment; several have fairly precise pathoanatomic correlations. In addition to the most classic syndromes, described in Figure 1–2, variations are sometimes observed. For example, global aphasia refers to a syndrome that incorporates elements of both expressive and receptive aphasia; however, it does not imply that aphasia is complete, and some degree of comprehension and of fluency may be preserved. Transcortical aphasias are conditions in which Wernicke area, the arcuate fasciculus, and Broca area are themselves preserved, but their connections to other parts of the brain are interrupted. These disconnection syndromes may be distinguished clinically by the fact that, since the circuit comprising Wernicke area, the arcuate fasciculus, and Broca area is intact, repetition is preserved.
Arcuate fasciculus
Broca area Wernicke area Language Functions Preserved Pathologic Site Wernicke area Arcuate fasciculus Broca area
Type of Aphasia Receptive Conductive Expressive
Comprehension – + +
Figure 1–2. Anatomic basis and clinical features of aphasias.
Repetition – – –
Fluency + + –
8 / CHAPTER 1 D. MOOD AND BEHAVIOR Demented patients may be apathetic, inappropriately elated, or depressed, and their moods can fluctuate. If the examination is otherwise normal, early dementia easily can be confused with depression. Delirious patients are agitated, noisy, and easily provoked to anger. E. CONTENT OF THOUGHT Abnormalities of thought content can help to distinguish organic from psychiatric disease. Visual hallucinations are common in acute confusional states, whereas auditory hallucinations and fixed delusions are most common with psychiatric disorders. Impairment of abstraction may be revealed by the patient’s concrete (literal) interpretation of proverbs or inability to recognize conceptual differences and similarities. Judgment is commonly tested by asking what the patient would do in a hypothetic situation, such as finding a stamped, addressed letter on the sidewalk. F. MEMORY 1. Functional components of memory—Memory is the ability to register, store, and ultimately retrieve information. Storage and retrieval of memories can be impaired by either diffuse cortical disease or focal bilateral dysfunction of the medial temporal lobes or their connections. a. Registration—The ability to receive information through the various sensory modalities is largely a function of attention. b. Storage—The process whereby selected new information is learned, or memorized, may be mediated by limbic structures, including the hippocampus. Stored memories are reinforced by repetition and by emotional significance; they are thought to be diffusely distributed in association areas of the cerebral cortex. c. Retrieval—Retrieval is the ability to access previously learned information. 2. Amnesia—Memory disorder (amnesia) may be an isolated deficit or one feature of global cognitive dysfunction. In acute confusional states, attention is impaired, resulting in defective registration and an inability to learn new material. In dementia, attention is typically normal and problems with recent and—to a lesser extent—remote memory usually predominate. In psychogenic amnesia, subjective and emotionally charged memories are affected more than retention of objective facts and events; in organic amnesia, the reverse is true. Isolated loss of memory for personal identity (the inability to remember one’s own name) in an awake and alert patient is virtually pathognomonic of a psychogenic disorder. Additional terms sometimes used to denote aspects of acute-onset amnesia (eg, following head trauma) include retrograde amnesia, loss of memory for events immediately prior to the onset of the disorder, and an-
terograde or posttraumatic amnesia, impairment of memory in the period following the insult. 3. Testing of memory—Memory is assessed clinically by testing immediate recall, recent memory, and remote memory, which correspond roughly to registration, storage, and retrieval, respectively. a. Immediate recall—Tests of immediate recall are similar to tests of attention and include having the patient repeat a random series of numbers or other information that has not been learned previously. The ability to repeat implies that the material has been registered. Most normal adults can repeat a series of seven numbers forward and five backward without difficulty. b. Recent memory—Tests of recent memory assess the ability to learn new material. Typically, the patient is given three or four items to remember and asked to recall them 3 minutes later. Nonverbal tests, in which an object previously shown to the patient is selected from a group of objects, may be useful, especially for patients with expressive aphasia. Orientation to place and time, which requires newly learned information, is another important test of recent memory. c. Remote memory—The practical distinction between recent and remote memory is that only recent memory requires an ongoing ability to learn new information. Remote memory is tested by asking the patient to recall material that someone of comparable cultural and educational background can be assumed to know. Common examples are personal, historical, or geographic data, but the questions selected must be appropriate for the patient, and personal items must be verifiable. G. INTEGRATIVE SENSORY FUNCTION Sensory integration disorders from parietal lobe lesions are manifested by misperception of or inattention to sensory stimuli on the contralateral side of the body, when the primary sensory modalities are intact. Patients with parietal lesions may exhibit the following signs: 1. Astereognosis—The patient cannot identify, by touch, an object placed in the hand. 2. Agraphesthesia—The patient is unable to identify a number written on the hand. 3. Absence of two-point discrimination—This is an inability to differentiate between a single stimulus and two simultaneously applied adjacent, but separated, stimuli that can be distinguished by a normal person. 4. Allesthesia—This is misplaced localization of a tactile stimulus. 5. Extinction—A visual or tactile stimulus is perceived when applied alone to the side contralateral to the lesion but not when stimuli are applied bilaterally. 6. Unilateral neglect and anosognosia—Body image disorders caused by parietal lobe lesions take the form of unilateral neglect. The patient tends not to use
DISORDERS OF COGNITIVE FUNCTION / 9 the contralateral limbs, may deny that there is anything wrong with them (anosognosia), and may even fail to recognize them. 7. Disorders of spatial thought—These include constructional apraxia, right/left disorientation, and neglect of external space on the side opposite the affected parietal lobe. Tests for constructional apraxia include having the patient fill in the numbers on a clock face, copy geometric figures, or build figures with blocks. H. INTEGRATIVE MOTOR FUNCTION Apraxia is the inability to perform previously learned tasks, such as finger snapping or clapping the hands together, despite intact motor and sensory function. Unilateral apraxias are commonly caused by contralateral premotor frontal cortex lesions. Bilateral apraxias, such as gait apraxia, may be seen with bifrontal or diffuse cerebral lesions.
Gait & Station It is useful to observe the patient standing and walking early in the neurologic examination, since these activities may reveal additional neurologic abnormalities associated with disturbed cognitive function.
Cranial Nerves In patients with impaired cognitive function, abnormalities associated with cranial nerves may suggest the underlying cause. A. LESIONS OF THE EYES AND EARS 1. Papilledema suggests an intracranial mass, hypertensive encephalopathy, or other process that increases intracranial pressure. 2. In the confused patient, pupillary constriction suggests opiate ingestion; dilated pupils are characteristic of anticholinergic intoxication but may also be a manifestation of generalized sympathetic hyperactivity. Small, irregular pupils that react poorly to light—but better to accommodation—can be seen in neurosyphilis. 3. Sedative drugs and Wernicke encephalopathy produce nystagmus or ophthalmoplegia. Selective impairment of vertical gaze (especially downward) occurs early in progressive supranuclear palsy. B. PSEUDOBULBAR PALSY This syndrome is characterized by dysarthria, dysphagia, hyperactive jaw jerk and gag reflexes, and uncontrollable laughing or crying unrelated to emotional state (pseudobulbar affect). It results from bilateral interruption of the corticobulbar and corticospinal tracts. Dementing processes that produce this syndrome include progressive supranuclear palsy and multiinfarct dementia.
C. MULTIPLE CRANIAL NEUROPATHIES These can accompany infectious or noninfectious meningitis or AIDS dementia complex.
Motor Findings A. ACUTE CONFUSIONAL STATE In the acutely confused patient, a variety of motor abnormalities may suggest the cause. 1. Hemiparesis is most apt to be due to an intracranial structural lesion, although focal neurologic signs may be present in metabolic disorders such as hypoglycemia and nonketotic hyperglycemia. 2. Tremor is common in sedative drug or ethanol withdrawal and other states accompanied by autonomic hyperactivity. 3. Asterixis, a flapping tremor of the outstretched hands or feet, is seen in hepatic, renal, and pulmonary encephalopathy and in drug intoxication. 4. Myoclonus, which consists of rapid shocklike muscle contractions, can occur with uremia, cerebral hypoxia, or hyperosmolar nonketotic states. 5. Cerebellar signs such as broad-based ataxic gait and, often, dysmetria on heel-knee-shin maneuver accompany Wernicke encephalopathy and sedative drug intoxication. B. DEMENTIA Motor signs are useful in the differential diagnosis of dementia. 1. Chorea—Huntington disease, Wilson disease. 2. Tremor, rigidity, or bradykinesia—Wilson disease, acquired hepatocerebral degeneration. 3. Myoclonus—Creutzfeldt-Jakob disease, AIDS dementia complex. 4. Ataxia—Spinocerebellar degenerations, Wilson disease, paraneoplastic syndromes, Creutzfeldt-Jakob disease, AIDS dementia complex. 5. Paraparesis—Vitamin B12 deficiency, hydrocephalus, AIDS dementia complex.
Abnormalities of Sensation & Tendon Reflexes Dementias associated with prominent sensory abnormalities and loss of tendon reflexes include vitamin B12 deficiency, neurosyphilis, and AIDS dementia complex.
Primitive Reflexes A number of reflexes that are present in infancy and subsequently disappear may be released by frontal lobe dysfunction in later life. It is presumed that such release results from loss of cortical inhibition of these primitive reflexes (frontal release signs), which include palmar and plantar grasps as well as palmomental, suck, snout,
10 / CHAPTER 1 rooting, and glabellar reflexes. Although these responses are often seen in both acute confusional states and dementia, many can also occur in normal elderly adults. Their presence alone does not constitute evidence of cognitive dysfunction. 1. The palmar grasp reflex is elicited by stroking the skin of the patient’s palm with the examiner’s fingers. If the reflex is present, the patient’s fingers close around those of the examiner. The force of the patient’s grasp may increase when the examiner attempts to withdraw the fingers, and the patient may be unable to voluntarily release the grasp. 2. The plantar grasp reflex consists of flexion and adduction of the toes in response to stimulation of the sole of the foot. 3. The palmomental reflex is elicited by scratching along the length of the palm of the hand and results in
contraction of ipsilateral chin (mentalis) and perioral (orbicularis oris) muscles. 4. The suck reflex consists of involuntary sucking movements following the stimulation of the lips. 5. The snout reflex is elicited by gently tapping the lips and results in their protrusion. 6. In the rooting reflex, stimulation of the lips causes them to deviate toward the stimulus. 7. The glabellar reflex is elicited by repetitive tapping on the forehead. Normal subjects blink only in response to the first several taps; persistent blinking is an abnormal response (Myerson sign).
LABORATORY INVESTIGATIONS Laboratory studies are critical in diagnosing disorders of cognitive function. Useful investigations are listed in Ta-
Table 1–6. Laboratory studies in acute confusional states. Test Blood WBC
Most Useful in Diagnosis of
Test ECG
Meningitis, encephalitis, sepsis
PT and PTT
Hepatic encephalopathy
Arterial blood gas
Hepatic encephalopathy, pulmonary encephalopathy, uremia, sepsis
Cerebrospinal fluid WBC, RBC
Most Useful in Diagnosis of Anticholinergic intoxication, vascular disorders Meningitis, encephalitis, subarachnoid hemorrhage
Gram’s stain
Bacterial meningitis
Sodium
Hyponatremia
AFB stain
Tuberculous meningitis
Serum urea nitrogen and creatinine
Uremia
India ink stain
Cryptococcal meningitis
Cultures
Infectious meningitis
Glucose
Hyperglycemia, hypoglycemia
Cytology
Leptomeningeal metastases
Osmolality
Alcohol intoxication, hyperglycemia
Glutamine
Hepatic encephalopathy
Liver function tests, ammonia
Hepatic encephalopathy, Reye syndrome
VDRL
Syphilitic meningitis Cryptococcal meningitis
Thyroid function tests
Hyperthyroidism, hypothyroidism
Cryptococcal antigen
Calcium
Hypercalcemia, hypocalcemia
Polymerase chain reaction
Drug screen
Drug intoxications
Cultures
Meningitis, sepsis
Bacterial meningitis, tuberculous meningitis, syphilitic meningitis, Lyme disease, viral meningitis and encephalitis, AIDS, leptomeningeal metastases
FTA or MHA-TP
Syphilitic meningitis
CT brain scan or MRI
HIV antibody titer
AIDS and related disorders
Cerebral infarction, intracranial hemorrhage, head trauma, toxoplasmosis, herpes simplex encephalitis, subarachnoid hemorrhage
EEG
Complex partial seizures, herpes simplex encephalitis, nonconvulsive seizures
Urine, gastric aspirate Drug screen Drug intoxication Stool Guaiac
Hepatic encephalopathy
DISORDERS OF COGNITIVE FUNCTION / 11 bles 1–6 and 1–7; those most likely to establish or support a diagnosis in acute confusional states are complete blood count, arterial blood gases and pH, serum sodium, serum glucose, serum urea nitrogen and creatinine, liver function tests, drug screens, blood cultures, stool test for occult blood, lumbar puncture, brain computed tomography (CT) scan or magnetic resonance imaging (MRI), and electroencephalogram (EEG). Some of these studies can yield a specific diagnosis. Abnormal arterial blood gas or cerebrospinal fluid (CSF) profiles, for example, narrow the differential diagnosis to one or a few possibilities (Tables 1–8 and 1–9). Reversible dementia may be diagnosed on the basis of laboratory studies (see Table 1–7). The most common reversible dementias are those due to intracranial masses, normal pressure hydrocephalus, thyroid dysfunction, and vitamin B12 deficiency.
II. ACUTE CONFUSIONAL STATES Common causes of acute confusional states are listed in Table 1–10. Table 1–7. Laboratory studies in dementia. Test Blood Hematocrit, mean corpuscular volume (MCV), peripheral blood smear, vitamin B12 level
Vitamin B12 deficiency
Liver function tests
Acquired hepatocerebral degeneration,Wilson disease
Ceruloplasmin, copper
Wilson disease
FTA or MHA-TP
Neurosyphilis
HIV antibody titer
AIDS dementia complex
CT scan or MRI
EEG
Differential Diagnosis
Metabolic acidosis (with increased anion gap)
Diabetic ketoacidosis, lactic acidosis (postictal, shock, sepsis), toxins (methanol, ethylene glycol, salicylates,1 paraldehyde), uremia
Respiratory alkalosis
Hepatic encephalopathy, pulmonary insufficiency, salicylates,1 sepsis
Respiratory acidosis
Pulmonary insufficiency, sedative drug overdose
1
Sepsis and salicylates produce a combined acid-base disorder.
DRUGS Many drugs can cause acute confusional states, especially when taken in greater than customary doses, in combination with other drugs, by patients with altered drug metabolism from hepatic or renal failure, by the elderly, or in the setting of preexisting cognitive impairment. A partial list of drugs that can produce acute confusional states is provided in Table 1–11.
ETHANOL INTOXICATION
Hypothyroidism
Cytology
Pattern
Most Useful in Diagnosis of
Thyroid function tests
Cerebrospinal fluid VDRL
Table 1–8. Arterial blood gases in acute confusional states.
Neurosyphilis Leptomeningeal metastases Brain tumor, chronic subdural hematoma, multiinfarct dementia, normal pressure hydrocephalus Creutzfeldt-Jakob disease
Ethanol intoxication produces a confusional state with nystagmus, dysarthria, and limb and gait ataxia. In nonalcoholics, signs correlate roughly with blood ethanol levels, but chronic alcoholics, who have developed tolerance to ethanol, may have very high levels without appearing intoxicated. Laboratory studies useful in confirming the diagnosis include blood alcohol levels and serum osmolality. In alcohol intoxication, serum osmolality determined by direct measurement exceeds the calculated osmolality (2 × serum sodium + 1⁄20 serum glucose + 1⁄3 serum urea nitrogen) by 22 mosm/L for every 100 mg/dL of ethanol present. Intoxicated patients are at high risk for head trauma. Alcohol ingestion may cause life-threatening hypoglycemia, and chronic alcoholism increases the risk of bacterial meningitis. Treatment is not required unless a withdrawal syndrome ensues, but alcoholic patients should receive thiamine to prevent Wernicke encephalopathy (see below).
ETHANOL WITHDRAWAL Three common withdrawal syndromes are recognized (Figure 1–3). Because of the associated risk of Wernicke encephalopathy (discussed later), patients presenting
12 / CHAPTER 1 Table 1–9. Cerebrospinal fluid profiles in acute confusional states. Opening Red Blood Appearance Pressure Cells
White Blood Cells
Glucose
Protein
Glutamine Smears −
Cultures
Normal
Clear, colorless
70–200 mm H2O
0/µL
≤5 mono- ≥45 nuclear/ mg/dL µL
≤451 mg/dL
<25 µg/dL
−
Bacterial meningitis
Cloudy
↑
Normal
↑↑ (PMN)2
↓↓
↑↑
Normal
Gram stain +
+
Tuberculous meningitis
Normal or cloudy
↑
Normal
↑ (MN)3,5
↓
↑
Normal
AFB stain +
±
Fungal meningitis
Normal or cloudy
Normal or ↑
Normal
↑ (MN)
↓
↑
Normal
India ink prep + (Cryptococcus)
±
Viral meningitis/ encephalitis
Normal
Normal or ↑
Normal4
↑ (MN)5
Normal6
Normal or ↑
Normal
−
±
Parasitic meningitis/ encephalitis
Normal or cloudy
Normal or ↑
Normal
↑ (MN,E)7 Normal
Normal or ↑
Normal
Amebas may be seen on wet mount
±
Leptomeningeal metastases
Normal or cloudy
Normal or ↑
Normal
Normal ↓↓ or ↑ (MN)
Normal or ↑
Normal
Cytology +
−
Subarachnoid hemorrhage
Pink-red (supernatant yellow)
↑
↑
Normal or ↑ (PMN)8
Normal or ↑8
↑
Normal
−
−
Hepatic encephalopathy
Normal
Normal
Normal
Normal
Normal
Normal
↑
−
−
1
Lumbar cerebrospinal fluid. PMN, polymorphonuclear predominance. 3 MN, mononuclear (lymphocytic or monocytic) predominance. 4 Red blood cell count may be elevated in herpes simplex encephalitis. 5 PMN predominance may be seen early in course. 6 Glucose may be decreased in herpes or mumps infections. 7 E, eosinophils often present. 8 Pleocytosis and low glucose, sometimes seen several days after hemorrhage, reflect chemical meningitis caused by subarachnoid blood. +, positive; −, negative; ±, can be positive or negative. 2
with these syndromes should be given thiamine, 100 mg/d, intravenously or intramuscularly, until a normal diet can be ensured. 1. TREMULOUSNESS & HALLUCINATIONS This self-limited condition occurs within 2 days after cessation of drinking and is characterized by tremulous-
ness, agitation, anorexia, nausea, insomnia, tachycardia, and hypertension. Confusion, if present, is mild. Illusions and hallucinations, usually visual, occur in about 25% of patients. Treatment with diazepam, 5–20 mg, or chlordiazepoxide, 25–50 mg, orally every 4 hours, will terminate the syndrome and prevent more serious consequences of withdrawal.
DISORDERS OF COGNITIVE FUNCTION / 13 Table 1–10. Common causes of acute confusional states. Metabolic Disorders Drugs1 Ethanol intoxication Ethanol withdrawal Sedative drug intoxication Sedative drug withdrawal Opioids Anticholinergics Phencyclidine Endocrine disorders Hypothyroidism Hyperthyroidism Hypoglycemia Hyperglycemia Electrolyte disorders Hyponatremia Hypocalcemia Hypercalcemia Nutritional disorders Wernicke encephalopathy Vitamin B12 deficiency Organ system failure Hepatic encephalopathy Reye syndrome Uremia Dialysis disequilibrium Pulmonary encephalopathy Organ transplantation 1
Infectious and Noninfectious Meningitis/Encephalitis Bacterial meningitis Tuberculous meningitis Syphilitic meningitis Viral meningoencephalitis Herpes simplex virus encephalitis AIDS Fungal meningitis Parasitic infections Leptomeningeal metastases Vascular Disorders Hypertensive encephalopathy Subarachnoid hemorrhage Vertebrobasilar ischemia Right (nondominant) hemisphere infarction Systemic lupus erythematosus Disseminated intravascular coagulation Thrombotic thrombocytopenic purpura Head Trauma Concussion Intracranial hemorrhage Seizures Postictal state Complex partial seizure
See also Table 1–11.
2. SEIZURES Ethanol withdrawal seizures occur within 48 hours of abstinence, and within 7–24 hours in about two-thirds of cases. Roughly 40% of patients who experience seizures have a single seizure; more than 90% have between one and six seizures. In 85% of the cases, the interval between the first and last seizures is 6 hours or less. Anticonvulsants are usually not required, as seizures cease spontaneously in most cases. Unusual features such as focal seizures, prolonged duration of seizures (>6–12 hours), more than six seizures, status epilepticus, or a prolonged postictal state should prompt a search for other causes or complicating factors, such as head trauma or infection. The patient should be observed for 6–12 hours to make certain that atypical features are not present. Because patients with withdrawal seizures may develop delirium tremens, diazepam or chlordiazepoxide is sometimes given prophylactically. 3. DELIRIUM TREMENS This most serious ethanol withdrawal syndrome typically begins 3–5 days after cessation of drinking and
lasts for up to 72 hours. It is characterized by confusion, agitation, fever, sweating, tachycardia, hypertension, and hallucinations. Death may result from concomitant infection, pancreatitis, cardiovascular collapse, or trauma. Treatment consists of diazepam, 10–20 mg intravenously, repeated every 5 minutes as needed until the patient is calm, and correction of fluid and electrolyte abnormalities and hypoglycemia. The total requirement for diazepam may exceed 100 mg/h. Concomitant β-adrenergic receptor blockade with atenolol, 50–100 mg/d, also has been recommended.
SEDATIVE DRUG INTOXICATION The classic signs of sedative drug overdose are confusional state or coma, respiratory depression, hypotension, hypothermia, reactive pupils, nystagmus or absence of ocular movements, ataxia, dysarthria, and hyporeflexia. The most commonly used sedative-hypnotic drugs are benzodiazepines and barbiturates. Glutethimide or very high doses of barbiturates may produce large, fixed pupils. Decerebrate and decorticate posturing can occur in coma that is caused by sedative
14 / CHAPTER 1 Table 1–11. Some therapeutic drugs associated with acute confusional states. Acyclovir Amantadine Aminocaproic acid Amphetamines Anticholinergics Anticonvulsants Antidepressants Antihistamines (H1 and H2) Antipsychotics L-Asparaginase Baclofen Barbiturates Benzodiazepines β-Adrenergic receptor antagonists Cephalosporins Chloroquine Clonidine Cocaine Corticosteroids Cycloserine Cyclosporine Digitalis glycosides
Disulfiram Ergot alkaloids Ethanol Ganciclovir Hallucinogens Isoniazid Ketamine Levodopa Lidocaine Methylphenidate Methylxanthines Nonsteroidal antiinflammatory drugs Opioids Penicillin Phenylpropanolamine Quinacrine Quinidine Quinine Salicylates Selegiline Thyroid hormones
Percentage onset in each group
drug overdose. The diagnosis can be confirmed by toxicologic analysis of blood, urine, or gastric aspirate, but blood levels of short-acting sedatives do not correlate with clinical severity. Management is directed at supporting the patient’s respiratory and circulatory function while the drug is being cleared. Complications include aspiration pneu-
60
Tremulousness and hallucinations
50
Seizures
40 30
SEDATIVE DRUG WITHDRAWAL Clinical Findings Like ethanol, sedative drugs can produce confusional states or seizures when intake is stopped abruptly. The frequency and severity of withdrawal syndromes depend upon the duration of drug intake and the dose and half-life of the drug. They occur most often in patients taking large doses for at least several weeks. Intermediate- or short-acting agents are those most likely to produce withdrawal symptoms when discontinued. Withdrawal syndromes commonly develop 1–3 days after cessation of short-acting agents but may not appear until a week or more after longer-acting drugs are discontinued. Symptoms are identical to those of ethanol withdrawal and are similarly self-limited. Myoclonus and seizures may appear after 3–8 days, however, and may require treatment. Seizures usually occur only when the average daily drug intake is several times the usual therapeutic dose. A syndrome indistinguishable from delirium tremens may also occur, and also tends to be restricted to patients taking several times the drug’s daily sedative dose. Sedative drug withdrawal syndrome can be confirmed by evaluating the patient about 1 hour after administering pentobarbital, 200 mg orally or intramuscularly. The absence of signs of sedative drug intoxication (sedation, nystagmus, dysarthria, or ataxia) establishes that the patient is tolerant to sedative drugs and makes sedative drug withdrawal a likely diagnosis, although other causes must be excluded. Sedative drug withdrawal is treated with a long-acting barbiturate such as phenobarbital, administered orally to maintain a calm state without signs of intoxication, and tapered over about 2 weeks.
Delirium tremens
OPIOIDS
20 10 0
monia and pulmonary edema caused by fluid overload. Barring the development of infections or cardiovascular complications, patients who arrive at the hospital with adequate cardiopulmonary function should survive without sequelae.
0
1
2
3
4
5
6
7
14
Days after cessation of drinking
Figure 1–3. Ethanol withdrawal syndromes in relation to the time since cessation of drinking. (Data from Victor M, Adams RD: The effect of alcohol on the nervous system. Res Publ Assoc Res Nerv Ment Dis 1952;32:526–573.)
Opioids can produce analgesia, mood changes, confusional states, coma, respiratory depression, pulmonary edema, nausea and vomiting, pupillary constriction, hypotension, urinary retention, and reduced gastrointestinal motility. Their chronic use is associated with tolerance and physical dependence. Examination may reveal needle tracks or the abovementioned signs, but the cardinal features of opioid overdose are pinpoint pupils—which usually constrict in bright light—and respiratory depression. These features can also result from pontine hemorrhage, but opi-
DISORDERS OF COGNITIVE FUNCTION / 15 oid overdose can be distinguished by the patient’s response to the opioid antagonist naloxone. After administration of naloxone, pupillary dilation and full recovery of consciousness occur promptly. When large doses of opioids or multiple drug ingestions are involved, however, slight dilation of the pupils may be the only observable effect. Treatment involves intravenous administration of naloxone, 0.4–0.8 mg, and sometimes ventilatory support. Because naloxone’s action may be as short as 1 hour—and many opioids are longer-acting—it should be readministered as the patient’s condition dictates. With appropriate treatment, patients should recover uneventfully.
ANTICHOLINERGIC DRUGS Muscarinic anticholinergic drugs are used to treat gastrointestinal disturbances, parkinsonism, motion sickness, and insomnia. Antipsychotic drugs, tricyclic antidepressants, and many antihistamines also exhibit prominent anticholinergic activity. Overdose with any of these agents can produce a confusional state with agitation, hallucinations, fixed and dilated pupils, blurred vision, dry skin and mucous membranes, flushing, fever, urinary retention, and tachycardia. In some cases, the diagnosis can be confirmed by toxicologic analysis of blood or urine. Symptoms usually resolve spontaneously, but treatment may be required, especially if life-threatening cardiac arrhythmias occur. In such cases, the cholinesterase inhibitor physostigmine can reverse the abnormality by interfering with the breakdown of acetylcholine. However, physostigmine may produce bradycardia and seizures, so it is rarely used.
PHENCYCLIDINE Phencyclidine (PCP) can produce drowsiness, agitation, disorientation, amnesia, hallucinations, paranoia, and violent behavior. Neurologic examination may show large or small pupils, horizontal and vertical nystagmus, ataxia, hypertonicity, hyperreflexia, and myoclonus. There may be analgesia to a surprising degree. In severe cases, complications include hypertension, malignant hyperthermia, status epilepticus, coma, and death. Benzodiazepines may be useful for sedation and treating muscle spasms, and antihypertensives, anticonvulsants, and dantrolene (for malignant hyperthermia) may be required. Symptoms and signs usually resolve within 24 hours.
ENDOCRINE DISTURBANCES HYPOTHYROIDISM Profound hypothyroidism (myxedema) may produce a confusional state, coma, or dementia. Cognitive distur-
bances include flat affect, psychomotor retardation, agitation, and psychosis. The neurologic examination may show dysarthria, deafness, or ataxia, but the most characteristic abnormality is delayed relaxation of the tendon reflexes. Untreated, the condition can progress to seizures and coma. Laboratory abnormalities include low thyroid hormone [triiodothyronine(T3) and tetraiodothyronine (T4)] levels and elevated thyroid-stimulating hormone (TSH) and serum cholesterol. Hypoglycemia and hyponatremia may occur, and arterial blood gases may reveal respiratory acidosis. CSF protein is typically elevated; CSF pressure is occasionally increased. Treatment is of the underlying thyroid disorder and, in severe myxedema madness or coma, rapid thyroid replacement with levothyroxine together with hydrocortisone for the possible coexistent adrenal insufficiency.
HYPERTHYROIDISM Acute exacerbation of hyperthyroidism (thyrotoxic crisis) may cause a confusional state, coma, or death. In younger patients, agitation, hallucinations, and psychosis are common (activated crisis), whereas those over age 50 tend to be apathetic and depressed (apathetic crisis). Seizures may occur. Neurologic examination shows an exaggerated physiologic (action) tremor and hyperreflexia; ankle clonus and extensor plantar responses are rare. The diagnosis is confirmed by assaying thyroid hormones (T3 and T4) in the blood. Treatment includes correction of hyperthermia, fluid and electrolyte disorders, cardiac arrhythmias, and congestive heart failure, and administration of antithyroid drugs (propylthiouracil or methimazole), iodide, propranolol, and hydrocortisone. The underlying disorder that precipitated thyrotoxic crisis should also be sought.
HYPOGLYCEMIA Prompt treatment of hypoglycemia is essential because hypoglycemic encephalopathy may progress rapidly from a reversible to an irreversible stage, and definitive therapy can be quickly and easily administered. The most common cause is insulin overdose in diabetic patients, but oral hypoglycemic drugs, alcoholism, malnutrition, hepatic failure, insulinoma, and non-insulin-secreting fibromas, sarcomas, or fibrosarcomas may also be responsible. Neurologic symptoms usually develop over minutes to hours. Although no strict correlation between blood glucose levels and the severity of neurologic dysfunction can be demonstrated, prolonged hypoglycemia at levels of 30 mg/dL or lower invariably leads to irreversible brain damage.
16 / CHAPTER 1
Clinical Findings Early signs of hypoglycemia include tachycardia, sweating, and pupillary dilation, which may be followed by a confusional state with somnolence or agitation. Neurologic dysfunction progresses in a rostral-caudal fashion (see Chapter 10), and may mimic a mass lesion causing transtentorial herniation. Coma ensues, with spasticity, extensor plantar responses, and decorticate or decerebrate posturing. Signs of brain stem dysfunction subsequently appear, including abnormal ocular movements and loss of pupillary reflexes. Respiratory depression, bradycardia, hypotonia, and hyporeflexia ultimately supervene, at which point irreversible brain damage is imminent. Hypoglycemic coma is often associated with focal neurologic signs and focal or generalized seizures.
Table 1–12. Features of hyperglycemic encephalopathies. Diabetic Ketoacidosis
Hyperosmolar Nonketotic State
Patient age
Young
Middle-aged to elderly
Type of diabetes
Juvenile-onset or insulindependent
Adult-onset
Blood glucose (mg/dL)
300–600
>800
Serum osmolality (mosm/L)
<350
>350
Treatment
Ketosis
+
−
The diagnosis is confirmed by measuring blood glucose levels, but treatment with glucose—50 mL of 50% dextrose intravenously—should be begun immediately, before the blood glucose level is known. Improvement in the level of consciousness is evident within minutes after glucose administration in patients with reversible hypoglycemic encephalopathy. The consequences of inadvertently worsening what later proves to be hyperglycemic encephalopathy are never as serious as those of a failure to treat hypoglycemia.
Metabolic acidosis
+
−
Coma
Uncommon
Common
Focal neurologic signs
−
+
Seizures
−
+
HYPERGLYCEMIA
Treatment & Prognosis
Two hyperglycemic syndromes, diabetic ketoacidosis and hyperosmolar nonketotic hyperglycemia, can produce encephalopathy or coma. Either syndrome, distinguished by a variety of clinical and laboratory features (Table 1–12), may be the presenting manifestation of diabetes. Impaired cerebral metabolism, intravascular coagulation from hyperviscosity, and brain edema from rapid correction of hyperglycemia contribute to pathogenesis. Whereas the severity of hyperosmolarity correlates well with depression of consciousness, the degree of systemic acidosis does not.
Treatment of diabetic ketoacidosis includes insulin, fluid and electrolyte (especially potassium and phosphate) replacement, and antibiotics for concomitant infections. Blood glucose levels should be allowed to remain at 200–300 mg/dL for 24 hours to reduce the risk of brain edema. Deaths are usually related to sepsis, cardiovascular or cerebrovascular complications, or renal failure. In hyperosmolar nonketotic hyperglycemia, fluid replacement is most important; 0.5 N saline is administered except to patients with circulatory collapse, who should receive normal saline. Insulin is also required. Death is usually due to misdiagnosis or coexisting disease.
Clinical Findings Symptoms include blurred vision, dry skin, anorexia, polyuria, and polydipsia. Physical examination may show hypotension and other signs of dehydration, especially in hyperosmolar nonketotic hyperglycemia. Deep, rapid (Kussmaul) respiration characterizes diabetic ketoacidosis. Impairment of consciousness varies from mild confusion to coma. Focal neurologic signs and generalized or focal seizures are common in hyperosmolar nonketotic hyperglycemia. Laboratory findings are summarized in Table 1–12.
+, present; −, absent.
HYPOADRENALISM Adrenocortical insufficiency produces fatigue, weakness, weight loss, anorexia, hyperpigmentation of the skin, hypotension, nausea and vomiting, abdominal pain, and diarrhea or constipation. Neurologic manifestations include confusional states, seizures, or coma. Treatment is administration of hydrocortisone and correction of hypovolemia, hypoglycemia, electrolyte disturbances, and precipitating illnesses.
DISORDERS OF COGNITIVE FUNCTION / 17
HYPERADRENALISM Hyperadrenalism (Cushing syndrome) usually results from the administration of exogenous glucocorticoids. Clinical features include truncal obesity, facial flushing, hirsutism, menstrual irregularities, hypertension, weakness, cutaneous striae, acne, and ecchymoses. Neuropsychiatric disturbances are common and include depression or euphoria, anxiety, irritability, memory impairment, psychosis, delusions, and hallucinations; fully developed acute confusional states are rare. The diagnosis is confirmed by elevated 24-hour urine-free cortisol level or a defective response to a low-dose dexamethasone suppression test. When a pituitary tumor is the cause, the usual treatment is transsphenoidal hypophysectomy.
includes water restriction or, for severe symptoms, infusion of hypertonic saline with or without intravenous furosemide. Excessively rapid correction of hyponatremia may cause central pontine myelinolysis, a disorder of white matter that can produce a confusional state, paraparesis or quadriparesis, dysarthria, dysphagia, hyper- or hyporeflexia, and extensor plantar responses. Severe cases can result in the locked-in syndrome (see Chapter 10), coma, or death. MRI may show pontine and extrapontine white matter lesions. There is no treatment, so prevention is essential, and may best be achieved by restricting water intake and using small amounts of hypertonic saline to raise the serum sodium concentration to 125–130 mmol/L, at a rate not exceeding 8 mmol/L/d.
ELECTROLYTE DISORDERS
HYPERCALCEMIA
HYPONATREMIA Clinical Findings
Symptoms include thirst, polyuria, constipation, nausea and vomiting, abdominal pain, anorexia, and flank pain from nephrolithiasis. Neurologic symptoms are always present with serum calcium levels higher than 17 mg/dL (8.5 meq/L) and include headache, weakness, and lethargy. Physical examination may show dehydration, abdominal distention, focal neurologic signs, myopathic weakness, and a confusional state that can progress to coma. Seizures are rare. The myopathy spares bulbar muscles and tendon reflexes are usually normal. The diagnosis is confirmed by an elevated serum calcium level, and sometimes increased parathyroid hormone levels and a shortened QT interval on the ECG. Severe hypercalcemia is treated initially by vigorous intravenous hydration with 0.45% or 0.9% saline and usually requires central venous pressure monitoring. Patients with hypercalcemia also should be evaluated for occult cancer.
Hyponatremia, particularly when acute, causes brain swelling due to hypoosmolality of extracellular fluid. Symptoms include headache, lethargy, confusion, weakness, muscle cramps, nausea, and vomiting. Neurologic signs include confusional state or coma, papilledema, tremor, asterixis, rigidity, extensor plantar responses, and focal or generalized seizures. Hyponatremia may also produce focal signs by unmasking preexisting structural brain lesions. Neurologic complications are usually associated with serum sodium levels less than 120 meq/L (Figure 1–4), but may be seen following a rapid fall to 130 meq/L—while chronic hyponatremia with levels as low as 110 meq/L may be asymptomatic.
Treatment Treatment is most effective when the underlying cause of hyponatremia is corrected. Immediate management
Plasma Na+ (meq/L)
Alert
Confused Stupor
Coma Seizures
130 120 110 100 90
Figure 1–4. Relationship between plasma sodium concentration and neurologic manifestations of hyponatremia. (Reproduced, with permission, from Arieff AI, Llach F, Massry SG: Neurologic manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine
HYPOCALCEMIA Symptoms include irritability, delirium, psychosis with hallucinations, depression, nausea, vomiting, abdominal pain, and paresthesias of the circumoral region and distal extremities. The most characteristic physical signs are those of overt or latent tetany. Neural hyperexcitability is exhibited by contraction of facial muscles in response to percussion of the facial (VII) nerve anterior to the ear (Chvostek sign). Carpopedal spasm may occur spontaneously or following tourniquet-induced limb ischemia (Trousseau sign). Cataracts and papilledema are sometimes present, and chorea has been reported. Seizures or laryngospasm can be life-threatening. Serum calcium levels are below 9 mg/dL (4.5 meq/L), but calcium is also decreased in hypoalbuminemia without affecting ionized calcium and hypocalcemia with normal ionized calcium is asympto-
18 / CHAPTER 1 matic. The ECG may show a prolonged QT interval. Treatment is with intravenous calcium gluconate and seizures, if present, are treated with phenytoin or phenobarbital.
within 1 month. Horizontal nystagmus and ataxia, however, resolve completely in only about 40% of cases. The major long-term complication of Wernicke encephalopathy is Korsakoff syndrome.
NUTRITIONAL DISORDERS
VITAMIN B12 DEFICIENCY
WERNICKE ENCEPHALOPATHY Wernicke encephalopathy is usually a complication of chronic alcoholism, but also occurs in other disorders associated with malnutrition. It is caused by deficiency of thiamine (vitamin B1). Pathologic features include neuronal loss, demyelination, and gliosis in periventricular gray matter. Proliferation of small blood vessels and petechial hemorrhages may be seen. The areas most commonly involved are the medial thalamus, mammillary bodies, periaqueductal gray matter, cerebellar vermis, and oculomotor, abducens, and vestibular nuclei.
Clinical Findings The classic syndrome comprises the triad of ophthalmoplegia, ataxia, and confusional state. The most common ocular abnormalities are nystagmus, abducens (VI) nerve palsy, and horizontal or combined horizontal-vertical gaze palsy. Ataxia affects gait primarily; ataxia of the arms is uncommon, as is dysarthria. The mental status examination reveals global confusion with a prominent disorder of immediate recall and recent memory. The confusional state progresses to coma in a small percentage of patients. Most patients have associated neuropathy with absent ankle jerks. Hypothermia and hypotension may occur due to hypothalamic involvement. Pupillary abnormalities, including mild anisocoria, or a sluggish reaction to light, are occasionally seen. The peripheral blood smear may show macrocytic anemia and MRI may show atrophy of the mammillary bodies.
Treatment Treatment requires prompt administration of thiamine. An initial dose of 100 mg is given intravenously, before or with dextrose, to avoid precipitating or exacerbating the disorder. Parenteral thiamine is continued for several days. The maintenance requirement for thiamine—about 1 mg/d—is usually available in the diet, although enteric absorption of thiamine is impaired in alcoholics.
Prognosis Following treatment, ocular abnormalities usually begin to improve within 1 day and ataxia and confusion within a week. Ophthalmoplegia, vertical nystagmus, and acute confusion are entirely reversible, usually
Vitamin B12 (cyanocobalamin) deficiency produces peripheral neuropathy, subacute combined degeneration of the spinal cord, nutritional amblyopia (visual loss), and cognitive dysfunction that ranges from a mild confusional state to dementia or psychosis (megaloblastic madness). Neurologic abnormalities may precede the development of macrocytic anemia. The most frequent cause of vitamin B12 deficiency is pernicious anemia, a defect in the production of intrinsic factor associated with gastric atrophy and achlorhydria, which is most common in those of northern European ancestry.
Clinical Findings The presenting symptoms are usually due to anemia or orthostatic lightheadedness, but may also be neurologic. Distal paresthesias, gait ataxia, a bandlike sensation of tightness around the trunk or limbs, and Lhermitte sign (an electric-shocklike sensation along the spine precipitated by neck flexion) may be present. Physical examination may show low-grade fever, glossitis, lemon-yellow discoloration of the skin, and cutaneous hyperpigmentation. Cerebral involvement produces confusion, depression, agitation, or psychosis with hallucinations. Spinal cord involvement is manifested by impaired vibratory and joint position sense, sensory gait ataxia and spastic paraparesis with extensor plantar responses. Associated peripheral nerve involvement may cause loss of tendon reflexes in the legs and urinary retention. Hematologic abnormalities include macrocytic anemia, leukopenia with hypersegmented neutrophils, and thrombocytopenia with giant platelets. Because folate deficiency can produce identical changes, the diagnosis must be confirmed by the serum vitamin B12 level. When this is low, Schilling test determines whether defective intestinal absorption of vitamin B12 (as in pernicious anemia) is the cause. In pernicious anemia, the urinary excretion of orally administered vitamin B12 is abnormally low, and this abnormality can be corrected by coadministration of intrinsic factor. Diagnosis may be difficult when cerebral symptoms occur without anemia or spinal cord disease, requiring that the serum vitamin B12 level be determined routinely in patients with cognitive disorders, myelopathy, or peripheral neuropathy, whether or not anemia is present.
Treatment Treatment of neurologic manifestations is by prompt intramuscular administration of cyanocobalamin, after
DISORDERS OF COGNITIVE FUNCTION / 19 blood is drawn to determine the serum vitamin B12 level. Daily injections are continued for 1 week, and Schilling test is performed to determine the cause of deficiency. If, as in pernicious anemia, deficiency is not correctable by dietary supplementation or treatment of intestinal malabsorption, intramuscular vitamin B12 (typically 100 µg) are given at weekly intervals for several months and monthly thereafter. The reversibility of neurologic complications depends upon their duration. Abnormalities present for more than 1 year are less likely to resolve with treatment. Encephalopathy may begin to clear within 24 hours after the first vitamin B12 dose, but full neurologic recovery, when it occurs, may take several months.
ORGAN SYSTEM FAILURE HEPATIC ENCEPHALOPATHY Hepatic encephalopathy occurs as a complication of cirrhosis, portosystemic shunting, chronic active hepatitis, or fulminant hepatic necrosis following viral hepatitis. Alcoholism is the most common underlying disorder. The syndrome may be chronic and progressive or acute in onset; in the latter case, gastrointestinal hemorrhage is a frequent precipitating cause. Liver disease produces cerebral symptoms by impairing hepatocellular detoxifying mechanisms or by the portosystemic shunting of venous blood. As a result, ammonia and other toxins accumulate in the blood and diffuse into the brain. Increased activity of γaminobutyric acid (GABA)-containing neuronal pathways in the brain and elevated levels of endogenous benzodiazepines may be involved in the pathogenesis of cerebral symptoms.
turing, and extensor plantar responses. Focal neurologic signs and focal or generalized seizures may occur. Laboratory studies may show elevated serum bilirubin, transaminases, ammonia, prothrombin time (PT) and partial thromboplastin time (PTT), and respiratory alkalosis. The most specific CSF abnormality is elevated glutamine (Figure 1–5). The EEG may be diffusely slow with triphasic waves.
Treatment Treatment includes restricting dietary protein, reversing electrolyte disturbances and hyperglycemia, discontinuing drugs that may have caused decompensation, providing antibiotics, and correcting coagulopathy with fresh-frozen plasma or vitamin K. Oral or rectal administration of lactulose, 20–30 g three or four times daily, decreases colonic pH and ammonia absorption. Neomycin, 1–3 g orally four times daily, may reduce ammonia-forming bacteria in the colon. Some success also has been reported with the benzodiazepine receptor antagonist flumazenil. Orthotopic liver transplantation is required in some cases. Prognosis in hepatic encephalopathy correlates best with the severity of hepatocellular rather than neurologic dysfunction.
REYE SYNDROME Reye syndrome is a rare disorder characterized by encephalopathy or coma with laboratory evidence of hepatic dysfunction. It usually occurs in children several days after a viral illness, especially varicella or influenza B. Administration of salicylates appears to be an additional risk factor. The incidence of Reye syndrome has declined dramatically in recent years, at least partly as a result of vaccination for varicella and the avoidance of aspirin in treating children with febrile illnesses.
Clinical Findings Hepatic encephalopathy
Other liver disease
Normal and other illnesses
100 Glutamine (mg/dL)
Symptoms of encephalopathy may precede systemic symptoms such as nausea, anorexia, and weight loss. Recent gastrointestinal bleeding, consumption of highprotein foods, use of sedatives or diuretics, or systemic infection may provide a clue to the cause of clinical decompensation. Physical examination may reveal systemic signs of liver disease. Cognitive disturbances include somnolence, agitation, and coma. Ocular reflexes are usually brisk. Nystagmus, tonic downward ocular deviation, and disconjugate eye movements may be seen. The most helpful neurologic sign of a metabolic disturbance, although not restricted to liver disease, is asterixis—a flapping tremor of the outstretched hands or feet that results from impaired postural control. Other motor abnormalities include tremor, myoclonus, paratonic rigidity, spasticity, decorticate or decerebrate pos-
80 60 40 20 0
Figure 1–5. Range of CSF glutamine concentrations in hepatic encephalopathy. (Reproduced, with permission, from Plum F: The CSF in hepatic encephalopathy. Exp Biol Med 1971;4:34–41.)
20 / CHAPTER 1
UREMIA Renal failure, particularly when acute in onset or rapidly progressive, may produce encephalopathy or coma with hyperventilation and prominent motor manifestations. These include tremor, asterixis, myoclonus, and tetany. Focal or generalized seizures and focal neurologic signs are common, and decorticate or decerebrate posturing may occur. Laboratory abnormalities include elevated serum urea nitrogen, creatinine and potassium, and metabolic acidosis, but their severity correlates poorly with symptoms. The EEG is diffusely slow and may show triphasic waves or paroxysmal spikes or sharp waves. Acute management includes hydration, protein and salt restriction, and treatment of complications such as seizures. Long-term management requires reversing the cause (eg, urinary tract obstruction), dialysis, or kidney transplantation. Although dialysis reverses the encephalopathy, clinical improvement often lags behind normalization of serum urea nitrogen and creatinine. Dialysis itself can produce an encephalopathy, termed dialysis disequilibrium syndrome, that is thought to result from hypoosmolality. This is most common with a patient’s first hemodialysis and can be prevented by correcting uremia more gradually or using briefer periods of dialysis at reduced rates of blood flow.
PULMONARY ENCEPHALOPATHY Patients with lung disease or brainstem or neurologic disorders that affect respiratory function may develop encephalopathy related to hypoventilation. Symptoms include headache, confusion, and somnolence. Examination shows papilledema, asterixis or myoclonus, and confusional state or coma. Tendon reflexes are often decreased, but pyramidal signs may be present, and seizures occur occasionally. Arterial blood gases show respiratory acidosis. Treatment involves ventilatory support to decrease hypercapnia and to maintain adequate oxygenation.
ORGAN TRANSPLANTATION Treatment of organ failure by transplantation can lead to acute confusional states as a consequence of surgical complications, immunosuppressive drug treatment, opportunistic infection, lymphoproliferative disorders, or transplant rejection. The problems encountered depend on the time in relation to transplantation and on the organ transplanted. Surgical complications that may produce encephalopathy include hypotension, hypoxia, thromboembolism, and air embolism, and are most common with heart and liver transplants. Immunosuppressive drugs used to prevent transplant rejection can cause acute confusional states by di-
rect effects on the nervous system or as a consequence of immunological impairment. Cyclosporine and tacrolimus (FK-506) produce encephalopathy that may be associated with seizures, tremor, visual disturbances, weakness, sensory symptoms, or ataxia. MRI shows abnormalities in the subcortical white matter. Symptoms are often associated with excessively high drug levels in the blood and may improve with reduction of drug dosage. Corticosteroids can produce psychosis, which may respond to substituting dexamethasone, and corticosteroid withdrawal is sometimes associated with lethargy, headache, myalgia, and arthralgia. OKT3 causes encephalopathy, aseptic meningitis, and seizures. Gabapentin is often used to treat seizures in transplant recipients because of its relative lack of pharmacokinetic interaction with other drugs typically given to these patients. Infections causing confusional states are most prominent following bone marrow transplantation, but are also common after transplantation of other organs. They are comparatively rare in the first month following transplantation and, when they occur, usually reflect preexisting infection in the recipient or in the donor organ, or a perioperative complication. Within this period, the most frequent organisms are gram-negative bacteria, herpes simplex virus, and fungi. Opportunistic infections are more common between 1 and 6 months posttransplant and include acute Listeria meningitis or encephalitis; chronic meningitis from Cryptococcus or Mycobacterium tuberculosis; and brain abscesses related to infection with Aspergillus, Nocardia, or Toxoplasma. Beyond 6 months, cytomegalovirus, Toxoplasma, Cryptococcus, Listeria, or Nocardia infection may be seen. Posttransplant lymphoproliferative disorder is related to immunosuppression and may be associated with primary central nervous system lymphoma. Transplant rejection may also produce encephalopathy, especially in recipients of kidney transplants.
MENINGITIS, ENCEPHALITIS, & SEPSIS BACTERIAL MENINGITIS Bacterial meningitis is a leading cause of acute confusional states and one in which early diagnosis greatly improves the outcome. Predisposing conditions include systemic (especially respiratory) or parameningeal infection, head trauma, anatomic meningeal defects, prior neurosurgery, cancer, alcoholism, and other immunodeficiency states. The etiologic organism varies with age and with the presence of predisposing conditions (Table 1–13).
DISORDERS OF COGNITIVE FUNCTION / 21 Table 1–13. Etiologic agents and empirical antibiotic treatment in bacterial meningitis, based on age and predisposing condition. Age or Condition
Etiologic Agents
Antibiotics of Choice
Less than 3 months
S agalactiae E coli L monocytogenes
Ampicillin, 100 mg/kg intravenously every 8 hours + cefotaxime, 50 mg/kg intravenously every 6 hours or ceftriaxone, 50–100 mg/kg intravenously every 12 hours
3 months to 8 years
N meningitidis S pneumoniae H influenzae
Cefotaxime, 50 mg/kg intravenously every 6 hours or ceftriaxone, 50–100 mg/kg intravenously every 12 hours + vancomycin, 15 mg/kg intravenously every 6 hours, to maximum of 4 g/d
18 to 50 years
S pneumoniae N meningitidis
Cefotaxime, 2 g intravenously every 6 hours or ceftriaxone, 2 g intravenously every 12 hours + vancomycin, 15 mg/kg intravenously every 6 hours, to maximum of 4 g/d
Older than 50 years
S pneumoniae L monocytogenes Gram-negative bacilli
Ampicillin, 2 g intravenously every 4 hours + cefotaxime, 2 g intravenously every 6 hours or ceftriaxone, 2 g intravenously every 12 hours
Impaired cellular immunity
L monocytogenes Gram-negative bacilli
Ampicillin, 100 mg/kg intravenously every 8 hours (neonate) or 2 g intravenously every 4 hours (adult) + ceftazidime, 50–100 mg/kg intravenously every 8 hours, to maximum of 2 g every 8 hours
Head trauma, neurosurgery, or CSF shunt
Staphylococci Gram-negative bacilli S pneumoniae
Vancomycin, 15 mg/kg intravenously every 6 hours, to maximum of 4 g/d + ceftazidime, 50–100 mg/kg intravenously every 8 hours, to maximum of 2 g every 8 hours
Adapted from Quagliarello VJ, Scheld WM: Treatment of bacterial meningitis. N Engl J Med 1997;336:708–716.
Pathogenesis & Pathology Bacteria typically gain access to the central nervous system by colonizing the mucous membranes of the nasopharynx, leading to local tissue invasion, bacteremia, and hematogenous seeding of the subarachnoid space. Bacteria can also spread to the meninges directly, through anatomic defects in the skull or from parameningeal sites such as the paranasal sinuses or middle ear. Polysaccharide bacterial capsules, lipopolysaccharides, and outer membrane proteins may contribute to the bacterial invasion and virulence. The low levels of antibody and complement present in the subarachnoid space are inadequate to contain the infection. The resulting inflammatory response is associated with the re-
lease of inflammatory cytokines, including interleukins 1 and 6 and tumor necrosis factor α, that promote blood-brain barrier permeability, vasogenic cerebral edema, changes in cerebral blood flow, and perhaps direct neuronal toxicity. Pathologically, bacterial meningitis is characterized by leptomeningeal and perivascular infiltration with polymorphonuclear leukocytes and an inflammatory exudate. These changes tend to be most prominent over the cerebral convexities in Streptococcus pneumoniae and Haemophilus infection and over the base of the brain with Neisseria meningitidis. Brain edema, hydrocephalus, and cerebral infarction may occur, although actual bacterial invasion of the brain is rare.
22 / CHAPTER 1
Clinical Findings A. SYMPTOMS AND SIGNS At presentation, most patients have had symptoms of meningitis for 1 to 7 days. These include fever, confusion, vomiting, headache, and neck stiffness, but the full syndrome is often not present. Physical examination may show fever and signs of systemic or parameningeal infection, such as skin abscess or otitis. A petechial rash is seen in 50–60% of patients with N meningitidis meningitis. Signs of meningeal irritation are seen in about 80% of cases, but are often absent in the very young and very old, or with profoundly impaired consciousness. These signs include neck stiffness on passive flexion, thigh flexion upon flexion of the neck (Brudzinski sign), and resistance to passive extension of the knee with the hip flexed (Kernig sign). The level of consciousness, when altered, ranges from mild confusion to coma. Focal neurologic signs, seizures, and cranial nerve palsies may occur. B. LABORATORY FINDINGS Peripheral blood may reveal polymorphonuclear leukocytosis from systemic infection or leukopenia due to immunosuppression. The causative organism can be cultured from the blood in 40–90% of meningitis cases. X-rays of the chest, sinuses, or mastoid bones may indicate a primary site of infection. A brain CT or MRI scan may show contrast enhancement of the cerebral convexities, the base of the brain, or the ventricular ependyma. The EEG is usually diffusely slow, and focal abnormalities suggest the possibility of focal cerebritis, abscess formation, or scarring. Although these studies may be helpful, the essential test in all cases of suspected meningitis is prompt lumbar puncture and CSF examination. CSF pressure is elevated in about 90% of cases, and the appearance of the fluid ranges from slightly turbid to grossly purulent. CSF white cell counts of 1000–10,000/mL are usually seen, consisting chiefly of polymorphonuclear leukocytes, although mononuclear cells may predominate in Listeria monocytogenes meningitis. Protein concentrations of 100–500 mg/dL are most common. The CSF glucose level is lower than 40 mg/dL in about 80% of cases and may be too low to measure. Gram-stained smears of CSF identify the causative organism in 70–80% of cases. CSF culture, which is positive in about 80% of cases, provides a definitive diagnosis and allows determination of antibiotic sensitivity. The polymerase chain reaction has also been used with CSF specimens to diagnose bacterial meningitis, including H influenzae, N meningitidis, and L monocytogenes meningitis.
Differential Diagnosis Signs of meningeal irritation may also be seen with subarachnoid hemorrhage, but the distinction is easily
made because lumbar puncture yields bloody CSF in that condition. Early viral meningitis can produce polymorphonuclear pleocytosis and symptoms identical to those of bacterial meningitis, but a repeat lumbar puncture after 6–12 hours should demonstrate a shift to lymphocytic predominance in viral meningitis, and the CSF glucose level is normal.
Prevention Children should be routinely immunized against H influenzae by vaccination. A vaccine is also available for some strains of N meningitidis and is recommended for military recruits, college students, and travelers to areas of ongoing epidemics. The risk of contracting H influenzae or N meningitidis meningitis can be reduced in household and other close contacts of affected patients by the prophylactic administration of rifampin, 20 mg/kg/d orally, given as a single daily dose for 4 days (H influenzae) or as two divided doses for 2 days (N meningitidis).
Treatment Unless the physical examination shows focal neurologic abnormalities or papilledema, lumbar puncture should be performed immediately; if the CSF is not clear and colorless, antibiotic treatment (see below) is started without delay. When focal signs or papilledema are present, blood and urine should be taken for culture, antibiotics begun, and a brain CT scan obtained. If the scan shows no focal lesion that would contraindicate lumbar puncture, the puncture is then performed. The initial choice of antibiotics is empirical, based upon the patient’s age and predisposing factors (see Table 1–13). Therapy is adjusted as indicated when the Gram stain or culture and sensitivity results become available (Table 1–14). Lumbar puncture can be repeated to assess the response to therapy. CSF should be sterile after 24 hours, and a decrease in pleocytosis and in the proportion of polymorphonuclear leukocytes should occur within 3 days. Dexamethasone, given immediately before the onset of antibiotic treatment and continued every 6 hours for 4 days, can improve outcome and decrease mortality in bacterial meningitis.
Prognosis Complications of bacterial meningitis include headache, seizures, hydrocephalus, syndrome of inappropriate secretion of antidiuretic hormone (SIADH), residual neurologic deficits (including cognitive disturbances and cranial—especially VIII—nerve abnormalities), and death. A CT scan will confirm suspected hydrocephalus and fluid and electrolyte status should be carefully monitored to detect SIADH. N meningitidis
DISORDERS OF COGNITIVE FUNCTION / 23 Table 1–14. Treatment of bacterial meningitis of known cause.
Etiologic Agents Gram’s stain Cocci Gram-positive
Gram-negative
Bacilli Gram-positive
Gram-negative
CSF culture S pneumoniae
Antibiotics of Choice
Duration of Tretament (days)
Vancomycin, 15 mg/kg intravenously every 6 hours, to maximum of 4 g/d; substitute rifampin (600 mg/d) for vancomycin in adults receiving dexamethasone + cefotaxime, 50 mg/kg intravenously every 6 hours (neonates) or ceftriaxone, 50–100 mg/kg intravenously every 12 hours (children); 2 g intravenously every 12 hours (adults)
—
Penicillin G, 300,000 units/kg/d intravenously, to maximum of 24 million units/d
—
Ampicillin, 100 mg/kg intravenously every 8 hours (children); 2 g intravenously every 4 hours (adults) or penicillin G, 300,000 units/kg/d intravenously, to maximum of 24 million units/d + gentamicin, 1.5 mg/kg intravenous loading dose followed by 1–2 mg/kg intravenously every 8 hours
—
Cefotaxime, 50 mg/kg intravenously every 6 hours (neonates) or ceftriaxone, 50–100 mg/kg intravenously every 12 hours (children); 2 g intravenously every 12 hours (adults) or ceftazidime, 50–100 mg/kg intravenously every 8 hours, to maximum of 2 g every 8 hours + gentamicin, 1.5 mg/kg intravenous loading dose followed by 1–2 mg/kg intravenously every 8 hours
—
Vancomycin, 15 mg/kg intravenously every 6 hours, to maximum of 4 g/d; substitute rifampin (600 mg/d) for vancomycin in adults receiving dexamethasone + cefotaxime, 50 mg/kg intravenously every 6 hours (neonates) or ceftriaxone, 50–100 mg/kg intravenously every 12 hours (children); 2 g intravenously every 12 hours (adults)
10–14
H influenzae
Ceftriaxone, 50–100 mg/kg intravenously every 12 hours (children); 2 g intravenously every 12 hours (adults)
7
N meningitidis
Penicillin G, 300,000 units/kg/d intravenously, to maximum of 24 million units/d
7
L monocytogenes
Ampicillin, 100 mg/kg intravenously every 8 hours (children); 2 g intravenously every 4 hours (adults) + gentamicin, 1.5 mg/kg intravenous loading dose followed by 1–2 mg/kg intravenously every 8 hours
14–21
S. agalactiae
Penicillin G, 300,000 units/kg/d intravenously, to maximum of 24 million units/d
14–21
(continued)
24 / CHAPTER 1 Table 1–14. Treatment of bacterial meningitis of known cause. (continued)
Etiologic Agents
Antibiotics of Choice
Duration of Tretament (days)
Enterobacteriaceae
Cefotaxime, 50 mg/kg intravenously every 6 hours (neonates) or ceftriaxone, 50–100 mg/kg intravenously every 12 hours (children); 2 g intravenously every 12 hours (adults) + gentamicin, 1.5 mg/kg intravenous loading dose followed by 1–2 mg/kg intravenously every 8 hours
21
Pseudomonas aeruginosa, acinetobacter
Ceftazidime, 50–100 mg/kg intravenously every 8 hours, to maximum of 2 g every 8 hours + gentamicin, 1.5 mg/kg intravenous loading dose followed by 1–2 mg/kg intravenously every 8 hours
21
Adapted from Quagliarello VJ, Scheld WM: Treatment of bacterial meningitis. N Engl J Med 1997;336:708–716.
infections may be complicated by adrenal hemorrhage related to meningococcemia, resulting in hypotension and often death (Waterhouse-Friderichsen syndrome). Morbidity and mortality from bacterial meningitis are high. Fatalities occur in about 20% of affected adults, and more often with some pathogens (eg, S pneumoniae, gram-negative bacilli) than others (eg, H influenzae, N meningitidis). Factors that worsen prognosis include extremes of age, delay in diagnosis and treatment, complicating illness, stupor or coma, seizures, and focal neurologic signs.
TUBERCULOUS MENINGITIS Tuberculous meningitis must be considered in patients who present with a confusional state, especially if there is a history of pulmonary tuberculosis, alcoholism, corticosteroid treatment, HIV infection, or other conditions associated with impaired immune responses. It should also be considered in patients from areas (eg, Asia, Africa) or groups (eg, the homeless and inner-city drug users) with a high incidence of tuberculosis.
Pathogenesis & Pathology Tuberculous meningitis usually results from reactivation of latent infection with Mycobacterium tuberculosis. Primary infection, typically acquired by inhaling bacillus-containing droplets, may be associated with metastatic dissemination of blood-borne bacilli from the lungs to the meninges and the surface of the brain. Here the organisms remain in a dormant state in tubercles that can rupture into the subarachnoid space at a later time, resulting in tuberculous meningitis.
The main finding is a basal meningeal exudate containing primarily mononuclear cells. Tubercles may be seen on the meninges and surface of the brain. The ventricles may be enlarged as a result of hydrocephalus, and their surfaces may show ependymal exudate or granular ependymitis. Arteritis can result in cerebral infarction, and basal inflammation and fibrosis can compress cranial nerves.
Clinical Findings A. SYMPTOMS AND SIGNS Symptoms usually have been present for less than 4 weeks at the time of presentation and include fever, lethargy or confusion, and headache. Weight loss, vomiting, neck stiffness, visual impairment, diplopia, focal weakness, and seizures may also occur. A history of contact with known cases of tuberculosis is usually absent. Fever, signs of meningeal irritation, and a confusional state are the most common findings on physical examination, but all may be absent. Papilledema, ocular palsies, and hemiparesis are sometimes seen. Complications include spinal subarachnoid block, hydrocephalus, brain edema, cranial nerve palsies, and stroke caused by vasculitis or compression of blood vessels at the base of the brain. B. LABORATORY FINDINGS Only one-half to two-thirds of patients show a positive skin test for tuberculosis or evidence of active or healed tubercular infection on chest x-ray. The diagnosis is established by CSF analysis. CSF pressure is usually in-
DISORDERS OF COGNITIVE FUNCTION / 25 creased, and the fluid is typically clear and colorless but may form a clot upon standing. Lymphocytic and mononuclear cell pleocytosis of 50–500 cells/mL is most often seen, but polymorphonuclear pleocytosis can occur early and may give an erroneous impression of bacterial meningitis. CSF protein is usually more than 100 mg/dL and may exceed 500 mg/dL, particularly in patients with spinal subarachnoid block. The glucose level is usually decreased and may be less than 20 mg/dL. Acid-fast smears of CSF should be performed in all cases of suspected tuberculous meningitis, but they are positive in only a minority of cases. Definitive diagnosis is most often made by culturing M tuberculosis from the CSF, a process that usually takes several weeks and requires large quantities of spinal fluid for maximum yield. However, the polymerase chain reaction has also been used for diagnosis. Finally, the CT scan may show contrast enhancement of the basal cisterns and cortical meninges, or hydrocephalus.
Differential Diagnosis Many other conditions can cause a subacute confusional state with mononuclear cell pleocytosis, including syphilitic, fungal, neoplastic, and partially treated bacterial meningitis. These can be diagnosed by appropriate smears, cultures, and serologic and cytologic examinations.
Treatment Treatment should be started as early as possible; it should not be withheld while awaiting culture results. The decision to treat is based on the CSF findings described above; lymphocytic pleocytosis and decreased glucose are particularly suggestive, even if acid-fast smears are negative. Four drugs are used for initial therapy, until culture and susceptibility test results are known. These are isoniazid, 300 mg; rifampin, 600 mg; pyrazinamide, 25 mg/kg; and ethambutol, 15 mg/kg, each given orally once daily. For susceptible strains, ethambutol can be discontinued, and triple therapy continued for 2 months, followed by 4–10 months of treatment with isoniazid and rifampin alone. Pyridoxine, 50 mg/d, can be used to decrease the likelihood of isoniazid-induced polyneuropathy. Complications of therapy include hepatic dysfunction (isoniazid, rifampin, and pyrazinamide), polyneuropathy (isoniazid), optic neuritis (ethambutol), seizures (isoniazid), and ototoxicity (streptomycin). Corticosteroids (eg, prednisone, 60 mg/d orally in adults or 1–3 mg/kg/d orally in children, tapered gradually over 3–4 weeks) are indicated as adjunctive therapy in patients with spinal subarachnoid block. They also may be indicated in seriously ill patients with focal
neurologic signs or with increased intracranial pressure from cerebral edema. The risk of using corticosteroids may be high, however, especially if tuberculous meningitis has been mistakenly diagnosed in a patient with fungal meningitis. Therefore, if fungal meningitis has not been excluded, antifungal therapy (see below) should be added along with corticosteroids.
Prognosis Even with appropriate treatment, about one-third of patients with tuberculous meningitis succumb. Coma at the time of presentation is the most significant predictor of a poor prognosis.
SYPHILITIC MENINGITIS Acute or subacute syphilitic meningitis usually occurs within 2 years after primary syphilitic infection. It is most common in young adults, affects men more often than women, and requires prompt treatment to prevent the irreversible manifestations of tertiary neurosyphilis. In about one-fourth of patients with Treponema pallidum infection, treponemes gain access to the central nervous system, where they produce a meningitis that is usually asymptomatic (asymptomatic neurosyphilis). Asymptomatic invasion of the central nervous system is associated with CSF pleocytosis, elevated protein, and positive serologic tests for syphilis.
Clinical Findings A. SYMPTOMS AND SIGNS In a few patients, syphilitic meningitis is a clinically apparent acute or subacute disorder. At the time of presentation, symptoms such as headache, nausea, vomiting, stiff neck, mental disturbances, focal weakness, seizures, deafness, and visual impairment usually have been present for up to 2 months. Physical examination may show signs of meningeal irritation, confusion or delirium, papilledema, hemiparesis, and aphasia. The cranial nerves most frequently affected are (in order) the facial (VII), acoustic (VIII), oculomotor (III), trigeminal (V), abducens (VI), and optic (II) nerves, but other nerves may be involved as well. Fever is typically absent. B. LABORATORY FINDINGS The diagnosis is established by CSF findings. Opening pressure is normal or slightly elevated. Pleocytosis is lymphocytic or mononuclear in character, with white cell counts usually in the range of 100–1000/mL. Protein may be mildly or moderately elevated (<200 mg/dL) and glucose mildly decreased. CSF VDRL and serum FTA or MHA-TP tests are usually positive. Protein electrophoretograms of CSF may show discrete γ-
26 / CHAPTER 1 globulin bands (oligoclonal bands) not visible in normal CSF.
Treatment Acute syphilitic meningitis is usually a self-limited disorder with no or minimal sequelae. More advanced manifestations of neurosyphilis, including vascular and parenchymatous disease (eg, tabes dorsalis, general paresis, optic neuritis, myelitis), can be prevented by adequate treatment of the early syphilitic infection. Syphilitic meningitis is treated with aqueous penicillin G, 2–4 × 106 units intravenously every 4 hours for 10 days. For penicillin-allergic patients, tetracycline or erythromycin, 500 mg orally every 6 hours for 20 days, can be substituted. The CSF should be examined every 6 months until all findings are normal. Another course of therapy must be given if the CSF cell count or protein remains elevated.
LYME DISEASE Clinical Findings Lyme disease is a tick-borne disorder that results from systemic infection with the spirochete Borrelia burgdorferi. Most cases occur during the summer months. Primary infection may be manifested by an expanding erythematous annular skin lesion (erythema migrans) that usually appears over the thigh, groin, or axilla. Less distinctive symptoms include fatigue, headache, fever, neck stiffness, joint or muscle pain, anorexia, sore throat, and nausea. Neurologic involvement may be delayed for up to 10 weeks and is characterized by meningitis or meningoencephalitis and disorders of the cranial or peripheral nerves or nerve roots. Cardiac abnormalities (conduction defects, myocarditis, pericarditis, cardiomegaly, or heart failure) can also occur at this stage. Lyme meningitis usually produces prominent headache that may be accompanied by signs of meningeal irritation, photophobia, pain when moving the eyes, nausea, and vomiting. When encephalitis is present, it is usually mild and characterized by insomnia, emotional lability, or impaired concentration and memory. The CSF usually shows a lymphocytic pleocytosis with 100–200 cells/mL, slightly elevated protein, and normal glucose. Oligoclonal immunoglobulin G (IgG) bands may be detected. Definitive diagnosis is usually made by serologic testing for B burgdorferi, preferably by enzyme-linked immunosorbent assay (ELISA) followed by Western blot, but the polymerase chain reaction, which can amplify spirochetal DNA in synovial fluid, blood, or CSF, has also been used.
Treatment Preventive measures include avoiding tick-infested areas and using insect repellents and protective clothing
when avoidance is impossible. A Lyme disease vaccine is also available, but its use is controversial. For patients with Lyme disease and Bell palsy, treatment is with doxycycline (100 mg twice daily) or amoxicillin (500 mg three times daily), each given orally for 3–4 weeks. With meningitis or other central nervous system (CNS) involvement, intravenous treatment is indicated with ceftriaxone (2 g intravenously daily), penicillin G (20–24 million units intravenously daily in six divided doses), or cefotaxime (2 g intravenously every 8 hours), continued for 2–4 weeks. Symptoms typically resolve within 10 days in treated cases. Untreated or inadequately treated infections may lead to recurrent oligoarthritis, and chronic neurologic disorders including memory, language, and other cognitive disturbances; focal weakness; and ataxia. In such cases, a CT scan or MRI may show hydrocephalus, lesions in white matter resembling those seen in multiple sclerosis, or abnormalities suggestive of cerebral infarction. Subtle chronic cognitive or behavioral symptoms should not be attributed to Lyme encephalitis in the absence of serologic evidence of B burgdorferi exposure, CSF abnormalities, or focal neurologic signs. The peripheral neurologic manifestations of Lyme disease are discussed in Chapter 6.
VIRAL MENINGITIS & ENCEPHALITIS Viral infections of the meninges (meningitis) or brain parenchyma (encephalitis) often present as acute confusional states. Children and young adults are frequently affected. Viral meningitis is most often caused by enteric viruses (Table 1–15) and viral encephalitis by childhood exanthems, arthropod-borne agents, and herpes simplex type 1 (Table 1–16). Some forms of viral encephalitis tend to show a restricted geographic distribution. However, the speed and volume of international travel can permit these disorders to spread, as was observed recently for West Nile virus in the northeastern United States.
Pathology Viral infections can affect the central nervous system in three ways—hematogenous dissemination of a systemic viral infection (eg, arthropod-borne viruses); neuronal spread of the virus by axonal transport (eg, herpes simplex, rabies); and autoimmune postinfectious demyelination (eg, varicella, influenza). Pathologic changes in viral meningitis consist of an inflammatory meningeal reaction mediated by lymphocytes. Encephalitis is characterized by perivascular cuffing, lymphocytic infiltration, and microglial proliferation mainly involving subcortical gray matter regions. Intranuclear or intracytoplasmic inclusions are often seen.
DISORDERS OF COGNITIVE FUNCTION / 27 Table 1–15. Etiologic agents in viral meningitis. Virus
Seasonal Variation
Incidence
Source
Susceptible Population
Systemic Involvement
Laboratory Findings −
Echoviruses
30%
Summer, fall
Fecal-oral
Children, Maculopapular, members of vesicular, or affected families petechial skin rash; gastroenteritis
Coxsackievirus A
10%
Summer, fall
Fecal-oral
Children, Maculopapular, − members of vesicular, or affected families petechial skin rash; herpangina; gastroenteritis
Coxsackievirus B
40%
Summer, fall
Fecal-oral
Children, Maculopapular, members of vesicular, or affected families petechial skin rash; pleuritis, pericarditis, myocarditis, orchitis; gastroenteritis
Mumps virus
15%
Late winter, spring
Inhalation
Children, male more than female
Parotitis, orchitis, Amylase ↑; CSF oophoritis, glucose may pancreatitis be ↑ or ↓
Herpes simplex virus (type 2)
Uncommon
—
Genital infection
Neonates with affected mothers
Vesicular genital lesions
Adenovirus
Uncommon
—
Inhalation
Infants, children Pharyngitis, pneumonitis
−
Lymphocytic Uncommon choriomeningitis virus
Late fall, winter
Mouse
Laboratory workers
Pharyngitis, pneumonitis
Marked CSF pleocytosis (1000–10,000 WBC/µL)
Hepatitis viruses
Uncommon
—
Fecal-oral, venereal, transfusion
Intravenous drug users, male homosexuals, blood recipients
Jaundice, arthritis
Liver function abnormalities
Epstein-Barr virus Uncommon (infectious mononucleosis)
—
Oral contact
Teenagers, young adults
Lymphadenopathy, pharyngitis, maculopapular skin rash, palatal petechiae, splenomegaly
Atypical lymphocytes, positive heterophil, liver function abnormalities
−
−
Table 1–16. Etiologic agents in viral encephalitis. Type of Encephalitis
Vector
Geographic Distribution
Comments
Childhood exanthems Measles, varicella, mumps, rubella
Human
Arthropod-borne (Arbo) viruses Alphaviruses Eastern equine Mosquito
Worldwide
Uncommon in USA because of vaccination
USA (Atlantic and Gulf coasts), Caribbean, South America
Children usually affected; mortality 50–75%; neurologic sequelae common
Western equine
Mosquito
Western and central USA, South America
Infants and adults >50 years usually affected; mortality 5–15%; neurologic sequelae uncommon except in infants
Venezuelan equine
Mosquito
Florida, southwestern USA, Central and South America
Adults usually affected; mortality 1%; neurologic sequelae rare
Flaviviruses Japanese B
Mosquito
China, Southeast Asia, India, Japan
Vaccine available
St. Louis
Mosquito
USA (rural west and midwest, New Jersey, Florida,Texas), Caribbean, Central and South America
Adults >50 years most often affected; mortality 2–20%; neurologic sequelae in about 20%
Murray Valley
Mosquito
Australia, New Guinea
West Nile
Mosquito
Middle East, Africa, Europe, Central Asia, northeastern USA
Rocio
Mosquito
Brazil
Kyasanur Forest
Tick
India
Powassan
Tick
New York, Ontario
Russian spring-summer
Tick
Northern Europe, Siberia
Louping-ill
Tick
United Kingdom
Mosquito
North America
Mosquito
Africa
Tick
Western and Rocky Mountain states of USA
Other Herpes simplex (type 1)
Human
Worldwide
Focal neurologic signs common; responds to treatment with acyclovir
Herpes simplex (type 2)
Human
Worldwide
Encephalitis usually affects neonates; causes meningitis in older children and adults
Wild and domestic mammals
Worldwide
Invariably fatal unless vaccine and antiserum administered before symptoms occur following bite by affected animal
Bunyaviruses California (including LaCrosse) Rift Valley
Orbiviruses Colorado tick fever
Rabies
Children usually affected; mortality < 1%; neurologic sequelae uncommon
DISORDERS OF COGNITIVE FUNCTION / 29
Clinical Findings A. SYMPTOMS AND SIGNS Clinical manifestations include fever, headache, neck stiffness, photophobia, pain with eye movement, and mild impairment of consciousness. Patients usually do not appear as ill as those with bacterial meningitis. Systemic viral infection may cause skin rash, pharyngitis, lymphadenopathy, pleuritis, carditis, jaundice, organomegaly, diarrhea, or orchitis, and these findings may suggest a particular etiologic agent. Because viral encephalitis involves the brain directly, marked alterations of consciousness, seizures, and focal neurologic signs can occur. When signs of meningeal irritation and brain dysfunction coexist, the condition is termed meningoencephalitis. B. LABORATORY FINDINGS CSF analysis is the most important laboratory test. CSF pressure is normal or increased, and a lymphocytic or monocytic pleocytosis is present, with cell counts usually less than 1000/mL. (Higher counts can be seen in lymphocytic choriomeningitis or herpes simplex encephalitis.) A polymorphonuclear pleocytosis can occur early in viral meningitis, while red blood cells may be seen with herpes simplex encephalitis. Protein is normal or slightly increased (usually 80–200 mg/dL). Glucose is usually normal, but may be decreased in mumps, herpes zoster, or herpes simplex encephalitis. Gram stains and bacterial, fungal, and acid-fast bacillus (AFB) cultures are negative. Oligoclonal bands and CSF protein electrophoresis abnormalities may be present. An etiologic diagnosis often can be made by virus isolation, polymerase chain reaction, or acute- and convalescent-phase CSF antibody titers. Blood counts may show a normal white cell count, leukopenia, or mild leukocytosis. Atypical lymphocytes in blood smears and a positive heterophil (Monospot) test suggest infectious mononucleosis. Serum amylase is frequently elevated in mumps; abnormal liver function tests are associated with both hepatitis viruses and infectious mononucleosis. The EEG is diffusely slow, especially if there is direct cerebral involvement.
Differential Diagnosis The differential diagnosis of meningitis with mononuclear cell pleocytosis includes partially treated bacterial meningitis as well as syphilitic, tuberculous, fungal, parasitic, neoplastic, and other meningitides. Evidence of systemic viral infection and CSF wet mounts, stained smears, cultures, and cytologic examination can distinguish among these possibilities. When presumed early viral meningitis is associated with a polymorphonuclear pleocytosis of less than 1000 white blood cells/mL and normal CSF glucose, one of two strategies
can be used. The patient can be treated for bacterial meningitis until the results of CSF cultures are known, or treatment can be withheld and lumbar puncture repeated in 6–12 hours. If the meningitis is viral in origin, the second sample should show a mononuclear cell pleocytosis. A disorder that may be clinically indistinguishable from viral encephalitis is the immune-mediated encephalomyelitis that may follow viral infections such as influenza, measles, or chickenpox. Progressive neurologic dysfunction typically begins a few days after the viral illness but can also occur either simultaneously or up to several weeks later. Neurologic abnormalities result from perivenous demyelination, which often severely affects the brainstem. The CSF shows a lymphocytic pleocytosis, usually with cell counts of 50–150/mL, and mild protein elevation.
Treatment Except for herpes simplex encephalitis, which is discussed separately (see below), no specific therapy for viral meningitis and encephalitis is available. Corticosteroids are of no proven benefit except in immunemediated postinfectious syndromes. Headache and fever can be treated with acetaminophen, but aspirin should be avoided, especially in children and young adults, because of its association with Reye syndrome (see p. 19). Seizures usually respond to phenytoin or phenobarbital. Supportive measures in comatose patients include mechanical ventilation and intravenous or nasogastric feeding.
Prognosis Symptoms of viral meningitis usually resolve spontaneously within 2 weeks regardless of the causative agent, although residual deficits may be seen. The outcome of viral encephalitis varies with the specific virus—for example, eastern equine and herpes simplex virus infections are associated with severe morbidity and high mortality rates. Mortality rates as high as 20% have also been reported in immune-mediated encephalomyelitis following measles infections.
HERPES SIMPLEX VIRUS (HSV) ENCEPHALITIS HSV is the most common cause of sporadic fatal encephalitis in the United States. About two-thirds of cases involve patients over 40 years of age. Primary herpes infections most often present as stomatitis (HSV type 1) or a venereally transmitted genital eruption (HSV type 2). The virus migrates along nerve axons to sensory ganglia, where it persists in a latent form and may be subsequently reactivated. It is not clear whether
30 / CHAPTER 1 HSV type 1 encephalitis, the most common type in adults, represents a primary infection or a reactivation of latent infection. Neonatal HSV encephalitis usually results from acquisition of type 2 virus during passage through the birth canal of a mother with active genital lesions. Central nervous system involvement by HSV type 2 in adults usually causes meningitis, rather than encephalitis.
Pathology HSV type 1 encephalitis is an acute, necrotizing, asymmetric hemorrhagic process with lymphocytic and plasma cell reaction, and usually involves the medial temporal and inferior frontal lobes. Intranuclear inclusions may be seen in neurons and glia. Patients who recover may show cystic necrosis of the involved regions.
Clinical Findings A. SYMPTOMS AND SIGNS The clinical syndrome may include headache, stiff neck, vomiting, behavioral disorders, memory loss, anosmia, aphasia, hemiparesis, and focal or generalized seizures. Active herpes labialis is seen occasionally, but does not reliably implicate HSV as the cause of encephalitis. HSV encephalitis is usually rapidly progressive over several days and may result in coma or death. The most common sequelae in patients who survive are memory and behavior disturbances, reflecting the predilection of HSV for limbic structures. B. LABORATORY FINDINGS The CSF in HSV type 1 encephalitis most often shows increased pressure, lymphocytic or mixed lymphocytic and polymorphonuclear pleocytosis (50–100 white blood cells/mL), mild protein elevation, and normal glucose. Red blood cells, xanthochromia, and decreased glucose are seen in some cases. The virus generally cannot be isolated from the CSF, but viral DNA has been detected by the polymerase chain reaction in some cases. The EEG may show periodic slow-wave complexes arising from one or both temporal lobes, and CT scans and MRI may show abnormalities in one or both temporal lobes. These can extend to frontal or parietal regions and are sometimes enhanced with the infusion of contrast material (Figure 1–6). However, imaging studies may also be normal.
Figure 1–6. T2-weighted MRI in herpes simplex encephalitis. Note the lack of differentiation between gray and white matter, because of edema, in the left anterior temporal lobe (arrows) compared with the right. (Courtesy of A Gean.)
tive diagnosis can be made by biopsy of affected brain areas, with the choice of biopsy site guided by the EEG, CT, or MRI findings. However, because treatment is most effective when begun early and is comparatively safe, the most common approach is to treat patients with possible HSV encephalitis as described below and to reserve biopsy for those who fail to improve.
Treatment The most effective drug is acyclovir, given intravenously at a dosage of 10–15 mg/kg every 8 hours, with each dose given over 1 hour. Treatment is continued for 14–21 days. Complications include erythema at the infusion site, gastrointestinal disturbances, headache, skin rash, tremor, seizures, and encephalopathy or coma. Treatment is started as early as possible, since outcome is greatly influenced by the severity of dysfunction at the time treatment is initiated.
Differential Diagnosis The symptoms and signs are not specific for herpes virus infection. The greatest diagnostic difficulty is distinguishing between HSV encephalitis and brain abscess, and the two disorders often cannot be differentiated on clinical grounds alone. Other CNS infections and vasculitis can also mimic HSV encephalitis. Defini-
Prognosis Patients under the age of 30 years and those who are only lethargic at the onset of treatment are more likely to survive than are older or comatose patients. The mortality rate is about 25% at 18 months in patients given acyclovir.
DISORDERS OF COGNITIVE FUNCTION / 31
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AIDS is caused by infection with human immunodeficiency virus type 1 (HIV-1) and is characterized by opportunistic infections, malignant neoplasms (typically non-Hodgkin lymphoma or Kaposi sarcoma), and a variety of neurologic disturbances. Transmission occurs through sexual activity or by transfer of virus-contaminated blood or blood products. Individuals at particular risk of infection include those who engage in unprotected sexual intercourse, intravenous drug users who share needles, hemophiliacs who have received factor VIII transfusions, and their sexual partners. Neurologic complications of AIDS include dementia (see below), myelopathy (see Chapter 5), neuropathy (see Chapter 6), myopathy (see Chapter 5), and stroke (see Chapter 9). In addition to the disorders that produce acute confusional states in persons without AIDS, patients with AIDS are at increased risk for direct HIV infection of the nervous system, other opportunistic infections, and certain tumors (Table 1–17). Treatment of AIDS is discussed in the section on AIDS dementia complex later in this chapter. 1. HIV-1 MENINGITIS Patients infected with HIV-1 can develop a syndrome characterized by headache, fever, signs of meningeal irritation, cranial nerve (especially VII) palsies, other focal neurologic abnormalities, or seizures. This usually occurs at about the time of HIV-1 seroconversion. An acute confusional state is occasionally present. HIV-1 meningitis is associated with mononuclear pleocytosis of up to about 200 cells/mL. Symptoms usually resolve spontaneously within about 1 month. Other causes of Table 1–17. Causes of acute confusional states in patients with AIDS. Meningitis HIV-1 meningitis Cryptococcal meningitis Encephalitis Herpes simplex encephalitis Varicella-zoster encephalitis Cytomegalovirus encephalitis Intracerebral mass lesions Cerebral toxoplasmosis Primary central nervous system lymphoma Metabolic encephalopathies Pulmonary encephalopathy (related to Pneumocystis carinii-pneumonia) Drug toxicity Stroke Seizures
pleocytosis associated with AIDS, including cryptococcal meningitis, herpes simplex encephalitis, and cerebral toxoplasmosis, must be excluded. 2. CRYPTOCOCCAL MENINGITIS Cryptococcal meningitis occurs in 5–10% of patients with AIDS. Clinical features include headache, confusion, stiff neck, fever, nausea and vomiting, seizures, and cranial nerve palsies. Because the CSF is otherwise normal in about 20% of patients with AIDS and cryptococcal meningitis, CSF cryptococcal antigen titers should always be obtained. Laboratory abnormalities and recommended treatment are discussed in the section on fungal meningitis below. 3. HERPES SIMPLEX & VARICELLA-ZOSTER ENCEPHALITIS Whereas HSV encephalitis in immunocompetent adults is almost always due to type 1 virus, either type 1 or type 2 HSV can produce the disorder in patients with AIDS. The focal neurologic signs and CSF abnormalities usually associated with HSV encephalitis may be absent in AIDS, and the disorder may follow a more indolent course. Varicella-zoster virus, a herpesvirus that rarely causes encephalitis in immunocompetent individuals, may do so in patients with AIDS. Treatment is as described above for HSV encephalitis. 4. CYTOMEGALOVIRUS ENCEPHALITIS Cytomegalovirus, another herpesvirus, has been implicated as a cause of retinitis and polyradiculomyelitis (see Chapter 5) in patients with AIDS. Cytomegalovirus can also be identified in CSF and biopsy specimens from patients with AIDS who are neurologically asymptomatic, acutely confused, or demented. Death usually occurs within a few weeks, although therapeutic responses to antiviral treatment with ganciclovir and foscarnet have been reported. 5. CEREBRAL TOXOPLASMOSIS Cerebral toxoplasmosis produces intracerebral mass lesions in patients with AIDS, although its frequency appears to be declining as antitoxoplasma drugs such as trimethoprim-sulfamethoxazole are widely used for prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. A confusional state lasting days to weeks exists at the time of presentation in about 30% of patients. Other clinical features include fever, focal neurologic abnormalities such as cranial nerve palsies or hemiparesis, seizures, headache, and signs of meningeal irritation. Serologic tests for toxoplasmosis are unreliable in patients with AIDS. MRI is more sensitive than CT scanning and typically reveals one or more lesions, which often show a contrast enhancement of the rim and are commonly located in the basal ganglia. Because toxoplasmosis is readily treatable, patients with AIDS and intracerebral mass lesions that are not
32 / CHAPTER 1 obviously due to stroke should be treated for presumed toxoplasmosis, as described in the section on parasitic infections below. Up to 90% of patients respond favorably to therapy within the first few weeks and the majority survive longer than 6 months. 6. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA Primary central nervous system lymphoma is the most common brain tumor associated with AIDS. Systemic non-Hodgkin lymphoma also occurs with increased frequency, but usually produces lymphomatous meningitis (see below) rather than intracerebral masses. Clinical features of primary central nervous system lymphoma include confusional state, hemiparesis, aphasia, seizures, cranial nerve palsies, and headache; signs of meningeal irritation are uncommon. CSF commonly shows elevated protein and mild mononuclear pleocytosis, and glucose may be low; cytology is rarely positive. MRI is more sensitive than CT scanning and shows single or multiple contrast-enhanced lesions, which may not be distinguishable from those seen with toxoplasmosis. Patients with AIDS and one or more intracerebral mass lesions that fail to respond to treatment for toxoplasmosis within 3 weeks should undergo brain biopsy for diagnosis of lymphoma. Although corticosteroids and radiation therapy may prolong survival, most patients die within a few months. 7. OTHER DISORDERS Pneumocystis carinii pneumonia in patients with AIDS may lead to hypoxia and a resulting confusional state. Patients with AIDS, especially those with central nervous system involvement, may be especially sensitive to drugs (eg, antidepressants) and metabolic disorders, and the antiretroviral drug zidovudine can produce a confusional state. Stroke can occur in patients with AIDS, especially when it is complicated by cryptococcal meningitis, and may produce an acute confusional state. Seizures are common in patients with AIDS, especially those with AIDS dementia complex, cerebral toxoplasmosis, or cryptococcal meningitis, and both complex partial seizures and the postictal state that follows generalized tonic-clonic seizures are associated with confusional states.
FUNGAL MENINGITIS In a small fraction of patients with systemic fungal infections (mycoses), fungi invade the central nervous system to produce meningitis or focal intraparenchymal lesions (Table 1–18). Several fungi are opportunistic organisms that cause infection in patients with cancer, those receiving corticosteroids or other immunosuppressive drugs, and other debilitated hosts. Intravenous drug abuse is a potential route for infection with Candida and Aspergillus. Diabetic acidosis is strongly corre-
lated with rhinocerebral mucormycosis. In contrast, meningeal infections with Coccidioides, Blastomyces, and Actinomyces usually occur in previously healthy individuals. Cryptococcus (the most common cause of fungal meningitis in the United States) and Histoplasma infection can occur in either healthy or immunosuppressed patients. Cryptococcal meningitis is the most common fungal infection of the nervous system in AIDS, but Coccidioides and Histoplasma infections can also occur in this setting. Geographic factors are also important in the epidemiology of certain mycoses (see Table 1–18).
Pathogenesis & Pathology Fungi reach the central nervous system by hematogenous spread from the lungs, heart, gastrointestinal or genitourinary tract, or skin, or by direct extension from parameningeal sites such as the orbits or paranasal sinuses. Invasion of the meninges from a contiguous focus of infection is particularly common in mucormycosis but may also occur in aspergillosis and actinomycosis. Pathologic findings in fungal infections of the nervous system include a primarily mononuclear meningeal exudative reaction, focal abscesses or granulomas in the brain or spinal epidural space, cerebral infarction related to vasculitis, and ventricular enlargement caused by communicating hydrocephalus.
Clinical Findings Fungal meningitis is usually a subacute illness that clinically resembles tuberculous meningitis. A history of a predisposing condition such as carcinoma, hematologic malignancy, AIDS, diabetes, organ transplantation, treatment with corticosteroids or cytotoxic agents, prolonged antibiotic therapy, or intravenous drug use increases the suspicion of opportunistic infection. Patients also should be asked about recent travel through areas where certain fungi are endemic. A. SYMPTOMS AND SIGNS Common symptoms include headache and lethargy or confusion. Nausea, vomiting, visual loss, seizures, or focal weakness may be noted, while fever may be absent. In a diabetic patient with acidosis, complaints of facial or eye pain, nasal discharge, proptosis, or visual loss should urgently alert the physician to the likelihood of Mucor infection. Careful examination of the skin, orbits, sinuses, and chest may reveal evidence of systemic fungal infection. Neurologic examination may show signs of meningeal irritation, a confusional state, papilledema, visual loss, ptosis, exophthalmos, ocular or other cranial nerve palsies, and focal neurologic abnormalities such as hemiparesis. Because some fungi (eg, Cryptococcus) can cause spinal cord compression, there may be evidence
DISORDERS OF COGNITIVE FUNCTION / 33 Table 1–18. Etiologic agents in fungal meningitis. Name
Geographic Distribution
Opportunistic Infection
Systemic Involvement
Distinctive CSF Findings
Treatment
Cryptococcus Nonspecific neoformans
Sometimes Lungs, skin, bones, (including AIDS) joints
Viscous fluid, positive India ink prep, positive cryptococcal antigen
Amphotericin B + flucytosine (amphotericin B or amphotericin B + fluconazole for AIDS patients)
Coccidioides immitis
Southwestern USA
No
Lungs, skin, bones
Positive complement fixation
Amphotericin B (intravenous and intrathecal), fluconazole, or itraconazole
Candida species
Nonspecific
Yes
Mucous membranes, skin, esophagus, genitourinary tract, heart
Positive Gram stain
Amphotericin B + flucytosine
Aspergillus species
Nonspecific
Yes
Lungs, skin
Polymorphonuclear pleocytosis
Amphotericin B
Mucor species
Nonspecific
Yes, diabetics
Orbits, paranasal sinuses
Amphotericin B + correction of hyperglycemia and acidosis
Histoplasma capsulatum
Eastern and midwestern USA
Sometimes
Lungs, skin, mucous membranes, heart, viscera
Amphotericin B
Blastomyces Mississippi dermatitidis River Valley
No
Lungs, skin, bones, joints, viscera
Amphotericin B
Actinomyces israelii1
Nonspecific
No
Jaw, lungs, abdomen, orbits, sinuses, skin
Sulfur granules, positive Gram stain, AFB smear
Penicillin G or tetracycline
Nocardia species1
Nonspecific
Yes
Lungs, skin
Positive Gram stain, AFB smear
Sulfonamides
1
Actinomyces and Nocardia are filamentous bacteria that are traditionally considered together with fungi.
of spine tenderness, paraparesis, pyramidal signs in the legs, and loss of sensation over the legs and trunk. B. LABORATORY FINDINGS Blood cultures should be obtained. Serum glucose and arterial blood gas levels should be determined in diabetic patients. The urine should be examined for Candida. Chest x-ray may show hilar lymphadenopathy, patchy or miliary infiltrates, cavitation, or pleural effusion. The CT scan or MRI may demonstrate intracerebral mass lesions associated with Cryptococcus (Figure 1–7) or other organisms, a contiguous infectious source in the orbit or paranasal sinuses, or hydrocephalus. CSF pressure may be normal or elevated, and the fluid is usually clear, but may be viscous in the presence of numerous cryptococci. Lymphocytic pleocytosis of
up to 1000 cells/mL is common, but a normal cell count or polymorphonuclear pleocytosis can be seen in early fungal meningitis and normal cell counts are common in immunosuppressed patients. Aspergillus infection typically produces a polymorphonuclear pleocytosis. CSF protein, which may be normal initially, subsequently rises, usually to levels not exceeding 200 mg/dL. Higher levels (<1 g/dL) suggest possible subarachnoid block. Glucose is normal or decreased but rarely below 10 mg/dL. Microscopic examination of Gram-stained and acid-fast smears and India ink preparations may reveal the infecting organism (see Table 1–18). Fungal cultures of CSF and other body fluids and tissues should be obtained, but are often negative. In suspected mucormycosis, biopsy of the affected tissue (usually nasal mucosa) is essential. Useful CSF sero-
34 / CHAPTER 1
T
T
Figure 1–7. T2-weighted MRI in cryptococcal meningitis. Note the bilateral increase in signal in the basal ganglia (arrows) with relative sparing of the thalami (T). This is due to the presence of gelatinous fungal pseudocysts in the territory of the lenticulostriate arteries. (Courtesy of A Gean.)
logic studies include cryptococcal antigen and Coccidioides complement-fixing antibody. Cryptococcal antigen is more sensitive than India ink for detecting Cryptococcus, and should always be looked for in both CSF and serum when that organism is suspected, as in patients with AIDS.
Differential Diagnosis Fungal meningitis may mimic brain abscess and other subacute or chronic meningitides, such as those due to tuberculosis or syphilis. CSF findings and contrast CT scans are useful in differential diagnosis.
Treatment & Prognosis For most organisms causing fungal meningitis, treatment is begun with amphotericin B deoxycholate, 1 mg intravenously as a test dose given over 20–30 minutes, followed the next day by 0.3 mg/kg intravenously in 5% dextrose, given over 2–3 hours. The dose is then increased daily in 5- to 10-mg increments until a maximal dose of 0.5–1.5 mg/kg/d is reached. Treatment is usually continued for 12 weeks.
Nephrotoxicity is common with amphotericin B and may force interruption of therapy for 2–5 days. Newer, lipid-based formulations (eg, amphotericin B lipid complex, amphotericin B cholesteryl sulfate, liposomal amphotericin B) are less nephrotoxic, and can be used in patients who develop such toxicity on amphotericin B deoxycholate. In patients with Coccidioides meningitis or those not responding to intravenous therapy, intrathecal amphotericin B (usually administered via an Ommaya reservoir) is added. The drug is given as a 0.1-mg test dose diluted in 10 mL of CSF, with or without added corticosteroids, and increased to 0.25–0.5 mg every other day. Because administration of amphotericin into the CSF may produce side effects, may require instillation at multiple sites, and may be unsuccessful, another approach is to give fluconazole, 400–600 mg/d, or itraconazole, 200 mg twice daily with meals, by the oral route. In this case, treatment must be continued indefinitely. In cryptococcal meningitis, flucytosine, 100 mg/kg/d orally, added to amphotericin B and given in four divided doses, reduces the duration of therapy from 12 to 6 weeks. The dose of flucytosine must be reduced in renal failure; the major side effect is bone marrow suppression, which is usually reversible. Because of this toxicity, flucytosine is usually omitted when treating cryptococcal meningitis in patients with AIDS. For patients with AIDS and cryptococcal meningitis who do not respond to amphotericin B alone, fluconazole can be added at an initial dose of 400 mg, followed by 200 mg/d, orally or intravenously, for at least 10–12 weeks after CSF cultures are negative. Long-term maintenance therapy with fluconazole, 100–200 mg/d orally, may also reduce the likelihood of recurrence following successful treatment of cryptococcal meningitis in patients with AIDS. Rapid correction of hyperglycemia and acidosis must be combined with amphotericin B treatment and surgical debridement of necrotic tissue in diabetics with mucormycosis. Mortality rates remain high in fungal meningitis. The complications of therapy are frequent, and neurologic residua are common.
PARASITIC INFECTIONS Protozoal and helminthic infections are important causes of central nervous system disease, particularly in immunosuppressed patients (including those with AIDS), and in certain regions of the world (Table 1–19). Rickettsias, the parasitic bacteria that cause Rocky Mountain spotted fever, rarely affect the nervous system. 1. MALARIA Malaria is caused by the protozoan Plasmodium falciparum or another Plasmodium species that is transferred
DISORDERS OF COGNITIVE FUNCTION / 35 Table 1–19. Parasitic infections of the central nervous system. Parasite Protozoa Plasmodium falciparum (malaria)
Epidemiologic and Geographic Factors
Clinical Syndrome
Laboratory Findings
Treatment
Africa, South America, Acute confusional state, Anemia, organisms Southeast Asia, Oceania coma, seizures within red blood cells on peripheral blood smear
Chloroquine (chloroquine sensitive) or quinidine or quinine sulfate (chloroquine resistant)
Toxoplasma gondii
Malignancy or immunosuppression (including AIDS)
Single or multiple focal mass lesions; meningoencephalitis; encephalopathy ± asterixis, myoclonus, or seizures
Positive CT/MRI brain scan; positive SabinFeldman dye test; positive IgM antibody; CSF: normal or lymphocytic pleocytosis, organism on wet mount
Pyrimethamine and sulfadiazine
Naegleria fowleri (primary amebic meningoencephalitis)
Freshwater swimming in southeastern USA
Acute fulminant meningoencephalitis with prominent headache and meningeal signs
CSF: polymorphonuclear pleocytosis, motile organisms on wet mount
Amphotericin B with or without rifampin and chloramphenicol or ketoconazole
Acanthamoeba or Hartmanella species (granulomatous amebic encephalitis)
Chronic illness or immunosuppression
Subacute-chronic meningoencephalitis, often with seizures and focal neurologic signs
CSF: lymphocytic or polymorphonuclear pleocytosis, sluggish organisms on wet mount
None proven
Latin America
Mass lesion or meningoencephalitis, often presenting with headache or seizures
CSF: lymphocytic, pleocytosis, eosinophilia, positive complement fixation or hemagglutination; calcifications on soft tissue x-rays or brain CT scan
Albendazole or praziquantel, corticosteroids, surgical excision of solitary lesion, shunting for hydrocephalus
Hawaii, Asia
Acute-subacute meningitis with headache; stiff neck, vomiting, fever, and paresthesias in about half of patients; selflimited course of 1–2 weeks
Peripheral blood eosinophilia; CSF: eosinophilic and lymphocytic pleocytosis
Mebendazole, levamisole, albendazole, thiabendazole, or ivermectin
Southeastern USA
Acute fever, headache, rash; confusion uncommon
Positive Weil-Felix reaction
Chloramphenicol or doxycycline
Helminths Taenia solium (cysticercosis)
Angiostrongylus cantonensis (eosinophilic meningitis)
Rickettsia Rickettsia rickettsii (Rocky Mountain spotted fever)
36 / CHAPTER 1 to humans by the female Anopheles mosquito. Clinical features include fever, chills, myalgia, nausea and vomiting, anemia, renal failure, hypoglycemia, and pulmonary edema. Although malaria is the most common parasitic infection of humans worldwide, cerebral involvement is rare. Plasmodia reach the central nervous system in infected red blood cells and cause occlusion of cerebral capillaries. Neurologic involvement becomes apparent weeks after infection. In addition to acute confusional states, cerebral malaria can produce seizures and, rarely, focal neurologic abnormalities. The diagnosis is made by finding plasmodia in red blood cells of peripheral blood smears. The CSF may show increased pressure, xanthochromia, mononuclear pleocytosis, or mildly elevated protein.
Prophylaxis Malaria prophylaxis is recommended for travelers to areas where the disease is endemic and consists of chloroquine phosphate, 500 mg orally weekly, beginning 1–2 weeks before travel and continuing until 4 weeks after returning. If exposure to chloroquine-resistant strains is expected, treatment options include mefloquine (250 mg orally weekly for 4 weeks, beginning 1–2 weeks before travel and continuing until 4 weeks after returning), doxycycline (100 mg orally daily, beginning 1–2 days before travel and continuing until 4 weeks after returning), or atovaquone/proguanil (250/100 mg orally daily, beginning 1–2 days before travel and continuing until 1 week after returning).
2. TOXOPLASMOSIS Toxoplasmosis results from ingestion of Toxoplasma gondii cysts in raw meat or cat excrement and is usually asymptomatic. Symptomatic infection is associated with underlying malignancy (especially Hodgkin disease), immunosuppressive therapy, or AIDS.
Clinical Findings Systemic manifestations include skin rash, lymphadenopathy, myalgias, arthralgias, carditis, pneumonitis, and splenomegaly. Central nervous system involvement can take several forms (see Table 1–19). The CSF may be normal, or it may show mild mononuclear cell pleocytosis or slight protein elevation. MRI is superior to CT scanning for demonstrating cerebral toxoplasmosis, and typically shows ring-enhancing lesions (Figure 1–8). The diagnosis is made by blood tests demonstrating a high (≥1:32,000) or rising Sabin-Feldman dye test titer or IgM antibodies to Toxoplasma by indirect immunofluorescence. Accurate diagnosis requires appropriate serologic studies in the immunosuppressed patient who develops neurologic symptoms.
Treatment Chloroquine-sensitive cerebral malaria is treated with chloroquine, 10 mg base/kg by continuous intravenous infusion over 8 hours followed by 15 mg base/kg over 24 hours, or 3.5 mg base/kg by the intramuscular or subcutaneous route every 6 hours to a cumulative dose of ∼25 mg base/kg. Chloroquine-resistant cerebral malaria is treated with quinidine, 10 mg base/kg by intravenous infusion over 1 hour followed by 0.02 mg base/kg/min, or with quinine dihydrochloride (not available in the United States), 20 mg/kg by intravenous infusion over 4 hours followed by 10 mg/kg infused over 2–8 hours every 8 hours. Each of these regimens is continued until oral therapy with chloroquine, amodiaquine, or sulfadoxine and pyrimethamine (for chloroquine-sensitive malaria) or with mefloquine, quinine, or quinidine (for chloroquine-resistant malaria) can be substituted. Cerebral edema is not a consistent finding in cerebral malaria, and corticosteroids are not helpful and may be deleterious. The mortality rate in cerebral malaria is 20–50% and reaches 80% in cases complicated by coma and seizures.
Figure 1–8. T1-weighted, gadolinium-enhanced MRI in cerebral toxoplasmosis complicating HIV infection. Note the multiple ring-enhanced lesions (arrows) with surrounding edema. (Courtesy of A Gean.)
DISORDERS OF COGNITIVE FUNCTION / 37
Treatment Treatment is with pyrimethamine, 25–100 mg/d orally and sulfadiazine, 1–1.5 g orally four times daily, and is continued for 3–4 weeks in immunocompetent patients and for at least several months in immunodeficient patients. Clindamycin, 600 mg orally four times a day, may be substituted for sulfonamides in patients who develop drug sensitivity rashes. Folinic acid (leucovorin), 10 mg orally daily, is added to prevent pyrimethamine-induced leukopenia and thrombocytopenia. 3. PRIMARY AMEBIC MENINGOENCEPHALITIS The free-living ameba Naegleria fowleri causes primary amebic meningoencephalitis in previously healthy young patients exposed to polluted water. Amebas gain entry to the central nervous system through the cribriform plate, producing a diffuse meningoencephalitis that affects the base of the frontal lobes and posterior fossa. It is characterized by headache, fever, nausea and vomiting, signs of meningeal irritation, and disordered mental status. The CSF shows a polymorphonuclear pleocytosis with elevated protein and low glucose; highly motile, refractile trophozoites can be seen on wet mounts of centrifuged CSF. The disease is usually fatal within 1 week, although treatment with amphotericin B, 1 mg/kg/d intravenously, may be effective, as may a combination of amphotericin B, rifampin, and chloramphenicol or ketoconazole.
manifestations of cysticercosis result from the mass effect of intraparenchymal cysts, obstruction of CSF flow by intraventricular cysts, or inflammation that causes basilar meningitis. They include seizures, headache, focal neurologic signs, hydrocephalus, myelopathy, and subacute meningitis. Peripheral blood eosinophilia, soft tissue calcifications, or parasites in the stool suggest the diagnosis. The CSF typically shows a lymphocytic pleocytosis (<100 cells/mL), with eosinophils usually present. Opening pressure is often increased but may be decreased with spinal subarachnoid block; if this is suspected, myelography should be performed. Protein is increased to 50–100 mg/dL, and glucose is 20–50 mg/dL in most cases. Complement fixation and hemagglutination studies can assist in the diagnosis. The CT scan or MRI may show contrast-enhanced mass lesions with surrounding edema, intracerebral calcifications, or ventricular enlargement (Figure 1–9). The indications for treatment of cerebral cysticercosis are controversial. However, patients with symptomatic neurologic involvement (usually seizures) and either meningitis or one or more noncalcified intraparenchymal cysts should be treated. Intraventricular, subarachnoid, and racemose cysts respond poorly to treatment, and calcified cysts do not require treatment. Albendazole, 15 mg/kg/d in three doses taken with meals, and continued for 8 days, is the preferred therapy. Praziquantel, 50 mg/kg/d in three divided
4. GRANULOMATOUS AMEBIC ENCEPHALITIS Granulomatous amebic encephalitis results from infection with Acanthamoeba/Hartmanella species and commonly occurs with chronic illness or immunosuppression. The disorder typically lasts for from 1 week to 3 months and is characterized by subacute or chronic meningitis and granulomatous encephalitis. The cerebellum, brainstem, basal ganglia, and cerebral hemispheres are affected. An acute confusional state is the most common clinical finding. Fever, headache, and meningeal signs each occur in only about half of patients. Seizures, hemiparesis cranial nerve palsies, cerebellar ataxia, and aphasia may occur. Pleocytosis may be primarily lymphocytic or polymorphonuclear; protein is elevated, and glucose is low or normal. Sluggishly motile trophozoites may be seen on wet mounts. Successful treatment has not been reported. 5. CYSTICERCOSIS Cysticercosis is common in Mexico, Central and South America, western and southern Africa, India, China, and southeast Asia. The disease follows ingestion of larvae of the pork tapeworm (Taenia solium) and affects the brain in 60–90% of cases. Larvae undergo hematogenous dissemination, forming cysts in the brain, ventricles, and subarachnoid space. Neurologic
Figure 1–9. Contrast-enhanced CT scan in cerebral cysticercosis. Note the multiple bilateral, small, rounded areas of high density, which represent intraparenchymal cysts. (Courtesy of A Gean.)
38 / CHAPTER 1 doses, can also be used, but blood levels are reduced by anticonvulsants and corticosteroids, which are often also required in these patients. Patients with seizures should also receive anticonvulsants. Corticosteroids are indicated for increased intracranial pressure or lesions near the cerebral aqueduct or intraventricular foramina; these may progress to cause obstructive hydrocephalus. Single accessible intraparenchymal lesions can be removed surgically, and shunting is required for intraventricular lesions causing hydrocephalus.
and a characteristic rash that involves the palms and soles and spreads centrally. Neurologic involvement, which is uncommon, produces a confusional state and, less often, coma or focal neurologic abnormalities. The CSF is normal or shows a mild mononuclear pleocytosis. Treatment is with chloramphenicol, 25–50 mg/kg/d orally or intravenously in four divided doses, or doxycycline, 200 mg/d orally or intravenously, and is continued for 7 days. Neurologic residua may occur.
6. ANGIOSTRONGYLUS CANTONENSIS MENINGITIS Angiostrongylus cantonensis is endemic to southeast Asia and to Hawaii and other Pacific islands. Infection is transmitted by ingestion of infected raw mollusks and produces meningitis with CSF eosinophilia (Table 1–20). Most patients complain of headache, and about half report stiff neck, vomiting, fever, and paresthesias. Most patients have a CSF leukocytosis of 150–1500/mL, mild elevation of protein, and normal glucose. The acute illness usually resolves spontaneously in 1–2 weeks, although paresthesias may persist longer. Levamisole, albendazole, thiabendazole, mebendazole, and ivermectin have been used for treatment; mebendazole 100 mg twice daily orally for 5 days may be preferable. Analgesics, corticosteroids, and reduction of CSF pressure by repeated lumbar punctures may be of value.
LEPTOMENINGEAL METASTASES
7. ROCKY MOUNTAIN SPOTTED FEVER Rocky Mountain spotted fever is caused by Rickettsia rickettsii, an intracellular parasite transmitted to humans by tick bites. R rickettsii damages endothelial cells, leading to vasculitis, microinfarcts, and petechial hemorrhage. Initial symptoms include fever, headache,
Table 1–20. Causes of CSF eosinophilia. Common causes Taenia solium (cysticercosis) Angiostrongylus cantonensis (eosinophilic meningitis) Uncommon causes Other helminthic infections Coccidioides immitis meningitis Hematologic malignancies with meningeal infiltration Foreign matter (including myelography dye) in subarachnoid space Possible causes (less well documented) Neurosyphilis Tuberculous meningitis Nonhematologic malignancies with meningeal infiltration Lymphocytic choriomeningitis Polyarteritis nodosa Allergic reactions
Diffuse metastatic seeding of the leptomeninges may complicate systemic cancer (especially acute lymphocytic leukemia, non-Hodgkin lymphoma, melanoma, acute myelogenous leukemia, carcinoma of the breast, Hodgkin lymphoma, carcinoma of the lung, carcinoma of the gastrointestinal tract, and sarcoma), producing neurologic syndromes with prominent cognitive dysfunction. Primary brain tumors may be associated with meningeal gliomatosis, and medulloblastomas and pineal tumors have a particular propensity for meningeal dissemination. Neoplastic meningitis usually occurs from 3 months to 5 years after the diagnosis of cancer, but may be the presenting manifestation or occur after many years of illness—sometimes in apparently cured patients. Its most frequent symptoms are headache and cognitive disorders, including lethargy, confusion, and memory impairment. Nausea, vomiting, seizures, and gait abnormalities are also common.
Clinical Findings A. SYMPTOMS AND SIGNS Abnormal neurologic signs are often more striking than the symptoms and usually suggest involvement at multiple levels of the neuraxis. The symptoms and signs most often seen when the patient presents with leptomeningeal metastases are listed in Table 1–21. B. LABORATORY FINDINGS The most useful diagnostic procedure is lumbar puncture, which may show increased opening pressure, pleocytosis and elevated protein, and markedly decreased or even immeasurably low glucose (see Table 1–21). Neoplastic meningitis is diagnosed by finding malignant cells in the CSF; large volumes of fluid and repeated lumbar punctures increase the yield of cytologic studies. Several biochemical markers for leptomeningeal metastases can be identified in CSF. These include carcinoembryonic antigen, human chorionic gonadotropin, and α-fetoprotein, which are specific for leptomeningeal metastases, as well as β2-microglobulin, β-glucuronidase, and lactic dehydrogenase isozyme V, which also can be elevated in inflammatory disorders.
DISORDERS OF COGNITIVE FUNCTION / 39 Table 1–21. Presenting symptoms, signs, and CSF findings with leptomeningeal metastases. Feature Symptoms Gait disturbance
Percentage of Patients
Differential Diagnosis 46
Headache
38
Altered mentation
25
Weakness
22
Back pain
18
Nausea or vomiting
12
Radicular pain
12
Paresthesias
10
Signs Lower motor neuron weakness
78
Treatment & Prognosis Untreated, leptomeningeal metastases are typically associated with death within about 2 months. Leptomeningeal leukemia and lymphoma can be successfully treated with radiation and chemotherapy, and some patients with breast cancer or small-cell lung cancer also respond to these approaches. However, even with treatment, most patients with leptomeningeal metastases from solid tumors live only a few months.
60
Cognitive disturbance
50
Extensor plantar response
50
SEPSIS
Dermatomal sensory deficit
50
Ophthalmoplegia
30
Facial weakness
25
Hearing loss
20
Neck meningeal signs
16
Seizures
14
Papilledema
12
Systemic sepsis can produce an encephalopathy that may be related to impaired cerebral blood flow, disruption of the blood-brain barrier, or cerebral edema. Gram-negative infections are the most common cause. Clinical findings include bacteremia and often liver or kidney failure. The EEG is often abnormal. Therapy involves supportive measures, such as assisted ventilation, and treatment of the underlying infection. Mortality is high, but can be prevented by prompt diagnosis and treatment.
Facial sensory deficit
12
Leg meningeal signs
12
VASCULAR DISORDERS HYPERTENSIVE ENCEPHALOPATHY
81
Pleocytosis2
57
Positive cytology
54
Opening pressure elevated3
50
Glucose decreased4
31
Normal
3
>50 mg/dL. >5 white blood cells/mm3. 3 >160 mm CSF. 4 <40 mg/dL. Data from Posner JB: Neurologic Complications of Cancer. Davis, 1997. 2
Neoplastic meningitis can simulate infectious meningitis, metabolic encephalopathy, intraparenchymal or spinal epidural metastasis, remote effects of carcinoma, or chemotherapeutic drug toxicity and may coexist with any of these conditions.
Absent tendon reflex
CSF findings Protein increased1
1
Where clinically indicated, MRI or a metrizamide CT study of the spine, or myelography is performed to exclude the possibility of intraparenchymal metastasis or spinal cord compression by epidural metastasis.
A sudden increase in blood pressure, with or without preexisting chronic hypertension, may result in encephalopathy and headache, which develop over a period of several hours to days. Vomiting, visual disturbances, focal neurologic deficits, and focal or generalized seizures can also occur. Blood pressure in excess of 250/150 mm Hg is usually required to precipitate the syndrome in patients with chronic hypertension; previously normotensive patients may be affected at lower pressures. Coexisting renal failure appears to increase the risk of hypertensive encephalopathy. Cerebrovascular spasm, impaired autoregulation of cerebral blood flow, and intravascular coagulation have all been proposed as the cause of neurological symptoms. These processes can lead to small infarcts and petechial hemorrhages that affect the brainstem most
40 / CHAPTER 1 prominently and other subcortical gray and white matter regions to a lesser extent.
Clinical Findings The physical findings most useful in confirming the diagnosis are those seen on ophthalmoscopy. Retinal arteriolar spasm is almost invariably present. Papilledema, retinal hemorrhages, and exudates are usually present. Lumbar puncture may show normal or elevated CSF pressure and protein. Low-density areas suggestive of edema in the posterior regions of hemispheric white matter are seen on CT scan and corresponding T2 hyperintense areas are seen on MRI (Figure 1–10); the changes are reversible with treatment. Blood studies are important to detect uremia.
Differential Diagnosis Hypertensive encephalopathy is a diagnosis of exclusion. Stroke and subarachnoid hemorrhage also produce encephalopathy with acutely elevated blood pressure, and when focal neurologic abnormalities are present, stroke is by far the most likely diagnosis. Elevated blood pressure, headache, papilledema, and altered consciousness are also seen with intracranial hemorrhage; where this is a consideration, it can be excluded by CT scan or MRI.
Prevention Hypertensive encephalopathy is best prevented by early treatment of uncomplicated hypertension and by prompt recognition of elevated blood pressure in settings—such as acute glomerulonephritis or eclampsia—in which it tends to occur in previously normotensive patients.
Treatment The diagnosis of hypertensive encephalopathy is established when lowering the blood pressure results in rapid resolution of symptoms. This is accomplished with sodium nitroprusside, given by continuous intravenous infusion at an initial rate of 0.5 mg/kg/min, and increased to as much as 3–10 mg/kg/min as required. Alternative approaches include diazoxide, 50–100 mg by intravenous bolus every 5–10 minutes (to a maximum of 600 mg) or 10–30 mg/min by constant intravenous infusion, or labetalol, 20–80 mg by intravenous bolus every 5–10 minutes (to a maximum of 600 mg) or 0.5–2 mg/min by constant intravenous infusion. The patient must be carefully monitored and the infusion rate adjusted to maintain a therapeutic effect without producing hypotension. In the first hour of treatment, mean arterial blood pressure should be reduced by no more than 20–25% and diastolic pressure should not
Figure 1–10. Axial T2-weighted images of the brain of a 39-year-old woman who developed hypertensive encephalopathy in the setting of chronic renal failure. Areas of abnormal high intensity (arrows) represent edema affecting posterior parietal and occipital regions, white matter more than gray. Similar imaging changes can sometimes be seen following generalized seizures and with certain drugs, particularly cyclosporine and chemotherapeutic agents. Imaging abnormalities typically resolve with treatment of the underlying condition. (Courtesy of HA Rowley.)
DISORDERS OF COGNITIVE FUNCTION / 41 be allowed to fall below 100 mm Hg. Treatment should be terminated immediately if neurologic function worsens. Untreated hypertensive encephalopathy can result in stroke, coma, or death but prompt treatment usually produces full clinical recovery.
SUBARACHNOID HEMORRHAGE Subarachnoid hemorrhage must receive early consideration in the differential diagnosis of an acute confusional state. This disorder is discussed in Chapter 2.
VERTEBROBASILAR ISCHEMIA Transient ischemia or stroke in the distribution of the posterior cerebral circulation can produce an acute confusional state. Vertebrobasilar ischemia is discussed in Chapter 9.
RIGHT (NONDOMINANT) HEMISPHERIC INFARCTION Agitated confusion of sudden onset can result from infarction (usually embolic) in the territory of the inferior division of the nondominant (usually right) middle cerebral artery. If the superior division is spared, there is no hemiparesis. Agitation may be so pronounced as to suggest an alcohol withdrawal syndrome, but autonomic hyperactivity is absent. The diagnosis is confirmed by CT brain scan or MRI. Rarely, isolated anterior cerebral artery infarcts or posterior cerebral artery infarcts cause acute confusion.
SYSTEMIC LUPUS ERYTHEMATOSUS Systemic lupus erythematosus (SLE) is the most common autoimmune cause of encephalopathy. SLE is nine times more common in women than in men and usually has its onset between the ages of 10 and 40 years. Neurologic involvement is reported in 37–75% of patients. The clinical features that correlate best with nervous system involvement are active mucocutaneous or visceral vasculitis and thrombocytopenia, but clinically active systemic disease need not be present for neurologic symptoms to occur. Neuropathologic findings include fibrinoid degeneration of arterioles and capillaries, microinfarcts, and intracerebral hemorrhages. True vasculitis of cerebral blood vessels is rare.
Clinical Findings A. SYMPTOMS AND SIGNS The most common neurologic features are seizures and an altered mental status. Cognitive disturbances include acute confusional states, schizophreniform psychosis,
depression, and mania. Seizures are usually generalized but may be focal. Less common neurologic manifestations include visual impairment from optic nerve involvement, ptosis, diplopia, hemiparesis, paraparesis, tremor, chorea, cerebellar ataxia, and polyneuropathy. B. LABORATORY FINDINGS Laboratory abnormalities in SLE include antinuclear antibodies, anemia, hypocomplementemia, antinative DNA antibodies, leukopenia, and autoantibodies against ribosomal P proteins. No laboratory finding is diagnostic of nervous system involvement, but CSF shows mild elevation of protein or a modest—usually mononuclear—pleocytosis in about one-third of cases. The EEG frequently shows diffuse slowing or focal abnormalities.
Differential Diagnosis Even in patients with known SLE, encephalopathy can be caused by a variety of factors other than cerebral lupus per se. Coagulopathy, infection, uremia, and emboli from endocarditis must be excluded. A common dilemma is the need to distinguish cerebral lupus from steroid-induced psychosis in patients receiving corticosteroid therapy for SLE. Cerebral lupus is by far the more frequent problem, particularly in patients receiving low or tapering doses of steroids.
Treatment Cerebral lupus is treated with corticosteroids, beginning at 60 mg/d of prednisone or the equivalent. In patients already receiving steroids, the dose should be increased by the equivalent of 5–10 mg/d of prednisone. After symptoms resolve, steroids should be tapered to a low maintenance dose. Seizures are treated with anticonvulsants.
Prognosis Neurologic symptoms of SLE improve in more than 80% of patients treated with corticosteroids, but may also resolve without treatment. Cerebral involvement in SLE has not been shown to adversely affect the overall prognosis.
DISSEMINATED INTRAVASCULAR COAGULATION Disseminated intravascular coagulation (DIC) results from pathologic activation of the coagulation and fibrinolytic systems, usually in the setting of a severe underlying systemic disease. The principal manifestation is hemorrhage. DIC tends to occur at the extremes of age, but patients of any age can be affected. Common findings in the brain include small multifocal infarctions
42 / CHAPTER 1 and petechial hemorrhages involving both gray and white matter. Subdural hematoma, subarachnoid hemorrhage, and hemorrhagic infarction in the distribution of large vessels may also occur.
matter. The antiplatelet drugs ticlopidine and clopidogrel can precipitate TTP, but how this occurs is unclear.
Clinical Findings
A. SYMPTOMS AND SIGNS Patients most often present with altered consciousness, headache, focal neurologic signs, or seizures or with cutaneous hemorrhages in the form of purpura, ecchymoses, or petechiae. Other symptoms include malaise, fatigue, generalized weakness, nausea, vomiting, diarrhea, fever, and abdominal pain. Bleeding from sites other than the skin may occur. Neurologic symptoms may be fleeting and recurrent. The physical examination is helpful in documenting fever, cutaneous hemorrhage, and neurologic dysfunction. TTP usually follows an acute, fulminant course but can be a chronic progressive or remitting and relapsing disorder lasting from months to years. What accounts for the defect in von Willebrand factor-cleaving protease activity in chronic cases is unknown.
Neurologic manifestations are common and include confusional states, coma, focal signs, and seizures. They may precede the definitive hematologic abnormalities of hypofibrinogenemia, thrombocytopenia, fibrin degradation products, and prolonged prothrombin time. Microangiopathic hemolytic anemia may also occur.
Differential Diagnosis Disorders that must be excluded include metabolic encephalopathy, meningoencephalitis, metastatic involvement of the brain or meninges, or stroke caused by nonbacterial thrombotic (marantic) endocarditis. Thrombotic thrombocytopenic purpura (TTP) is distinguished by its tendency to occur in previously healthy patients and its association with normal plasma fibrinogen and normal or only slightly elevated fibrin degradation products.
Treatment Treatment is directed at the underlying disease. Transfusion of red blood cells, platelets, and coagulation factors from fresh-frozen plasma may be indicated. Transfused platelets are often rapidly destroyed, however, and transfused coagulation factors may be converted to anticoagulant fibrin degradation products and worsen the hemorrhagic tendency. Heparin sometimes has been advocated because of its ability to inhibit the coagulation cascade, but its utility is uncertain. Prognosis is related to the severity of the underlying disease.
THROMBOTIC THROMBOCYTOPENIC PURPURA Thrombotic thrombocytopenic purpura (TTP) is a rare multisystem disorder defined by the pentad of thrombocytopenic purpura, microangiopathic hemolytic anemia, neurologic dysfunction, fever, and renal disease. In most cases, the cause is thought to be an IgG-mediated autoimmune reaction against a von Willebrand factorcleaving protease, which allows unusually large multimers of von Willebrand factor to accumulate in the plasma, where they stimulate platelet aggregation. The result is platelet-fibrin thrombus formation with occlusion of small blood vessels, especially at arteriolar-capillary junctions. Pathologic findings in the brain include disseminated microinfarcts and, less frequently, petechial hemorrhages that are present mainly in gray
Clinical Findings
B. LABORATORY FINDINGS Hematologic studies show a Coombs-negative hemolytic anemia with hemoglobin levels usually less than 10 g/dL, normochromic red blood cell indices, fragmented and misshapen erythrocytes, and often nucleated red cells. Platelet counts are less than 20,000/mL in about half the cases and less than 60,000/mL in almost all cases; the white blood cell count is normal or elevated. Coagulation studies are normal or slightly abnormal in most patients: PT and PTT are normal in about 90% of cases and fibrinogen is normal in 80%. Fibrin degradation products are normal in about 50% of cases and slightly elevated in about 25%. Renal involvement may cause hematuria, proteinuria, or azotemia. Spinal fluid is usually normal, but protein may be elevated. Antemortem pathologic diagnosis may be made by gingival biopsy or splenectomy.
Differential Diagnosis DIC is also associated with hemolytic anemia or thrombocytopenia. Idiopathic thrombocytopenic purpura (ITP) is not accompanied by microangiopathic hemolytic anemia or by evidence of multisystem disease. The hemolytic anemias of SLE, autoimmune hemolytic anemia (AIHA), and Evans syndrome (both ITP and AIHA) are Coombs-positive.
Treatment & Prognosis Plasmapheresis is the mainstay of therapy and is sometimes combined with prednisone and antiplatelet agents (aspirin, 325 mg three times daily and dipyridamole, 75 mg three times daily). With treatment, >80% of patients recover, although relapses may occur.
DISORDERS OF COGNITIVE FUNCTION / 43
HEAD TRAUMA Blunt head trauma can produce a confusional state or coma. Acceleration or deceleration forces and physical deformation of the skull can cause shearing of white matter, contusion from contact between the inner surface of the skull and the polar regions of the cerebral hemispheres, torn blood vessels, vasomotor changes, brain edema, and increased intracranial pressure.
CONCUSSION Concussion is characterized by transient loss of consciousness for seconds to minutes without demonstrable structural defects. Unconsciousness is associated with normal pupillary and ocular reflexes, flaccidity, and extensor plantar responses. The return of consciousness is followed by a confusional state that usually lasts from minutes to hours, and is characterized by prominent retrograde and anterograde amnesia (see below). Patients with simple concussion usually recover uneventfully, although headache, dizziness, or mild cognitive impairment may persist for weeks. When unconsciousness is prolonged, delayed in onset after a lucid interval, or associated with focal neurologic abnormalities, the possibility of posttraumatic intracranial hemorrhage should be considered.
INTRACRANIAL HEMORRHAGE Traumatic intracranial hemorrhage can be epidural, subdural, or intracerebral. Epidural hematoma most often results from a lateral skull fracture that lacerates the middle meningeal artery or vein. Patients may or may not lose consciousness initially, but in either event a lucid interval lasting several hours to 1–2 days is followed by the rapid evolution—over hours—of headache, progressive obtundation, hemiparesis, and finally ipsilateral pupillary dilatation from uncal herniation. Death may follow if treatment is delayed. Subdural hematoma after head injury can be acute, subacute, or chronic. In each case, headache and altered consciousness are the principal manifestations. Delay in diagnosis and treatment may lead to a fatal outcome. In contrast to epidural hematoma, the time between trauma and the onset of symptoms is typically longer, the hemorrhage tends to be located over the cerebral convexities, and associated skull fractures are uncommon. Subdural hematoma in the posterior fossa is uncommon. Intracerebral contusion (bruising) or hemorrhage related to head injury is usually located at the frontal or temporal poles. Blood typically enters the CSF, resulting in signs of meningeal irritation and sometimes hydrocephalus. Focal neurologic signs are usually absent or subtle. The diagnosis of posttraumatic intracranial hemor-
rhage is made by CT scan or MRI. Epidural hematoma tends to appear as a biconvex, lens-shaped, extra-axial mass that may cross the midline or the tentorium but not the cranial sutures. Subdural hematoma is typically crescent-shaped and may cross the cranial sutures but not the midline or tentorium. Midline structures may be displaced contralaterally. Epidural and subdural hematomas are treated by surgical evacuation. The decision to use surgery to treat intracerebral hematoma depends upon the clinical course and location. Evacuation, decompression, or shunting for hydrocephalus may be indicated.
SEIZURES POSTICTAL STATE Generalized tonic-clonic (grand mal) seizures are typically followed by a transient confusional state (postictal state) that resolves within 1–2 hours. Disturbances of recent memory and of attention are prominent. When postictal confusion does not clear rapidly, an explanation for the prolonged postictal state must be sought. This occurs in three settings: status epilepticus, an underlying structural brain abnormality (eg, stroke, intracranial hemorrhage), and an underlying diffuse cerebral disorder (eg, dementia, meningitis or encephalitis, metabolic encephalopathy). Patients with an unexplained prolonged postictal state should be evaluated with blood chemistry studies, lumbar puncture, EEG, and CT scan or MRI.
COMPLEX PARTIAL SEIZURES Complex partial (formerly called temporal lobe or psychomotor) seizures produce alterations in consciousness characterized by confusion alone, or by cognitive, affective, psychomotor, or psychosensory symptoms. Complex partial seizures rarely cause diagnostic problems in the patient presenting with an acute confusional state, because spells are typically brief and stereotypical, psychomotor manifestations are often obvious to the observer, and patients themselves may describe classic cognitive, affective, or psychosensory symptoms (see Chapter 8). Complex partial seizures produce a confusional state that may be characterized by a withdrawn or unresponsive state or by agitated behavior. Automatisms such as staring, repetitive chewing, swallowing, lip-smacking, or picking at clothing are characteristic. Complex partial status epilepticus, which is rare, lasts for hours to days. The diagnosis is made or confirmed by EEG.
PSYCHIATRIC DISORDERS Symptoms similar to those associated with acute confusional states—incoherence, agitation, distractibility, hy-
44 / CHAPTER 1 pervigilance, delusions, and hallucinations—also can be seen in a variety of psychiatric disorders. These include psychotic disorders (schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder), mood (depressive and bipolar) disorders, anxiety disorders (posttraumatic stress disorder), and factitious disorders. Such diagnoses may be mistakenly assigned to patients with acute confusional states; conversely, patients with psychiatric disturbances may be thought—incorrectly—to have organic disease. Unlike acute confusional states, psychiatric disorders are rarely acute in onset but typically develop over a period of at least several weeks. The history may reveal previous psychiatric disease or hospitalization or a precipitating psychological stress. Physical examination may show abnormalities related to autonomic overactivity, including tachycardia, tachypnea, and hyperreflexia but no definitive signs of neurologic dysfunction. Routine laboratory studies are normal in the psychiatric disorders listed above, but are useful for excluding organic disorders. Although the mental status examination in acute confusional states is often characterized by disorientation and fluctuating consciousness, patients with psychiatric disorders tend to maintain a consistent degree of cognitive impairment and to be oriented to person, place, and time. Disorientation as to person, especially in the face of preserved orientation in other spheres, is virtually diagnostic of psychiatric disease. Patients with psychiatric disorders exhibit a normal level of consciousness, usually appearing awake and alert, and memory is intact. Disturbances in the content and form of thought (eg, persecutory delusions, delusions of reference, loosening of associations), perceptual abnormalities (eg, auditory hallucinations), and flat or inappropriate affect are common, however. Psychiatric consultation should be sought regarding diagnosis and management.
III. DEMENTIA Dementia is an acquired, generalized, and usually progressive impairment of cognitive function that affects the content, but not the level, of consciousness. Although its incidence increases with advancing age (it has been estimated to affect 5–20% of individuals over age 65), dementia is not an invariable accompaniment of aging. It reflects instead a disorder that affects the cerebral cortex, its subcortical connections, or both. Minor changes in neurologic function, including alterations in memory and other cognitive spheres, can occur with normal aging (Table 1–22). Enlargement of ventricles and cerebral cortical sulci seen on CT or
Table 1–22. Neurologic changes in normal aging. Cognitive Memory loss (benign senescent forgetfulness) Neuroophthalmologic Small, sluggishly reactive pupils Impaired upgaze Impaired convergence Motor Muscular atrophy (intrinsic hand and foot muscles) Increased muscle tone Flexion (stooped) posture Gait disorders (small-stepped or broad-based gait) Sensory Impaired vision Impaired hearing Impaired taste Impaired olfaction Decreased vibration sense Reflexes Primitive reflexes Absent abdominal reflexes Absent ankle jerks
MRI scans (Figure 1–11) is also common with normal aging. These findings should not by themselves be considered indicative of dementia.
APPROACH TO DIAGNOSIS The first step in evaluating a patient with a disorder of cognitive function is to classify the disorder as either a disturbance of the level of consciousness (wakefulness or arousal), such as an acute confusional state or coma, or a disturbance of the content of consciousness, in which wakefulness is preserved. The latter category includes both global cognitive disorders (dementia) and more circumscribed deficits, such as aphasia and amnestic syndromes. This distinction is important because the initial classification of the disorder determines the subsequent diagnostic approach. The most common problem in this area is distinguishing dementia from an acute confusional state, such as that produced by drug intoxication. The clinical features presented in Table 1–1 may be useful in making this distinction. Another common problem is differentiating between dementia and so-called pseudodementia, such as that produced by depression (see below). In the clinical evaluation of patients with suspected dementia, it is important to try to find the cause, even though only about 10% of dementias are reversible. The possibility of reversing or arresting the disorder through appropriate treatment and dramatically improving the quality and duration of life justifies a thor-
DISORDERS OF COGNITIVE FUNCTION / 45
A
B
Figure 1–11. CT scan in cerebrocortical atrophy, showing ventricular dilation (A) and prominent cortical sulci (B). ough diagnostic investigation. A diagnosis is important in other cases for purposes of providing a prognosis and genetic counseling, or alerting family members and medical personnel to the risk of a transmissible disease. As better treatments are developed for dementing disorders that are unresponsive or poorly responsive to current therapy, the importance of arriving at an etiologic diagnosis of dementia will continue to increase.
History Because dementia implies deterioration in cognitive ability, it is important to establish that the patient’s level of functioning has declined. Data that can help to establish the cause of dementia include the time course of deterioration; associated symptoms such as headache, gait disturbance, or incontinence; family history of a similar condition; concurrent medical illnesses; and the use of alcohol and prescribed or unprescribed drugs.
General Physical Examination The general physical examination can contribute to the etiologic diagnosis when it reveals signs of a systemic disease responsible for the dementia. Particularly helpful signs are listed in Table 1–3.
Mental Status Examination The mental status examination helps to determine whether it is the level or the content of consciousness that is impaired and whether the cognitive dysfunction is global or circumscribed. A disorder of the level of consciousness is suggested by sleepiness, inattention, impairment of immediate recall, or disorientation as to place or time. Abnormalities in these areas are unusual in dementia until the disorder is far advanced. To determine the scope of the cognitive dysfunction (global or circumscribed), various spheres of cognition are tested in turn. These include memory, language, parietal lobe functions (pictorial construction, right-left discrimination, localization of objects in space), and frontal lobe or diffuse cerebral cortical functions (judgment, abstraction, thought content, the ability to perform previously learned acts). Multiple areas of cognitive function are impaired in dementia. The Minimental Status Examination (see Table 1–5) provides a useful bedside screening test when dementia is suspected.
Neurologic Examination Certain disorders that produce dementia also affect vision, coordination, or motor or sensory function. De-
46 / CHAPTER 1 tecting such associated neurologic abnormalities can help to establish an etiologic diagnosis. Neurologic signs suggesting causes of dementia are listed in Table 1–3.
mentias), such as depression. Drug intoxication, commonly cited as a cause of dementia in the elderly, actually produces an acute confusional state, rather than dementia.
Laboratory Investigations Laboratory studies that can help to identify the cause of dementia are listed in Table 1–7.
CEREBRAL DISORDERS WITHOUT EXTRAPYRAMIDAL FEATURES
DIFFERENTIAL DIAGNOSIS Common Causes of Dementia
ALZHEIMER DISEASE
Although a wide variety of diseases can produce dementia (Table 1–23), it is generally agreed that Alzheimer disease is the most common cause. Dementia with Lewy bodies, which has been recognized as a distinct entity rather than simply concurrent Alzheimer disease and Parkinson disease, may be second in frequency. Vascular dementia, sometimes referred to as multiinfarct dementia, is the next most common. Other causes of dementia, including reversible dementias, are comparatively rare.
Reversible Causes of Dementia Reversible causes of dementia—such as normal pressure hydrocephalus, intracranial mass lesions, vitamin B12 deficiency, hypothyroidism, and neurosyphilis—are rare. They are important disorders to diagnose promptly, however, because treatment can arrest or reverse the intellectual decline.
Other Important Causes of Dementia Diagnosing dementia caused by Huntington disease allows patients with this disorder (and their families) to benefit from genetic counseling. If Creutzfeldt-Jakob disease or AIDS dementia complex is diagnosed, precautions can be instituted against transmission; the course of AIDS dementia complex may also be modified by antiviral treatment. Progressive multifocal leukoencephalopathy may indicate underlying immunosuppression from HIV infection, lymphoma, leukemia, or another disorder.
Controversial Causes of Dementia Some disorders to which dementia is often attributed may not directly cause the disorder. For example, the existence of a primary alcoholic dementia is questionable, since dementia in alcoholic patients may be the result of related problems such as head trauma or nutritional deficiency.
Pseudodementias About 15% of patients referred for evaluation of possible dementia instead have other disorders (pseudode-
Alzheimer disease is the most common cause of dementia. Its incidence rises from less than 1% per year to more than 7% per year, and its prevalence from 3% to almost 50%, between the ages of 65 and 85 years. This translates into a prevalence of 10–20 million cases worldwide. Men and women are affected with equal frequency, when adjusted for age. Alzheimer disease is a progressive, degenerative disorder of uncertain cause, although abnormal metabolism and deposition of β-amyloid protein appears to be closely linked to pathogenesis (see below). The disease is defined by characteristic histopathologic features, especially neurofibrillary tangles and neuritic (senile) plaques. Neuritic plaques are extracellular deposits that contain the proteins β-amyloid, presenilin 1, presenilin 2, α1-antichymotrypsin, apolipoprotein E, α2-macroglobulin, and ubiquitin. Neurofibrillary tangles are intracellular deposits containing hyperphosphorylated tau (a microtubule-associated protein) and ubiquitin.
Pathogenesis A. GENETICS Alzheimer disease is usually sporadic, but a genetic basis can be identified in about 5% of cases (Table 1–24). Patients with trisomy 21 (Down syndrome) have a high incidence of Alzheimer disease beginning in the fourth decade. Familial Alzheimer disease with autosomal dominant inheritance is genetically heterogeneous. In some families there are mutations in the gene for amyloid precursor protein (APP) on chromosome 21. In other kindreds, familial Alzheimer disease has an especially early onset and more virulent course and is linked to mutations in the gene for presenilin 1, a transmembrane protein, on chromosome 14. Mutations in another transmembrane protein, presenilin 2, have been associated with familial Alzheimer disease in a German kindred. Some cases of familial Alzheimer disease are not caused by these defects, and mutations at other sites are presumed responsible. Genetic factors may also modify susceptibility to Alzheimer disease without being directly causal. In lateonset familial (and to a lesser extent sporadic)
Table 1–23. Causes of dementia. Disorder Cerebral disorders Without extrapyramidal features Alzheimer disease
Distinctive Features
Prominent memory loss, language impairment, visuospatial disturbance, depression, anxiety, delusions
Pick disease
Apathy, disinhibition, anosognosia, logorrhea, echolalia, palilalia
Creutzfeldt-Jakob disease
Myoclonus, ataxia, periodic EEG complexes
Normal-pressure hydrocephalus
Incontinence, gait disorder
With extrapyramidal features Dementia with Lewy bodies (includes diffuse Lewy-body disease and Lewy-body variant of Alzheimer disease)
Fluctuating cognitive function, visual hallucinations, parkinsonism
Corticobasal ganglionic degeneration
Parkinsonism, apraxia (including orofacial apraxia that can mimic aphasia), cortical sensory loss, alien-hand syndrome)
Huntington disease
Chorea, psychosis
Progressive supranuclear palsy
Supranuclear ophthalmoplegia, pseudobulbar palsy, axial dystonia in extension
Systemic disorders Cancer Brain tumor Meningeal neoplasia
Infection AIDS
Headache, focal neurologic signs, papilledema Focal weakness or sensory deficit, areflexia, pyramidal signs, headache Opportunistic infections, memory loss, psychomotor retardation, ataxia, pyramidal signs, white matter lesions on MRI brain scan
Neurosyphilis
Reactive CSF VDRL, psychosis, Argyll-Robertson pupils, facial tremor, strokes, tabes dorsalis
Progressive multifocal leukoencephalopathy
Visual disturbances, white matter lesions on MRI brain scan
Metabolic disorders Alcoholism
Prominent memory loss, nystagmus, gait ataxia
Hypothyroidism
Myxedema, hair loss, skin changes, hypothermia, headache, hearing loss, tinnitus, vertigo, ataxia, delayed relaxation of tendon reflexes
Vitamin B12 deficiency
Macrocytic anemia, low serum vitamin B12 level, psychosis, sensory disturbance, spastic paraparesis
Organ failure Dialysis dementia
Dysarthria, myoclonus, seizures
Non-Wilsonian hepatocerebral degeneration
Cirrhosis, esophageal varices, fluctuating mental status, dysarthria, pyramidal and extrapyramidal signs, ataxia
Wilson disease
Cirrhosis, dysarthria, pyramidal and extrapyramidal signs, ataxia, Kayser-Fleischer pigmented corneal rings, decreased serum ceruloplasmin
Trauma
Headache, variable pyramidal and extrapyramidal signs
Vascular disorders Chronic subdural hematoma
Headache, hemiparesis, extraaxial collection on CT or MRI brain scan
Vascular dementia
Pseudodementia Depression
Hypertension, diabetes, stepwise progression of deficits, hemiparesis, aphasia, infarcts on CT or MRI brain scan Depressed mood, anhedonia, anorexia, weight loss, insomnia or hypersomnia, suicidality
48 / CHAPTER 1 Table 1–24. Genes implicated in Alzheimer’s disease. Gene
Gene Locus
Protein
Genotype
APP
21q21.3-q22.05
Amyloid β A4 precursor protein
Various missense mutations
Familial Alzheimer disease (autosomal dominant)
PS1
14q24.3
Presenilin 1 (PS1)
Various missense mutations
Familial Alzheimer disease (autosomal dominant) with early onset (age 35–55)
PS2
1q31-q42
Presenilin 2 (PS2)
Various missense mutations
Familial Alzheimer disease (autosomal dominant) in Volga Germans
APOE
19q13.2
Apolipoprotein E
APOE4 polymorphism
Increased susceptibility to Alzheimer disease
Multiple
21
Unknown
Trisomy 21 or chromosome 21-to-14 or 21-to-21 translocation
Down syndrome (early-onset Alzheimer disease)
Alzheimer disease, the risk of being affected and the age at onset are related to the number of apolipoprotein E ε-4 (APOE4) alleles on chromosome 19. How the APOE4 allele (or the absence of other APOE alleles) confers disease susceptibility is unclear. It has been speculated that apolipoprotein E produced by astrocytes may be taken up into neurons and interact abnormally with microtubule-associated proteins, like tau, to produce paired helical filaments in neurofibrillary tangles. Other proteins that may be involved in pathogenesis include α2-macroglobulin and its receptor, low density lipoprotein-related protein-1. B. β-AMYLOID β-Amyloid is the principal constituent of neuritic plaques and is also deposited in cerebral and meningeal blood vessels in Alzheimer disease. β-Amyloid is a 40–
Phenotype
to 42–amino acid peptide produced by proteolytic cleavage of the transmembrane protein, APP (Figure 1–12). Normal processing of APP involves its cleavage by an enzyme called α-secretase to form the 40–amino acid fragment β-amyloid 1–40, which is secreted and cleared from the brain. In Alzheimer disease, APP is cleaved abnormally. The first cleavage is in the extracellular region of APP by an enzyme called β-secretase, which has been identified as the transmembrane protease BACE (β-site APP cleaving enzyme). Then γ-secretase acts within the transmembrane region to generate the abnormal β-amyloid 1–42, which is secreted and accumulates in extracellular plaques. Presenilin 1 and 2 appear to be involved in this latter cleavage step. β-Amyloid, especially in its aggregated form, can be toxic to neurons under some circumstances. It therefore
Aβ
Extracellular
γ -secretase
β -secretase
Intracellular Presenilin
BACE
APP
C99
Figure 1–12. Molecular mechanisms of disease: Proteolytic processing of APP to form β-amyloid. (Adapted from Vassar R, Citron M. Aβ-generating enzymes: recent advances in β- and γ-secretase research. Neuron 2000;27:419–422.)
DISORDERS OF COGNITIVE FUNCTION / 49 has been suggested that the abnormal accumulation of β-Amyloid in Alzheimer disease is responsible for the death of selectively vulnerable neurons. However, others have cited the lack of a clear correlation between the extent of amyloid deposition in the brain and the severity of dementia as evidence against the amyloid hypothesis. C. CHOLINERGIC DEFICIENCY Cholinergic neurons are lost and the acetylcholine-synthesizing enzyme choline acetyltransferase is markedly depleted in the cerebral cortex and hippocampus of patients with Alzheimer disease. Degeneration of the nucleus basalis of Meynert (the principal origin of cortical cholinergic innervation) and of the cholinergic septalhippocampal tract may underlie this abnormality. The cholinergic deficiency in Alzheimer disease has led to the therapeutic use of acetylcholinesterase inhibitors, which enhance cholinergic neurotransmission by inhibiting acetylcholine breakdown (see below).
Clinical Findings A. EARLY MANIFESTATIONS Impairment of recent memory is typically the first sign of Alzheimer disease—often noticed only by family members. As the memory disorder progresses, the patient becomes disoriented to time and then to place. Aphasia, anomia, and acalculia may develop, forcing the patient to leave work or give up the management of family finances. The depression apparent in the earlier stages of the disorder may give way to an agitated, restless state. Apraxias and visuospatial disorientation ensue, causing the patient to become lost easily. Primitive reflexes are commonly found. A frontal lobe gait disorder may become apparent, with short, slow, shuffling steps, flexed posture, wide base, and difficulty in initiating walking. B. LATE MANIFESTATIONS In the late stages, previously preserved social graces are lost, and psychiatric symptoms, including psychosis with paranoia, hallucinations, or delusions, may be prominent. Seizures occur in some cases. Examination at this stage may show rigidity and bradykinesia. Rare and usually late features of the disease include myoclonus, incontinence, spasticity, extensor plantar responses, and hemiparesis. Mutism, incontinence, and a bedridden state are terminal manifestations, and death typically occurs from 5 to 10 years after the onset of symptoms.
Investigative Studies Laboratory investigations do not assist in the diagnosis—except to exclude other disorders. The CT scan or MRI often shows cortical atrophy and enlarged ventri-
cles, but such changes may also be seen in elderly nondemented patients. Cognitive testing may be useful in some cases in helping to distinguish between Alzheimer disease and other causes of dementia.
Differential Diagnosis Early Alzheimer disease may resemble depression or pure memory disorders such as the Korsakoff amnestic syndrome (see below). More advanced Alzheimer disease must be distinguished from Lewy body dementia, multiinfarct dementia, Creutzfeldt-Jakob disease, and other dementing disorders (see below).
Treatment No currently available treatment has been shown unequivocally to reverse existing deficits or to arrest disease progression. However, memantine, an NMDAtype glutamate receptor antagonist drug, may produce modest improvement in patients with moderate or severe Alzheimer disease. Because cholinergic neuronal pathways degenerate and choline acetyltransferase is depleted in the brains of patients with Alzheimer disease, cholinergic replacement therapy has been used in an effort at symptomatic treatment of cognitive dysfunction (Table 1–25). The acetylcholinesterase inhibitors tacrine, donepezil, rivastigmine, galantamine, physostigmine, metrifonate, and eptastigmine have all been shown to produce small (∼5%) improvements in tests of cognitive function. Among these drugs, tacrine, donepezil, rivastigmine, and galantamine are available in the United States. Side effects include nausea, vomiting, diarrhea, and dizziness; tacrine also elevates serum transaminase levels. The better side-effect profile of donepezil and its once-daily dosage schedule have made it the agent of choice. Experimental treatments under investigation include vaccines directed against β-amyloid and the metal chelator, clioquinol. Several drugs also have been tested for their ability to delay the progression of Alzheimer disease, including α-tocopherol, selegiline, idebenone, propentofylline, Gingko biloba, and acetyl-L-carnitine. Of these, only α-tocopherol and selegiline have shown evidence of slight benefit. Antipsychotic drugs, antidepressants, and anxiolytics may be useful in controlling behavioral disturbances associated with Alzheimer disease.
Prognosis Early in the course of the disease, patients can usually remain at home and continue social, recreational, and limited professional activities. Early diagnosis can allow patients time to plan orderly retirement from work, to arrange for management of their finances, and to discuss with physicians and family members the management of future medical problems. Patients in advanced
50 / CHAPTER 1 Table 1–25. Drugs used in the treatment of Alzheimer’s disease. Indication
Drug Class
Cognitive dysfunction
Glutamate antagonist
Memantine (Namenda)
5 mg orally daily, increased by 5 mg each week to 10 mg orally twice daily
Dizziness, headache, constipation, confusion
Acetylcholinesterase inhibitor
Tacrine (Cognex)
10 mg orally four times per day; may be increased to 20 mg orally four times per day after 6 weeks
Abdominal cramps, nausea, vomiting, diarrhea, hepatocellular toxicity (liver enzymes should be monitored twice monthly for 4 months)
Donepezil (Aricept)
5 mg orally at bedtime; may be increased to 10 mg orally at bedtime after 4–6 weeks
Nausea, diarrhea, vomiting, insomnia, fatigue, muscle cramps, anorexia
Rivastigmine (Exelon)
1.5–6 mg orally twice per day
Nausea, vomiting, diarrhea, anorexia
Galantamine (Reminyl)
4–12 mg orally twice per day
Nausea, vomiting, dizziness, diarrhea, anorexia, weight loss
Haloperidol (Haldol)
0.5–2 mg orally at bedtime, or every 4–6 hours
Parkinsonism, akathisia, tardive dyskinesia, increased cognitive dysfunction
Loxapine (Loxitane)
50–250 mg orally daily
Parkinsonism, akathisia, tardive dyskinesia, increased cognitive dysfunction
Risperidone (Risperdal)
2–4 mg orally daily
Parkinsonism, akathisia, tardive dyskinesia, increased cognitive dysfunction
Thioridazine (Mellaril)
25–300 mg orally daily
Parkinsonism, akathisia, tardive dyskinesia, increased cognitive dysfunction
Thiothixene (Navane)
2–20 mg orally daily
Parkinsonism, akathisia, tardive dyskinesia, increased cognitive dysfunction
Citalopram (Celexa)
20–40 mg orally daily
Insomnia, anorexia, ejaculatory failure, nausea, diarrhea
Fluoxetine (Prozac)
5–20 mg orally with breakfast
Insomnia, anorexia, ejaculatory failure, nausea, diarrhea
Paroxetine (Paxil)
5–20 mg orally with breakfast, or in two divided daily doses
Insomnia, anorexia, ejaculatory failure, nausea, diarrhea
Carbamazepine (Tegretol)
400–1200 mg orally in two (extended-release form) or four divided doses
Ataxia
Behavioral disturbance
Antipsychotic
Antidepressant
Anxiolytic
Drug
Dose
Toxicity
Adapted from Mayeux R, Sano M: Treatment of Alzheimer’s disease. N Engl J Med 1999;341:1670–1679.
DISORDERS OF COGNITIVE FUNCTION / 51 stages of the disease may require care in a nursing facility and the use of psychoactive medications. These patients must be protected and prevented from injuring themselves and their families by injudicious actions or decisions. Death from inanition or infection generally occurs 5–10 years after the first symptoms.
FRONTOTEMPORAL DEMENTIA The frontotemporal dementias, including Pick disease, sometimes can be distinguished from Alzheimer disease during life by their generally earlier onset, more prominent behavioral than cognitive dysfunction at presentation, and preferential atrophy of the frontal and anterior temporal lobes on CT scan or MRI of the brain. However, definitive diagnosis is usually not possible during life, and relies instead on histopathological features. These include the distinctively circumscribed pattern of lobar atrophy, the presence of Pick cells and Pick inclusion bodies, the absence of amyloid plaque and neurofibrillary tangles characteristic of Alzheimer disease, and inclusions in neurons and glia that contain the microtubule-associated protein, tau. This latter feature accounts for the classification of frontotemporal dementia as a tauopathy. Familial occurrence of frontotemporal dementia has been documented and mapped to chromosome 17 (17q21). There is no treatment.
CREUTZFELDT-JAKOB DISEASE Creutzfeldt-Jakob disease is an invariably fatal transmissible disorder of the central nervous system characterized by rapidly progressive dementia and variable focal involvement of the cerebral cortex, basal ganglia, cerebellum, brainstem, and spinal cord. The annual incidence is about 1:1,000,000 population. The naturally acquired disease occurs in patients 16–82 years of age, with a peak incidence between 60 and 64 years and an equal sex incidence. More than one member of a family is affected in 5–10% of cases. Conjugal cases are rare. Although transmission from humans to animals has been demonstrated experimentally, documented human-to-human transmission (by corneal transplantation, cortical electrode implantation, or administration of human growth hormone) is rare. The infectious agent is present in the brain, spinal cord, eyes, lungs, lymph nodes, kidneys, spleen, liver, and CSF, but not other body fluids.
Pathogenesis A proteinaceous infectious particle (prion) is the etiologic agent. Familial cases, which are uncommon, have been associated with mutations in a form of the prion protein (cellular isoform, or PrPc) that is expressed by normal neurons but whose function is unknown. In
sporadic cases, an abnormal prion protein (scrapie isoform, or PrPSc), which differs from PrPc in its secondary (folding) structure, has been proposed as the infectious agent. In both circumstances, the result is accumulation of abnormal PrPSc prions in brain tissue. To explain the ability of PrPSc prions to replicate in the brain (despite the fact that they contain no detectable nucleic acids), it has been suggested that infectious PrPSc prions induce a conformational change in normally expressed PrPc prions that converts them to the PrPSc form. Prions have also been implicated in diseases of animals and in three other rare human disorders (Table 1–26)—kuru, a dementing disease of Fore-speaking tribes of New Guinea (apparently spread by cannibalism); Gerstmann-Straussler syndrome, a familial disorder characterized by dementia and ataxia; and fatal familial insomnia, which produces disturbances of sleep and of autonomic, motor, and endocrine function.
Clinical Findings The clinical picture may be that of a diffuse central nervous system disorder or of a more localized dysfunction (Table 1–27). Dementia is present in virtually all cases and may begin as a mild global cognitive impairment or a focal cortical disorder such as aphasia, apraxia, or agnosia. Progression to akinetic mutism or coma typically ensues over a period of months. Psychiatric symptoms including anxiety, euphoria, depression, labile affect, delusions, hallucinations, and changes in personality or behavior may be prominent. Aside from cognitive abnormalities, the most frequent clinical manifestations are myoclonus (often induced by a startle), extrapyramidal signs (rigidity,
Table 1–26. Prion diseases. Human diseases Creutzfeldt-Jakob disease (sporadic) Creutzfeldt-Jakob disease (familial) Creutzfeldt-Jakob disease (new variant) Fatal familial insomnia Gerstmann-Straussler-Scheinker disease Kuru Animal diseases Bovine spongiform encephalopathy Feline spongiform encephalopathy Scrapie (sheep and goats) Transmissible mink encephalopathy Wasting disease of deer and elk Transmissible spongiform encephalopathy of captive wild ruminants Adapted from Johnson RT, Gibbs CJ: CreutzfeldtJakob disease and related transmissible spongiform encephalopathies. N Engl
52 / CHAPTER 1 Table 1–27. Clinical features of sporadic Creutzfeldt-Jakob disease. Feature Cognitive Memory loss Behavioral abnormalities Other Motor Myoclonus Cerebellar ataxia Pyramidal signs Extrapyramidal signs Lower motor neuron signs Visual disturbances Periodic EEG complexes
Percentage 100 57 73 78 71 62 56 12 42 60
Data from Brown P et al: Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994;35:513.
bradykinesia, tremor, dystonia, chorea, or athetosis), cerebellar signs, and extrapyramidal signs. Visual field defects, cranial nerve palsies, and seizures occur less often. A distinct variant of Creutzfeldt-Jakob disease is thought to result from the transmission of bovine spongiform encephalopathy (“mad cow disease”) to humans. This variant is characterized by earlier onset (mean age, about 30 years), a more prolonged course (greater than 1 year), invariable cerebellar involvement, prominent early psychiatric abnormalities, and diffuse amyloid plaques.
midal signs. Where subcortical involvement is prominent, Parkinson disease, cerebellar degeneration, or progressive supranuclear palsy may be suspected. Striking focal signs raise the possibility of an intracerebral mass lesion. Acute metabolic disorders that produce altered mentation and myoclonus (eg, sedative drug withdrawal) can mimic Creutzfeldt-Jakob disease.
Prognosis No treatment is currently available. The disease is usually relentlessly progressive and, although transient improvement may occur, is invariably fatal. In most sporadic cases, death occurs within 1 year after the onset of symptoms: the mean duration of illness in these patients is 7 months. Depending on the specific mutation present, familial forms of the disease may have similar short or much longer courses.
NORMAL-PRESSURE HYDROCEPHALUS Normal-pressure hydrocephalus, a potentially reversible cause of dementia, is characterized by the clinical triad of dementia, gait apraxia, and incontinence. It may be idiopathic or secondary to conditions that interfere with cerebrospinal fluid absorption, such as meningitis or subarachnoid hemorrhage. The dementia is often mild and insidious in onset, and is typically preceded by gait disorder and incontinence. It is characterized initially by mental slowness and apathy and later by global cognitive dysfunction. Deterioration of memory is common, but aphasia and agnosia are rare.
Pathophysiology
The EEG may show periodic sharp waves or spikes (Figure 1–13), which are absent in the variant form described above. CSF protein may be elevated (≤100 mg/dL) and levels of 14–3–3, a normal brain protein that is also elevated in herpes simplex virus encephalitis, are increased. MRI scans may show hyperintense signals in the basal ganglia on T2-weighted images. Definitive diagnosis is by immunodetection of PrPSc in brain tissue obtained at biopsy or, in familial cases, by detection of mutant forms of PrPc in DNA from lymphocytes.
Normal-pressure hydrocephalus is sometimes called communicating (because the lateral, third, and fourth ventricles remain in communication) or nonobstructive hydrocephalus (because the flow of CSF between the ventricles is not obstructed). It is presumed to be due to impaired CSF absorption from arachnoid granulations in the subarachnoid space over the convexity of the hemispheres (Figure 1–14), eg, from meningeal fibrosis and adhesions following meningitis or subarachnoid hemorrhage. In contrast, noncommunicating or obstructive hydrocephalus is caused by a blockade of CSF circulation within the ventricular system (eg, by an intraventricular cyst or tumor) and is associated with increased CSF pressure and often with headache and papilledema.
Differential Diagnosis
Clinical Findings
A variety of other disorders must be distinguished from Creutzfeld-Jakob disease. Alzheimer disease is often a consideration, especially in patients with a less fulminant course and a paucity of cerebellar and extrapyra-
Normal-pressure hydrocephalus usually develops over a period of weeks to months; a gait disorder is often the initial manifestation. This typically takes the form of gait apraxia, characterized by unsteadiness on standing
Investigative Studies
DISORDERS OF COGNITIVE FUNCTION / 53 and difficulty in initiating walking even though there is no weakness or ataxia. The patient can perform the leg movements associated with walking, bicycling, or kicking a ball and can trace figures with the feet while lying or sitting but is unable to do so when the legs are bearing weight. The patient typically appears to be glued to
the floor, and walking, once under way, is slow and shuffling. Pyramidal signs, including spasticity, hyperreflexia, and extensor plantar responses, are sometimes present. Motor perseveration (the inappropriate repetition of motor activity) and grasp reflexes in the hands and feet may occur. Urinary incontinence is a later de-
Fp2-F4 F4-C4 C4-P4 P4-O2 Fp2-F8 F8-T4 T4-T6
T6-O2 Fp1-F3
F3-C3 C3-P3 P3-O1
Fp1-F7 F7-T3 T3-T5 T5-O1 200 µV
1s
Figure 1–13. Electroencephalogram of a patient with Creutzfeldt-Jakob disease, showing triphasic waves with sharpened outlines; these occur repetitively about once every second.
54 / CHAPTER 1 Choroid plexus of lateral ventricle
Arachnoid granulation
Interventricular foramen of Monro
Choroid plexus of third ventricle
Superior sagittal sinus
Dura mater
Arachnoid Pia mater
Cerebral vein
Subarachnoid space Cerebral aqueduct Choroid plexus of fourth ventricle
Foramen of Magendie
Foramen of Luschka
Figure 1–14. Circulation of cerebrospinal fluid (CSF). CSF is produced by the choroid plexus, which consists of specialized secretory tissue located within the cerebral ventricles. It flows from the lateral and third ventricles through the cerebral aqueduct and fourth ventricle and exits the ventricular system through two laterally situated foramina of Luschka and a single, medially located foramen of Magendie. CSF then enters and circulates through the subarachnoid space surrounding the brain and spinal cord. It is ultimately absorbed through arachnoid granulations into the venous circulation.
velopment, and patients may be unaware of it; fecal incontinence is uncommon.
Investigative Studies Lumbar puncture reveals normal or low opening pressure. The CT scan or MRI typically shows enlarged lateral ventricles without increased prominence of cortical sulci (Figure 1–15). Radionuclide cisternography classi-
cally shows isotope accumulation in the ventricles, delayed clearance, and failure of ascent over the cerebral convexities. This pattern is not necessarily present in patients who respond to shunting, however. Transient improvement in gait, cognitive testing, or sphincteric function following the removal of 30–50 mL of CSF by lumbar puncture is probably the best predictor of a favorable clinical response to shunting (see below).
DISORDERS OF COGNITIVE FUNCTION / 55
Figure 1–15. CT scan at two levels in normal-pressure hydrocephalus, showing enlarged lateral ventricles without enlargement of the cortical sulci.
Differential Diagnosis A variety of conditions that produce dementia must be considered in the differential diagnosis. Alzheimer disease tends to follow a longer course, often with prominent focal cortical dysfunction and enlarged cortical sulci shown in a CT scan or MRI. Parkinsonism may be simulated by the gait disorder but can be distinguished by extrapyramidal rigidity, tremor, and response to antiparkinsonian medications. Vascular dementia should be suspected if the disorder follows a stepwise course, or pseudobulbar palsy, focal sensorimotor signs, or a history of stroke is encountered.
Treatment Some patients, especially those with hydrocephalus from meningitis or subarachnoid hemorrhage, recover or improve following ventriculoatrial, ventriculoperitoneal, or lumboperitoneal shunting. In idiopathic normal-pressure hydrocephalus, about one-half of patients have sustained improvement and about one-third have a good or excellent response (ie, return to work) after shunting. As noted above, a favorable response to the removal of CSF by lumbar puncture may be the best predictor of successful surgery. Complications of shunting occur in about one-third of patients and include shunt infection, subdural hematoma, and shunt malfunction that necessitates replacement.
CEREBRAL DISORDERS WITH EXTRAPYRAMIDAL FEATURES DEMENTIA WITH LEWY BODIES Dementia with Lewy bodies is probably the second most common cause of dementia, as up to one-fourth of elderly demented patients who come to autopsy have round, eosinophilic, intracytoplasmic neuronal inclusions (Lewy bodies) in the cerebral cortex and brainstem. These contain α-synuclein, a protein that is also found in Lewy bodies in Parkinson disease, and tau, which is present in Alzheimer disease and frontotemporal dementia (see above). Dementia with Lewy bodies is found in patients with (Lewy-body variant of Alzheimer disease) and without (diffuse Lewy-body disease) histopathological features of Alzheimer disease, and is probably a heterogeneous disorder. In contrast to Alzheimer disease, it is characterized clinically by cognitive decline without prominent early memory impairment. Other distinctive features include fluctuating cognitive ability, well-formed visual hallucinations, and signs of parkinsonism, especially rigidity and bradykinesia. These patients may respond well to anticholinesterase drugs such as tacrine or donepezil (Table 1–25), but are especially sensitive to extrapyramidal side effects of antipsychotic drugs, which therefore should be avoided or used with caution.
56 / CHAPTER 1
CORTICOBASAL GANGLIONIC DEGENERATION This dementing disorder is also associated with parkinsonism, especially rigidity, bradykinesia, postural instability, and action (but rarely resting) tremor, as well as with a variety of asymmetric cortical motor and sensory defects. These include apraxias affecting the eye movements, speech, and limbs, the latter of which may produce the alien-hand sign, in which the limb moves seemingly of its own accord.
HUNTINGTON DISEASE Huntington disease is an autosomal dominant heredodegenerative condition characterized by a movement disorder, psychiatric symptoms, and dementia. The cause is an expanded CAG trinucleotide repeat coding for a polyglutamine tract in the Huntington gene on chromosome 4 (4p16.3). Dementia, which usually becomes apparent after chorea and psychiatric symptoms have been present for a few years, precedes chorea in about one-fourth of cases. A memory disturbance affecting all aspects of memory is an early and prominent feature; aphasia, apraxia, agnosia, and global cognitive dysfunction tend to occur later. Huntington disease is discussed further in Chapter 7.
PROGRESSIVE SUPRANUCLEAR PALSY Progressive supranuclear palsy is an idiopathic degenerative disorder that primarily affects subcortical gray matter regions of the brain. The classic clinical features are supranuclear ophthalmoplegia, pseudobulbar palsy, axial dystonia with or without extrapyramidal rigidity of the limbs, and dementia. The disorder of movement is a conspicuous feature of this syndrome, which is discussed further in Chapter 7.
SYSTEMIC DISORDERS CANCER 1. BRAIN TUMOR Brain tumors produce dementia and related syndromes by a combination of local and diffuse effects, including edema, compression of adjacent brain structures, increased intracranial pressure, and impairment of cerebral blood flow. The tumors most likely to produce generalized cerebral syndromes are gliomas arising in the frontal or temporal lobes or the corpus callosum. Although such lesions tend to infiltrate subcortical white matter extensively, they initially give rise to few focal neurologic signs. The dementia associated with brain tumor is charac-
terized by prominent mental slowness, apathy, impaired concentration, and subtle alterations in personality. Depending on the areas of involvement, memory disorder, aphasia, or agnosia may be seen early. Brain tumors ultimately produce headache, seizures, or focal sensorimotor disturbances. Brain tumor is covered in detail in Chapter 2. 2. MENINGEAL NEOPLASIA Meningeal neoplasia, discussed above as a cause of confusional states, may also produce dementia that is commonly associated with headache as well as symptoms and signs of dysfunction at multiple sites in the nervous system. The diagnosis is established by cytologic studies of the CSF.
INFECTION 1. AIDS AIDS dementia complex is the most common neurologic complication of AIDS. Although especially common in severely immunosuppressed patients late in the course of the disease, it can also be an early or presenting manifestation.
Pathogenesis AIDS dementia complex results from invasion of the brain by a retrovirus, human immunodeficiency virus type 1 (HIV-1). The virus appears to reach the central nervous system early in the course of systemic HIV-1 infection; monocytes, macrophages, and microglia are the principal cell types affected. Neurologic involvement at this stage may be asymptomatic, or it can produce transient symptomatic HIV-1 meningitis (see above). The infection then seems to be contained until progressive immunosuppression impairs the normal host defense mechanisms, leading to increased HIV-1 production in the brain and, perhaps, the emergence of neurotropic strains. Productive viral infection within the brain seems to be associated with multinucleated cells. HIV-1 does not appear to replicate within neurons, astrocytes, or oligodendrocytes in vivo, and the loss of these cell types is not prominent in brains of patients with AIDS dementia complex. It has therefore been suggested that neuronal function is impaired by an indirect neurotoxic mechanism. This might involve cytokines released from HIV-infected monocytes or macrophages, viral products such as the HIV-1 envelope protein gp120, or molecules that mimic the effects of excitotoxic amino acids.
Pathology The earliest histopathologic sign is pallor of subcortical and periventricular cerebral white matter associated
DISORDERS OF COGNITIVE FUNCTION / 57 with reactive astrocytosis but few inflammatory changes. More advanced cases are associated with parenchymal and perivascular infiltration by macrophages, microglia, lymphocytes, and multinucleated cells; the last are thought to result from the virus-induced fusion of macrophages. These changes affect the white matter, basal ganglia, thalamus, and pons and are accompanied by reactive astrocytosis. Spongy vacuolation of white matter occurs infrequently. Neuronal loss has been reported. The spinal cord may also be affected by a vacuolar myelopathy (see Chapter 5) resembling that caused by vitamin B12 deficiency.
Clinical Findings The onset is usually insidious and is associated with cognitive and behavioral symptoms, such as forgetfulness, apathy, social withdrawal, and motor symptoms, including impaired balance, leg weakness, and deterioration of handwriting (Table 1–28). Examination at this early stage may also show cerebellar ataxia, pyramidal signs such as hyperreflexia and extensor plantar responses, weakness in one or both legs, postural tremor, and dysarthria. As the disease progresses, hypertonia, fecal and urinary incontinence, primitive reflexes, myoclonus, seizures, quadriparesis, and organic psychosis with delusions and visual hallucinations can occur.
Investigative Studies Antibodies to HIV are detectable in the blood. The CSF is usually abnormal and may show a mild to moderate elevation of protein (≤200 mg/dL), a modest, usually mononuclear pleocytosis (≤50 cells/µL), and oligoclonal bands. CT scans and MRI usually demonstrate cerebrocortical atrophy with ventricular dilation and may also show diffuse involvement of subcortical white matter (Figure 1–16).
Treatment Combination pharmacotherapy of HIV infection can prolong life by inhibiting replication of HIV and improving immune function. The available drugs fall into three classes: nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors. Treatment must be individualized, and continually updated treatment guidelines are available from the United States Department of Health and Human Services website at http://www.aidsinfo.nih.gov/ guidelines/. Preferred therapy for antiretroviral drugnaive, non-pregnant patients includes a nonnucleoside reverse transcriptase inhibitor-based regimen consisting of efavirenz, lamivudine, and either zidovudine, tenofovir DF or stavudine, and a protease inhibitor-based regimen that employs lopinavir/ritonavir (Kaletra), lamivudine, and either zidovudine or stavudine.
Table 1–28. Clinical features of AIDS dementia complex. Feature
Percentage of Patients Early Stage
Symptoms Memory loss Behavioral changes (eg, social withdrawal) Depression Motor symptoms (eg, imbalance, weakness, deteriorated handwriting) Apathy Confusion Hallucinations Signs Cognitive Psychomotor retardation Dementia Psychosis Mutism Motor Ataxia Hypertonia Tremor Paraparesis or quadriparesis Monoparesis or hemiparesis Myoclonus Other Hyperreflexia Primitive reflexes Seizures Incontinence Investigative studies1 CSF Mononuclear pleocytosis Increased protein Decreased glucose Oligoclonal IgG bands Imaging Cerebral cortical atrophy (CT) Cerebral cortical atrophy (MRI) White matter lesions (CT) White matter lesions (MRI)
Late Stage
80 30
74 11
30 20
16 21
15 15 5
58 42 11
61 39 5 0
84 100 16 40
34 22 16 13 5 0
71 44 45 33 2 20
36 22 7 0
78 38 20 47
19 66 1 25 79 55 11 35
1 All stages. Adapted from Navia BA et al: The AIDS dementia complex. 1. Clinical features. 2. Neuropathology. Ann Neurol 1986; 19:517–524 and 525–535, and McArthur JC: Neurologic manifestations of AIDS. Medicine 1987;66:407–437.
58 / CHAPTER 1
Clinical Findings A. EARLY SYPHILIS Syphilis is caused by Treponema pallidum transmitted by sexual contact, which results in infection in about one-third of encounters with infected individuals. Primary syphilis is characterized by local skin lesions (chancres) that usually appear within 1 month of exposure. There are no neurologic symptoms. Hematogenous spread of T pallidum produces symptoms and signs of secondary syphilis within 1–6 months. These include fever, skin rash, alopecia, anogenital skin lesions, and ulceration of mucous membranes; neurologic symptoms are still uncommon at this stage. Meningeal syphilis, the earliest form of symptomatic neurosyphilis, is most often seen 2–12 months after primary infection. Clinical features include headache, stiff neck, nausea and vomiting, and cranial nerve (especially II, VII, or VIII) involvement.
Figure 1–16. T2-weighted MRI in AIDS dementia complex, showing extensive, bilaterally symmetrical increases in signal intensity (arrows) in white matter (centrum semiovale) of the frontal lobes.
Side effects vary, but certain class-specific patterns have been noted. Nucleosides can cause fatal lactic acidosis with hepatic steatosis, nonnucleosides are associated with skin rash (including Stevens-Johnson syndrome with nevirapine), and protease inhibitors may produce gastrointestinal disturbances and increased blood levels of aminotransferases. Neurologic side effects of drugs used to treat HIV include myopathy (zidovudine), neuropathy (stavudine, didanosine, zalcitabine), paresthesias (ritonavir, amprenavir), and nightmares and hallucinations (efavirenz).
Prognosis The course may be steadily progressive, or it can be acutely exacerbated by concurrent pulmonary infection. Patients usually die 1–9 months after the onset of dementia from aspiration or opportunistic infection. 2. NEUROSYPHILIS Neurosyphilis was a common cause of dementia before the widespread use of penicillin permitted effective treatment of early syphilis. Dementia from neurosyphilis is now rare, but the resurgence of syphilis in recent years suggests that it may become more common.
B. MENINGOVASCULAR SYPHILIS This delayed manifestation of neurosyphilis occurs 4–7 years into the course of the disease and usually presents with transient ischemic attacks or stroke (see Chapter 9). C. LATE (PARENCHYMATOUS) NEUROSYPHILIS This produces the syndromes of general paresis and tabes dorsalis, which can occur separately or together (taboparesis); either one can occur in combination with optic atrophy. 1. General paresis—A chronic meningoencephalitis caused by active spirochetal infection, this was the usual cause of dementia and psychiatric disorders related to neurosyphilis in the prepenicillin era. Onset is with gradual memory loss or altered affect, personality, or behavior. This is followed by global intellectual deterioration with grandiosity, depression, psychosis, and focal weakness. Terminal features include incontinence, seizures, or strokes. Neurologic examination may show tremor of the face and tongue, paucity of facial expression, dysarthria, and pyramidal signs. 2. Taboparesis—In taboparesis—the coexistence of tabes dorsalis (see Chapter 6) with general paresis— signs and symptoms include Argyll Robertson pupils (see Chapter 4), lancinating pains, areflexia, posterior column sensory deficits with sensory ataxia and Romberg sign, incontinence, impotence, Charcot (hypertrophic) joints, and genu recurvatum (hyperextended knees). Optic atrophy may also be present.
Investigative Studies Treponemal serologic blood tests (FTA-ABS or MHATP) are reactive in almost all patients with active neurosyphilis, but nontreponemal blood tests (VDRL or RPR) can be negative; therefore, a treponemal blood test should be obtained in all suspected cases. If this is
DISORDERS OF COGNITIVE FUNCTION / 59 nonreactive, neurosyphilis is effectively excluded; if it is reactive, lumbar puncture should be performed to confirm the diagnosis of neurosyphilis and provide a baseline CSF profile against which to gauge the efficacy of subsequent treatment. The CSF in active neurosyphilis shows a lymphocytic pleocytosis and reactive nontreponemal CSF serology in almost all cases. The exceptions are acute syphilitic meningitis and meningovascular syphilis, in which pleocytosis may precede seroconversion so that nontreponemal CSF tests are falsely negative early on, and end-stage tabes dorsalis, in which the CSF can be normal. Other CSF abnormalities include protein elevation, increased γ-globulin, and the presence of oligoclonal bands.
Treatment Neurosyphilis is treated with a 10-day course of aqueous penicillin G, 2–4 × 106 units intravenously every 4 hours. Tetracycline or erythromycin can be used for patients allergic to penicillin. Fever and leukocytosis may occur shortly after therapy is started (Herxheimer reaction) but are transient. Failure of the CSF to return to normal within 6 months requires retreatment. Neither failure of treatment nor relapse is convincingly more common in HIV-1-infected patients.
Prognosis
The CSF is usually normal but may show a mild increase in pressure, white cell count, or protein. The CT scan or MRI shows multifocal white matter abnormalities (Figure 1–17). When the diagnosis is in doubt, it can be established by brain biopsy. The disorder is almost uniformly fatal, and treatment with such antiviral agents as cytosine arabinoside, adenine arabinoside, or amantadine generally has been unsuccessful.
METABOLIC DISORDERS 1. ALCOHOLISM Certain complications of alcoholism can cause dementia. These include acquired hepatocerebral degeneration from alcoholic liver disease, chronic subdural hematoma from head trauma, and nutritional deficiency states. Pellagra, caused by deficiency of nicotinic acid (niacin), affects neurons in the cerebral cortex, basal ganglia, brainstem, cerebellum, and anterior horns of the spinal cord. Systemic involvement is manifested by diarrhea, glossitis, anemia, and erythematous skin lesions. Neurologic involvement may produce dementia; psychosis; confusional states; pyramidal, extrapyramidal, and cerebellar signs; polyneuropathy; and optic neuropathy. Treatment is with nicotinamide, but the neurologic deficits may persist despite treatment.
After penicillin (or other antibiotic) treatment for general paresis, the clinical condition may improve or stabilize; in some cases it continues to deteriorate. Patients with persistent CSF abnormalities or symptomatic progression despite therapy should be retreated. Patients with reactive CSF serological tests but no pleocytosis are unlikely to respond to penicillin therapy but are usually treated nevertheless. 3. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Progressive multifocal leukoencephalopathy results from infection with a papovavirus called JC virus. Antibodies are present in most adults, but symptomatic infection is rare. It is most common in patients with AIDS, lymphoma or leukemia, carcinoma, sarcoidosis, tuberculosis, or pharmacologic immunosuppression following organ transplantation, and rare in those with normal immune function. The virus infects oligodendrocytes, leading to diffuse and patchy demyelination that primarily affects white matter of the cerebral hemispheres but also involves the brainstem and cerebellum. The course is subacute and progressive, leading to death in 3–6 months. Fever and systemic symptoms are absent. Dementia and focal cortical dysfunction are prominent. Signs of the latter include hemiparesis, visual deficits, aphasia, dysarthria, and sensory impairment. Ataxia and headache are uncommon and seizures do not occur.
Figure 1–17. T2-weighted MRI in progressive multifocal leukoencephalopathy, showing abnormally high signal intensity (arrows) in white matter of the right parietal and occipital lobes. (Courtesy of A Gean.)
60 / CHAPTER 1 Marchiafava Bignami syndrome is characterized by necrosis of the corpus callosum and subcortical white matter and occurs most often in malnourished alcoholics. The course can be acute, subacute, or chronic. Clinical features include dementia, spasticity, dysarthria, gait disorder, and coma. The diagnosis can sometimes be made by CT scan or MRI. No specific treatment is available, but cessation of drinking and improvement of nutrition are advised. The outcome is variable: patients may die, survive with dementia, or recover. Alcoholic dementia due to direct toxic effects of ethanol on the brain has been proposed to occur, but no distinctive abnormalities have been identified in the brains of demented alcoholics. Dementia in alcoholics is more likely to result from one or more of the metabolic and traumatic disorders mentioned above.
tia supervenes. The EEG shows paroxysmal high-voltage slowing with intermixed spikes and slow waves; these abnormalities can be reversed by diazepam. Aluminum in the dialysate is a major etiologic suspect, and removing trace metals from the dialysate has decreased the syndrome’s incidence. Mean survival is 6 months.
2. HYPOTHYROIDISM Hypothyroidism (myxedema), which is discussed above as a cause of acute confusional states, can also produce a reversible dementia or chronic organic psychosis. The dementia is a global disorder characterized by mental slowness, memory loss, and irritability. Focal cortical deficits do not occur. Psychiatric manifestations are typically prominent and include depression, paranoia, visual and auditory hallucinations, mania, and suicidal behavior. Patients with myxedema may complain of headache, hearing loss, tinnitus, vertigo, weakness, or paresthesia. Examination may show deafness, dysarthria, or cerebellar ataxia. The most suggestive finding is delayed relaxation of the tendon reflexes. Diagnosis and treatment are discussed above. Cognitive dysfunction is usually reversible with treatment.
Systemic manifestations of chronic liver disease are usually present. The neurologic syndrome is fluctuating but progressive over 1–9 years, and may be punctuated by episodes of acute hepatic encephalopathy. Dementia, dysarthria, and cerebellar, extrapyramidal, and pyramidal signs are the most common features. Dementia is marked by mental slowness, apathy, impaired attention and concentration, and memory disturbance. Cerebellar signs include gait and limb ataxia and dysarthria; nystagmus is rare. Extrapyramidal involvement may produce rigidity, resting tremor, dystonia, chorea, or athetosis. Asterixis, myoclonus, hyperreflexia, and extensor plantar responses are common; paraparesis is rare. Laboratory studies show abnormal hepatic blood chemistries and elevated blood ammonia, but the degree of abnormality bears no direct relationship to the severity of neurologic symptoms. The CSF is normal, except for increased glutamine and occasional mild elevation of protein.
3. VITAMIN B12 DEFICIENCY Vitamin B12 deficiency is a rare cause of reversible dementia and organic psychosis. Like the acute confusional state associated with vitamin B12 deficiency (see above), dementia can occur with or without hematologic and other neurologic manifestations. The dementia consists of global cognitive dysfunction with mental slowness, impaired concentration, and memory disturbance; aphasia and other focal cortical disorders do not occur. Psychiatric manifestations are often prominent and include depression, mania, and paranoid psychosis with visual and auditory hallucinations. Laboratory findings and treatment are discussed above.
ORGAN FAILURE 1. DIALYSIS DEMENTIA This rare disorder typically occurs in patients receiving chronic hemodialysis. Clinical features include dysarthria, myoclonus, and seizures. These are initially intermittent, but later become permanent, and demen-
2. NON-WILSONIAN HEPATOCEREBRAL DEGENERATION Acquired (non-Wilsonian) hepatocerebral degeneration is an uncommon complication of chronic hepatic cirrhosis with spontaneous or surgical portosystemic shunting. Symptoms may be related to failure of the liver to detoxify ammonia. Neurologic symptoms precede hepatic symptoms in about one-sixth of patients.
Clinical Findings
Differential Diagnosis Wilson disease can be distinguished by its earlier onset, Kayser-Fleischer rings and abnormal copper metabolism. Alcoholic cerebellar degeneration primarily affects gait and is not accompanied by extrapyramidal or pyramidal signs.
Treatment & Prognosis Patients may benefit from a low-protein diet, lactulose, neomycin, liver transplantation, or portosystemic shunting, and improvement following levodopa or bromocriptine therapy has been described. Death results from progressive liver failure or variceal bleeding. 3. WILSON DISEASE Wilson disease (hepatolenticular degeneration) is a rare but treatable autosomal recessive hereditary disorder of copper metabolism that produces dementia and ex-
DISORDERS OF COGNITIVE FUNCTION / 61 trapyramidal symptoms. The disease results from mutations in the ATP7B gene on chromosome 13 (13q14.3–q21.1), which codes for the β polypeptide of a copper-transporting ATPase. Wilson disease is discussed further in Chapter 7.
TRAUMA Severe open or closed head injury, particularly when followed by prolonged unconsciousness, may cause impaired memory and concentration, personality changes, headache, focal neurologic disorders, or seizures. Cognitive impairment is nonprogressive, and the cause is usually obvious. Delayed, progressive posttraumatic dementia in boxers (dementia pugilistica) is characterized by cheerful or labile affect, mental slowness, memory deficit, and irritability. Associated neurologic abnormalities include tremor, rigidity, bradykinesia, dysarthria, cerebellar ataxia, pyramidal signs, and seizures. Neuroradiologic investigations may show cortical atrophy and cavum septi pellucidi.
VASCULAR DISORDERS 1. CHRONIC SUBDURAL HEMATOMA Chronic subdural hematoma usually affects patients aged 50–70 years, often after minor head trauma. Other risk factors include alcoholism, cerebral atrophy, epilepsy, the use of anticoagulation, ventricular shunts, and long-term hemodialysis. The onset of symptoms may be delayed for months after trauma. Hematomas are bilateral in about one-sixth of cases.
Clinical Findings Headache is the initial symptom in most patients. Confusion, dementia, hemiparesis, and vomiting may ensue. The most frequent signs are cognitive disturbance, hemiparesis, papilledema, and extensor plantar responses. Aphasia, visual field defects, and seizures are uncommon, but can occur. The hematoma can usually be seen on CT scan or MRI (Figure 1–18) as an extraaxial crescent-shaped area of decreased density, with ipsilateral obliteration of cortical sulci and often ventricular compression. The scan should be carefully reviewed for evidence of bilateral subdural collections. Isodense collections may become more apparent after contrast infusion. In a few cases, demonstration of the hematoma may require cerebral arteriography, which should always be undertaken bilaterally.
Treatment Unless contraindicated by medical problems or spontaneous improvement, symptomatic hematomas should be surgically evacuated.
Figure 1–18. CT scan in chronic subdural hematoma, showing bilateral low-density collections between the inner table of the skull and the cerebral hemispheres (arrows).
2. VASCULAR DEMENTIA Vascular dementia is thought to be the third most common cause of dementia, after Alzheimer disease and dementia with Lewy bodies. Most patients with this diagnosis have either multiple large cortical infarcts from occlusion of major cerebral arteries or several smaller infarcts (lacunar state; see Chapter 9) affecting subcortical white matter, basal ganglia, or thalamus. The relationship between cerebral vascular disease and dementia is poorly characterized. For example, the number of strokes, their locations, and the total infarct volume required for strokes to produce dementia are uncertain, making it often difficult to determine if strokes are the cause of dementia in a given patient. Whether dementia can result from cerebrovascular disease without frank infarction, as is commonly presumed to exist when periventricular white matter lesions are detected by neuroimaging, is also controversial. Thus, the absence of neuroradiologic signs of cerebrovascular disease argues strongly against a vascular basis for dementia, but the presence of vascular lesions does not prove that they are causal. This is especially true when another cause of dementia, such as Alzheimer disease, coexists with cerebrovascular disease.
62 / CHAPTER 1
Clinical Findings As classically described, patients with multiinfarct dementia have a history of hypertension, a stepwise progression of deficits, a more or less abrupt onset of dementia, and focal neurologic symptoms or signs. Because extensive pathologic changes may already exist at presentation, it is assumed that patients can remain functionally well compensated until a new and perhaps otherwise innocuous infarct tips the balance. The neurologic examination commonly shows pseudobulbar palsy with dysarthria, dysphagia, and pathologic emotionality (pseudobulbar affect), focal motor and sensory deficits, ataxia, gait apraxia, hyperreflexia, and extensor plantar responses.
Investigative Studies The MRI (Figure 1–19) may show multiple small subcortical lucencies. Extensive areas of low density in subcortical white matter are seen in Binswanger disease (subcortical arteriosclerotic encephalopathy), which may be a related condition. MRI is more sensitive than CT for detecting these abnormalities. Additional laboratory studies should be performed to exclude cardiac emboli, polycythemia, thrombocyto-
sis, cerebral vasculitis, and meningovascular syphilis as causes of multiple infarctions, particularly in younger patients or those without a history of hypertension.
Treatment Hypertension, when present, should be treated to reduce the incidence of subsequent infarction and to prevent other end-organ diseases. Antiplatelet agents (discussed in Chapter 9) may help to reduce the risk of future strokes.
PSEUDODEMENTIA Depression is the disorder most commonly mistaken for dementia. Because depression is common and treatable, distinguishing between the two conditions is important. Both dementia and depression can be characterized by mental slowness, apathy, self-neglect, withdrawal, irritability, difficulty with memory and concentration, and changes in behavior and personality. In addition, depression can be a feature of dementing illnesses, and the two frequently coexist. Clinical features that help in the differentiation are listed in Table 1–29. When depression is being considered, psychiatric consultation should be obtained. If depression is identified as a significant problem and is not correctable by treatment of an underlying disease or by a change in medication, it should be treated directly. Modes of treatment include psychotherapy, tricyclic and related antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, and electroconvulsive therapy.
IV. AMNESTIC SYNDROMES A disorder of memory (amnestic syndrome) may occur as one feature of an acute confusional state or dementia, or as an isolated abnormality (Table 1–30). The latter condition is discussed in this section.
Memory
Figure 1–19. T2-weighted MRI in multiinfarct dementia, showing foci of abnormal high signal intensity adjacent to the lateral ventricles (arrows) and within the basal ganglia (arrowheads).
Memory is a complex function that can be viewed for clinical purposes as comprising phases of registration, storage, and retrieval. Autopsy and imaging studies of the brains of patients with memory disorders suggest that the hippocampus and related structures, such as the dorsomedial nucleus of the thalamus, are important in memory processing. Bilateral damage to these regions results in impairment of short-term memory, which is manifested clinically by the inability to form new memories. Long-term memory, which involves retrieval of previously learned information, is relatively preserved, perhaps because well-established memories are stored
DISORDERS OF COGNITIVE FUNCTION / 63 Table 1–29. Dementia and the pseudodementia of depression: distinguishing features. Dementia
Depression
Insidious onset
Abrupt onset
Progressive deterioration
Plateau of dysfunction
No history of depression
History of depression may exist
Patient typically unaware of extent of deficits and does not complain of memory loss
Patient aware of and may exaggerate deficits and frequently complains of memory loss
Somatic complaints uncommon
Somatic complaints or hypochondriasis common
Variable affect
Depressed affect
Few vegetative symptoms
Prominent vegetative symptoms
Impairment often worse at night
Impairment usually not worse at night
Neurologic examination and laboratory studies may be abnormal
Neurologic examination and laboratory studies normal
diffusely in the cerebral cortex. Some patients with amnestic syndromes may attempt to fill in gaps in memory with false recollections (confabulation), which can take the form of elaborate contrivances or of genuine memories misplaced in time. The longest-standing and most deeply ingrained memories, however, such as one’s own name, are almost always spared in organic memory disturbances. In contrast, such personal memories may be prominently or exclusively impaired in dissociative (psychogenic) amnesia. The cellular basis of memory is poorly understood, but repetitive neuronal firing produces lasting pre- and postsynaptic changes that facilitate neurotransmission at hippocampal synapses (long-term potentiation). These changes appear to involve the release of glutamate, which stimulates the entry of calcium into post-
Table 1–30. Causes of amnestic syndromes. Acute Accompanying acute confusional states Head trauma Hypoxia or ischemia Bilateral posterior cerebral artery occlusion Transient global amnesia Alcoholic blackouts Wernicke encephalopathy Dissociative (psychogenic) amnesia Chronic Accompanying dementias Alcoholic Korsakoff amnestic syndrome Postencephalitic amnesia Brain tumor Paraneoplastic limbic encephalitis
synaptic neurons, and the production of retrograde signals that act on presynaptic nerve terminals to increase transmitter release upon subsequent firing.
ACUTE AMNESIA HEAD TRAUMA Head injuries resulting in loss of consciousness are invariably associated with an amnestic syndrome. Patients seen shortly after such an injury exhibit a confusional state in which they are unable to incorporate new memories (anterograde, or posttraumatic amnesia; see Figure 1–20), although they may behave in an apparently normal automatic fashion. In addition, retrograde amnesia is present, covering a variable period prior to the trauma. Features characteristic of transient global amnesia (see below) may be seen. As full consciousness returns, the ability to form new memories is restored. Events occurring in the confusional interval tend to be permanently lost to memory, however. Exceptions are islands of memory, for a lucid interval between trauma and unconsciousness, or for periods of lesser impairment in the course of a fluctuating posttraumatic confusional state. The period of retrograde amnesia begins to shrink, with the most remote memories the first to return. The severity of the injury tends to correlate with the duration of confusion and with the extent of permanent retrograde and posttraumatic amnesia.
HYPOXIA OR ISCHEMIA Because of the selective vulnerability of pyramidal neurons in the Sommer sector (h1 sector of Scholz) of the
64 / CHAPTER 1 Trauma
Recovery
Level of consciousness
Normal
Confused
Comatose
Retrograde amnesia
Anterograde amnesia
Time
Figure 1–20. Retrograde and anterograde amnesia in posttraumatic memory disorders. Head trauma may produce transient coma, followed by a confusional state during which the patient is unable to form new memories.With recovery, this ability is restored, but there is persistent amnesia for the period of coma and confusion (anterograde amnesia) and for a variable period preceding the trauma (retrograde amnesia); the latter deficit may improve with time.
hippocampus, conditions resulting in cerebral hypoxia or ischemia, such as cardiac arrest or carbon monoxide poisoning, can produce amnestic syndromes. Amnesia tends to occur in patients in whom coma has lasted at least 12 hours. There is severe impairment of the ability to incorporate new memories, with relative preservation of registration and remote memory; patients typically appear to have an isolated disorder of short-term memory. A period of retrograde amnesia preceding the insult may occur. Patients exhibit a lack of concern about their impairment and sometimes confabulate. Amnesia following cardiac arrest may be the sole manifestation of neurologic dysfunction, or it may coexist with other cerebral watershed syndromes, such as bibrachial paresis, cortical blindness, or visual agnosia (see Chapter 9). Recovery often occurs within several days, although deficits may persist. Amnestic syndromes from carbon monoxide poisoning are frequently associated with affective disturbances. Other associated abnormalities include focal cortical and extrapyramidal dysfunction. Acute carbon monoxide poisoning is suggested by cherry-red coloration of the skin and mucous membranes, elevated carboxyhemoglobin levels, or cardiac arrhythmia. The CT brain scan may show lucencies in the basal ganglia and dentate nuclei.
BILATERAL POSTERIOR CEREBRAL ARTERY OCCLUSION The posterior cerebral artery supplies the medial temporal lobe, thalamus, posterior internal capsule, and oc-
cipital cortex (Figure 1–21). Ischemia or infarction in this territory, typically when bilateral, may produce a transient or permanent amnestic syndrome. Emboli in the vertebrobasilar system (see Chapter 9) are frequent causes of such disorders. The amnestic syndrome is usually associated with unilateral or bilateral hemianopia and sometimes with visual agnosia, alexia without agraphia, anomia, sensory disturbances, or signs of upper midbrain dysfunction (especially impaired pupillary light reflex). Recent memory tends to be selectively impaired, with relative preservation of remote memory and registration. The CT scan shows lucencies—which may or may not be enhanced by use of contrast material—in any combination of the above-mentioned regions. Evaluation and treatment are described in Chapter 9.
TRANSIENT GLOBAL AMNESIA Transient global amnesia is a syndrome of acute memory loss that tends to occur in middle-aged or elderly patients with risk factors for atherosclerotic disease, especially a prior ischemic event in the posterior cerebral circulation. The disorder is recurrent in fewer than 10% of patients. A primary disorder of short-term memory that can last for minutes or days, it typically lasts for hours. Patients appear agitated and perplexed and may repeatedly inquire about their whereabouts, the time, and the nature of what they are experiencing. Knowledge of personal identity is preserved, as are remote memories and registration. New memories cannot be formed,
DISORDERS OF COGNITIVE FUNCTION / 65 (especially serotonin- or glutamate-mediated) neurotransmission. The disorder is self-limited and no specific treatment is required, but reduction of the ethanol intake should be counseled, and thiamine should be given to treat possible Wernicke encephalopathy (see p. 18).
WERNICKE ENCEPHALOPATHY Wernicke encephalopathy is caused by thiamine deficiency and classically produces an acute confusional state, ataxia, and ophthalmoplegia. Amnesia may be the major or sole cognitive disturbance, however, especially after thiamine treatment is begun and other cognitive abnormalities improve. Because patients with Wernicke encephalopathy usually present with global confusion rather than isolated amnesia, the disorder is discussed more fully above (see p. 18).
DISSOCIATIVE (PSYCHOGENIC) AMNESIA Figure 1–21. T1-weighted MRI in a patient with an old left posterior cerebral artery occlusion, showing tissue loss in the medial temporal (small arrows) and occipital (large arrows) lobes and associated dilation of the temporal and occipital horns of the lateral ventricle. (Courtesy of A Gean.) however, which accounts for the patient’s repetitive questions. Retrograde amnesia for a variable period preceding the episode may be present, but this period shrinks as the episode resolves. The patient’s obvious concern about the condition distinguishes transient global amnesia from most other organically based amnestic syndromes and may give rise to the suspicion that amnesia is psychogenic. A CT scan or MRI may demonstrate focal thalamic or temporal lobe abnormalities. Diffusion-weighted MRI has shown signal abnormalities in the temporal lobe during spells of transient global amnesia. These are compatible with cellular edema and may be related to spreading depression—a wave of cellular depolarization accompanied by cellular swelling in the brain.
ALCOHOLIC BLACKOUTS Short-term consumption of large amounts of ethanol by alcoholic or nonalcoholic individuals may lead to “blackouts”—transient amnestic episodes that are not due to global confusion, seizures, head trauma, or the Wernicke-Korsakoff syndrome. These spells are characterized by an inability to form new memories, without impairment of long-term memory or immediate recall. Although the cause is unknown, alcoholic blackouts may result from ethanol-induced depression of synaptic
Amnesia may be a manifestation of a dissociative disorder or of malingering. In such patients a prior psychiatric history, additional psychiatric symptoms, or a precipitating emotional stress can often be identified. Dissociative amnesia is characterized by an isolated or a disproportionate loss of traumatic or stressful personal memories. Dissociative amnesia is usually localized in time to the immediate aftermath of a traumatic experience or selective for some but not other events during such a period. Less frequent patterns include systematized amnesia restricted to certain categories of information, continuous amnesia for events from some time in the past up to and including the present, and generalized amnesia. In some cases, patients may be unable to remember even their own name—an exceedingly rare finding in organic amnesia. Despite such disorientation to person, orientation to place and time may be preserved. In addition, recent memories may be less affected than remote memories—the reverse of the pattern customarily seen in amnesia caused by organic disease. Examination under hypnosis or after administration of amobarbital sodium may be helpful in establishing that amnesia is of psychogenic origin.
CHRONIC AMNESIA ALCOHOLIC KORSAKOFF AMNESTIC SYNDROME The Korsakoff amnestic syndrome, which occurs in chronic alcoholism and other malnourished states, is thought to be caused by thiamine deficiency. It is usually preceded by one or more episodes of Wernicke encephalopathy, but such a history may be lacking. The memory disorder may be related to bilateral degeneration of the dorsomedial thalamic nuclei.
66 / CHAPTER 1 An amnestic syndrome of variable severity follows recovery from Wernicke encephalopathy in about three-fourths of cases and is often associated with polyneuropathy and other residua such as nystagmus or gait ataxia. The essential defect is an inability to form new memories, resulting in significant impairment of short-term memory. Long-term memory is also frequently affected, although to a lesser extent. Registration is intact. Patients are typically apathetic and lack insight into their disorder. They may attempt to reassure the physician that no impairment exists and try to explain away their obvious inability to remember. Confabulation is often, but not invariably, a feature. Korsakoff syndrome can be prevented or its severity decreased by prompt administration of thiamine to patients with Wernicke encephalopathy. Patients with established Korsakoff syndrome should also receive thiamine to prevent the progression of deficits, although existing deficits are unlikely to be reversed.
POSTENCEPHALITIC AMNESIA Patients who recover from acute viral encephalitis—particularly that caused by herpes simplex virus—may be left with a permanent and static amnestic syndrome. The syndrome is similar to that produced by chronic alcoholism in that an inability to form new memories is its outstanding feature. Remote memories are affected to a lesser extent than are recent ones, and registration is intact. Confabulation may occur. Often there is total amnesia for the period of the acute encephalitis. Patients may also exhibit other symptoms of limbic system disease. These include docility, indifference, flatness of mood and affect, inappropriate jocularity and sexual allusions, hyperphagia, impotence, repetitive stereotyped motor activity, and the absence of goal-oriented activity. Complex partial seizures, with or without secondary generalization, may occur.
BRAIN TUMOR Brain tumor is a rare cause of amnestic syndrome. Tumors that can present in this manner include those that are located in the third ventricle or that compress its floor or walls from without. The amnestic syndrome closely resembles Korsakoff syndrome. In addition, patients with deep midline tumors often exhibit marked lethargy, headache, endocrine disturbances, visual field deficits, or papilledema. The diagnosis of brain tumor is made by CT scan or MRI. Treatment consists of surgery or irradiation or both, depending upon the type of tumor and its location.
as a remote effect of systemic cancer. When limbic structures are primarily affected, the clinical picture is that of an amnestic syndrome. The disorder is thought to be autoimmune in origin since, as in other paraneoplastic neurologic syndromes, antineuronal autoantibodies can be detected. Paraneoplastic limbic encephalitis is most often associated with small-cell cancer of the lung, and symptoms typically precede diagnosis of the underlying cancer. Histopathologic findings include neuronal loss, reactive gliosis, microglial proliferation, and perivascular lymphocytic cuffing. Gray matter of the hippocampus, cingulum, piriform cortex, inferior frontal lobes, insula, and amygdala is characteristically affected. Symptoms develop over several weeks. The disorder is characterized by profound impairment of recent memory, corresponding to the inability to learn new material. Remote memory is less impaired, and registration is unaffected; confabulation occurs in some cases. Affective symptoms, either anxiety or depression, are common early features. Hallucinations and complex partial or generalized seizures may occur. In many instances, the amnestic syndrome progresses to a global dementia. Depending upon the extent to which gray matter regions outside the limbic system are involved, cerebellar, pyramidal, bulbar, and peripheral nerve disturbances may coexist with the amnestic disorder. The CSF may also show a modest mononuclear pleocytosis and mildly elevated protein. Diffuse slowing or bitemporal slow waves and spikes are sometimes seen on EEG. An MRI may reveal abnormal signal intensity in the medial temporal lobes. About 60% of patients have antineuronal antibodies in serum or CSF. Anti-Hu antibodies are most common and are usually associated with small-cell lung cancer and anti-Ta antibodies are seen in patients with testicular cancer; in both groups, prognosis is poor. Patients with neither anti-Hu nor anti-Ta antibodies have a better outcome and often improve after treatment of the underlying tumor. The paraneoplastic amnestic syndrome can be static, it can progress, or it can remit. Excluding other, especially treatable, disorders is of primary importance. Korsakoff syndrome caused by thiamine deficiency should be especially considered, because patients with cancer are susceptible to nutritional deficiency and thiamine administration may prevent these symptoms from worsening.
REFERENCES ACUTE CONFUSIONAL STATES
PARANEOPLASTIC LIMBIC ENCEPHALITIS
Metabolic Disorders
An inflammatory and degenerative disorder of gray matter regions of the central nervous system can occur
Adrogu HJ, Madias NE: Hyponatremia. N Engl J Med 2000;342: 1581–1589.
DISORDERS OF COGNITIVE FUNCTION / 67 Bilezikian JP: Management of acute hypercalcemia. N Engl J Med 1992;326:1196–1203. Chen HC, Marsharani U: Hashimoto’s encephalopathy. South Med J 2000;93:504–506. Kosten TR, O’Connor PG: Management of drug and alcohol withdrawal. N Engl J Med 2003;348:1786–1795. Lewis MB, Howdle PD: Neurologic complications of liver transplantation in adults. Neurology 2003;61:1174–1178. Oelkers W: Adrenal insufficiency. N Engl J Med 1996;335:1206– 1212. Patchell RA: Neurological complications of organ transplantation. Ann Neurol 1994;36:688–703. Riordan SM, Williams R: Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473–479. Toh BH et al: Pernicious anemia. N Engl J Med 1997;337:1441– 1448.
Meningitis & Encephalitis Anon. Choice of Antibacterial Drugs. Treatment Guidelines from Med Lett 2:13–26, 2004. Chaudhuri A: Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol 2004;3:54–62. de Gans J, van de Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549–1556. Garcia HH et al: Taenia solium cysticercosis. Lancet 2003;362: 547–556. Garcia HH et al: A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350:249–258. Gottfredsson M, Perfect JR: Fungal meningitis. Semin Neurol 2000;20:307–322. Hughes PA et al: Eosinophilic meningitis: a case series report and review of the literature. Mil Med 2003;168:817–821. Marra CM: Encephalitis in the 21st century. Semin Neurol 2000;20:323–327. McJunkin JE et al: La Crosse encephalitis in children. N Engl J Med 2001;344:801–807. Newton CR, Hien TT, White N: Cerebral malaria. J Neurol Neurosurg Psychiat 2000;69:433–441. Papadopoulos MC et al: Pathophysiology of septic encephalopathy: a review. Crit Care Med 2000;28:3019–3024. Quagliarello VJ, Scheld WM: Treatment of bacterial meningitis. N Engl J Med 1997;336:708–716. Rosenstein NE et al: Meningococcal disease. N Engl J Med 2001;344:1378–1388. Sejvar JJ et al: Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003;290:511–515. Slom TJ et al: An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. N Engl J Med 2002;346:668–675. Steere AC: Lyme disease. N Engl J Med 2001;345:115–125. Thwaites GE et al: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741–1751.
Vascular Disorders Gold R et al: Therapy of neurological disorders in systemic vasculitis. Semin Neurol 2003;23:207–214.
Levi M, ten Cate, H: Disseminated intravascular coagulation. N Engl J Med 1999;341:586–592. Raife TJ, Montgomery RR: von Willebrand factor and thrombotic thrombocytopenic purpura. Curr Opin Hematol 2000;7: 278–283. Vaughan CJ, Delanty N: Hypertensive emergencies. Lancet 2000; 356:411–417. Yarranton H, Machin SJ: An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura. Curr Opin Neurol 2003;16:367–373.
Head Trauma Guskiewicz KM et al: Cumulative effects associated with recurrent concussion in collegiate football players: the NCAA Concussion Study. JAMA 2003;290:2549–2555. McCrea M et al: Acute effects and recovery time following concussion in collegiate football players: the NCAA Concussion Study. JAMA 2003;290:2556–2563.
Psychiatric Disorders Richards CF, Gurr DE: Psychosis. Emerg Med Clin North Am 2000;18:253–262.
DEMENTIA (GENERAL) Aguzzi A, Haass C: Games played by rogue proteins in prion disorders and Alzheimer’s disease. Science 2003;302:814–818. Caselli RJ. Current issues in the diagnosis and management of dementia. Semin Neurol 2003;23:231–240. Luis CA et al: Mild cognitive impairment: directions for future research. Neurology 2003;61:438–444. Sampson EL et al: Young onset dementia. Postgrad Med J 2004;80: 125–139. Shumaker SA et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–2662. Verghese J et al: Abnormality of gait as a predictor of nonAlzheimer’s dementia. N Engl J Med 2002;347:1761–1768.
Alzheimer Disease Clark CM, Karlawish JH: Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;138:400–410. Cummings JL: Alzheimer’s disease. N Engl J Med 2004;351:56–67. Hock C et al: Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003;38:547–554. Hui JS et al: Rate of cognitive decline and mortality in Alzheimer’s disease. Neurology 2003;61:1356–1361. Kawas CH: Clinical practice. Early Alzheimer’s disease. N Engl J Med 2003;349:1056–1063. Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999;341:1670–1679. Monsonego A, Weiner H: Immunotherapeutic approaches to Alzheimer’s disease. Science 2003;302:834–838. Nicoll JA et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448–452.
68 / CHAPTER 1 Reisberg B et al: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333–1341. Scarpini E et al: Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003;2:539–547. Tariot PN et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317–324. Trinh NH et al: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210–216.
Other Cerebral Disorders McKeith I et al: Dementia with Lewy bodies. Lancet Neurol 2004;3:19–28. Mendez MF et al: Frontotemporal dementia versus Alzheimer’s disease: differential cognitive features. Neurology 1996;47: 1189–1194. Riley DE et al: Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–1212. Van Everbroeck B et al: Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol 2004;251:298– 304. Van Everbroeck B et al: A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiat 2003;74:1210–1214. Vanneste JA: Diagnosis and management of normal-pressure hydrocephalus. J Neurol 2000;247:5–14. Will RG et al: Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000;47:575–582.
Systemic Disorders Berger JR, Major EO: Progressive multifocal leukoencephalopathy. Semin Neurol 1999;19:193–200.
Clifford DB: AIDS dementia. Med Clin North Am 2002;86:537– 550. Iantosca MR, Simon RH: Chronic subdural hematoma in adult and elderly patients. Neurosurg Clin N Am 2000;11:447– 454. Roman GC: Vascular dementia today. Rev Neurol (Paris) 1999;155 (Suppl 4):S64–S72. Toh BH et al: Pernicious anemia. N Engl J Med 1997;337:1441– 1448. Truelsen T et al: Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002;59: 1313–1319. Vermeer SE et al: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
Pseudodementia Raskind MA: The clinical interface of depression and dementia. J Clin Psychiatry 1998;59(Suppl 10):9–12.
AMNESTIC SYNDROMES Gultekin SH et al: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481–1494. Jordan BD: Chronic traumatic brain injury associated with boxing. Semin Neurol 2000;20:179–185. Lynch MA: Long-term potentiation and memory. Physiol Rev 2004;84:87–136. Pantoni L, Lamassa M, Inzitari D: Transient global amnesia: a review emphasizing pathogenic aspects. Acta Neurol Scand 2000;102:275–283. Small SA et al: Imaging hippocampal function across the human life span: is memory decline normal or not? Ann Neurol 2002;51:290–295.
2
Headache & Facial Pain
CONTENTS Approach to diagnosis, 70 Pathophysiology of headache & facial pain, 70 History, 70 Physical examination, 73 Neurologic examination, 74 Headaches of acute onset, 74 Subarachnoid hemorrhage, 74 Other cerebrovascular disorders, 79 Meningitis or encephalitis, 80
Other causes of acute headache, 80 Headaches of subacute onset, 81 Giant cell arteritis, 81 Intracranial mass, 82 Idopathic Intracranial Hypertension, 83 Trigeminal neuralgia, 83 Glossopharyngeal neuralgia, 84 Postherpetic neuralgia, 84
Hypertension, 85 Atypical facial pain, 85 Chronic headaches, 85 Migraine, 85 Analgesic withdrawal headache, 90 Cluster headache, 90 Tension-type headache, 91 Ice pick pain, 92 Cervical spine disease, 92 Sinusitis, 92 Dental disease, 92
KEY CONCEPTS Headache results from disorders that affect painsensitive structures of the head and neck, such as meninges, blood vessels, nerves, and muscle.
urgent lumbar puncture and away from imaging procedures. Subarachnoid hemorrhage from a ruptured intracranial aneurysm often can be diagnosed by the presence of subarachnoid blood on a noncontrast CT scan; however, in the absence of this finding, a lumbar puncture showing no blood in the cerebrospinal fluid is required to exclude the diagnosis.
Headaches that are new in onset or different from previous headaches are those most likely to be caused by a serious illness, whereas headaches of long standing usually have a benign cause. Signs of meningeal irritation—such as neck stiffness on passive flexion in the anteroposterior direction or hip and knee flexion in response to passive neck flexion—must be sought in patients with acute headache; detecting these signs is critical in the rapid diagnosis of meningitis, and directs the diagnostic evaluation toward
High blood pressure alone does not cause chronic headache. For maximum effect, drugs for migraine should be taken immediately at the onset of symptoms.
69 Copyright © 2005, 2002 by The McGraw-Hill Companies, Inc. Click here for terms of use.
70 / CHAPTER 2 Headache occurs in all age groups and accounts for 1–2% of emergency department evaluations and for up to 4% of medical office visits; the causes are myriad (Table 2–1). Although most often a benign condition (especially when chronic and recurrent), headache of new onset may be the earliest or the principal manifestation of serious systemic or intracranial disease and therefore requires thorough and systematic evaluation. An etiologic diagnosis of headache is based on understanding the pathophysiology of head pain; obtaining a history, with characterization of the pain as acute, subacute, or chronic; performing a careful physical examination; and formulating a differential diagnosis.
APPROACH TO DIAGNOSIS PATHOPHYSIOLOGY OF HEADACHE & FACIAL PAIN Pain-Sensitive Structures Headache is caused by traction, displacement, inflammation, vascular spasm, or distention of the pain-sensitive structures in the head or neck. Isolated involvement of the bony skull, most of the dura, or most regions of brain parenchyma does not produce pain. A. PAIN-SENSITIVE STRUCTURES WITHIN THE CRANIAL VAULT These include the venous sinuses (eg, sagittal sinus); the anterior and middle meningeal arteries; the dura at the base of the skull; the trigeminal (V), glossopharyngeal (IX), and vagus (X) nerves; the proximal portions of the internal carotid artery and its branches near the Circle of Willis; the brainstem periaqueductal gray matter; and the sensory nuclei of the thalamus. B. EXTRACRANIAL PAIN-SENSITIVE STRUCTURES These include the periosteum of the skull; the skin; the subcutaneous tissues, muscles, and arteries; the neck muscles; the second and third cervical nerves; the eyes, ears, teeth, sinuses, and oropharynx; and the mucous membranes of the nasal cavity.
Radiation or Projection of Pain The trigeminal (V) nerve carries sensation from intracranial structures in the anterior and middle fossae of the skull, above the cerebellar tentorium. Discrete intracranial lesions in these locations can produce pain that radiates in the trigeminal nerve distribution (Figure 2–1). The glossopharyngeal (IX) and vagus (X) nerves supply part of the posterior fossa; pain originating in
Table 2–1. Causes of headache and facial pain. Acute onset Common causes Subarachnoid hemorrhage Other cerebrovascular diseases Meningitis or encephalitis Ocular disorders (glaucoma, acute iritis) Less common causes Seizures Lumbar puncture Hypertensive encephalopathy Coitus Subacute onset Giant cell (temporal) arteritis Intracranial mass (tumor, subdural hematoma, abscess) Pseudotumor cerebri (benign intracranial hypertension) Trigeminal neuralgia (tic douloureux) Glossopharyngeal neuralgia Posttherpetic neuralgia Hypertension (including pheochromocytoma and the use of monoamine oxidase inhibitors plus tyramine) Atypical facial pain Chronic Migraine Cluster headache Tension headache Cervical spine disease Sinusitis Dental disease
this area may also be referred to the ear or throat (eg, glossopharyngeal neuralgia). The upper cervical nerves transmit stimuli arising from infratentorial and cervical structures; therefore, pain from posterior fossa lesions projects to the second and third cervical dermatomes (Figure 2–1).
HISTORY Classification & Approach to the Differential Diagnosis A. ACUTE HEADACHES AND FACIAL PAIN Headaches that are new in onset and clearly different from any the patient has experienced previously are commonly a symptom of serious illness and therefore demand prompt evaluation. The sudden onset of “the worst headache I’ve ever had in my life” (classic subarachnoid hemorrhage), diffuse headache with neck stiffness and fever (meningitis), and head pain centered about one eye (acute glaucoma) are striking examples. Acute headaches may also accompany more benign processes such as viral syndromes or other febrile illnesses.
HEADACHE & FACIAL PAIN / 71 Anterior fossa
V1 V1, 2, 3 C2 C2, 3
Middle fossa
C1, 2, 3
V2 C3
Tentorium cerebelli C2, 3
Posterior fossa
V3 C4 C3, 4
A
B
Figure 2–1. Innervation of pain-sensitive intracranial compartments A and corresponding extracranial sites of pain radiation B.The trigeminal (V) nerve, especially its ophthalmic (V1) division, innervates the anterior and middle cranial fossae; lesions in these areas can produce frontal headache.The upper cervical nerve roots (especially C2) innervate the posterior fossa; lesions here can cause occipital headache.
B. SUBACUTE HEADACHES AND FACIAL PAIN Subacute headaches occur over a period of weeks to months. Such headaches may also signify serious medical disorders, especially when the pain is progressive or when it develops in elderly patients. Inquiries should be made about recent head trauma (subdural hematoma or postconcussive syndrome); a history of malaise, fever, or neck stiffness (subacute meningitis); other neurologic abnormalities or weight loss (primary or metastatic brain tumor); symptoms of vasculitis, especially giant cell arteritis; and medical conditions (eg, optic neuritis in multiple sclerosis; cutaneous herpes zoster) or medications predisposing to any of the disorders listed in Table 2–1. C. CHRONIC HEADACHES AND FACIAL PAIN Headaches that have occurred for years (eg, migraine or tension headaches) usually have a benign cause, although each acute attack may be profoundly disabling. When treating these patients, it is important to determine whether the present headache is similar to those suffered previously or is new—and thus represents a different process.
Precipitating Factors Precipitating factors can provide a guide to the cause of headache. Such factors include recent eye or dental surgery; acute exacerbation of chronic sinusitis or hay fever; systemic viral infection; tension, emotional stress, or fatigue; menses; hunger; ice cream; foods containing nitrite (hot dogs, salami, ham, and most sausage), phenylethylamine (chocolate), or tyramine (cheddar cheese); and bright lights. Precipitation of headache by alcohol is especially typical of cluster headache. Chewing and eating commonly trigger glossopharyngeal neuralgia, tic douloureux, and the jaw claudication of giant cell arteritis; these activities also trigger pain in patients with temporomandibular joint dysfunction. The use of oral contraceptive agents or other drugs such as nitrates may precipitate or exacerbate migraine and even lead to stroke. Intense headache can occur in response to coughing in patients with structural lesions in the posterior fossa; in other instances no specific cause for cough headache can be identified.
72 / CHAPTER 2
Prodromal Symptoms and Auras
Associated Symptoms
Prodromal symptoms or auras, such as scintillating scotomas or other visual changes, often occur with migraine; they may also occur in patients with a seizure disorder who present with postictal headaches.
Manifestations of underlying systemic disease can aid in the etiologic diagnosis of headache and should always be sought. Recent weight loss may accompany cancer, giant cell arteritis, or depression. Fever or chills may indicate systemic infection or meningitis. Dyspnea or other symptoms of heart disease raise the possibility of subacute infective endocarditis and resultant brain abscess. Visual disturbances suggest an ocular disorder (eg, glaucoma), migraine, or an intracranial process involving the optic nerve or tract or the central visual pathways. Nausea and vomiting are common in migraine and posttraumatic headache syndromes and can be seen in the course of mass lesions. Some patients with migraine also report that diarrhea accompanies the attacks. Photophobia may be prominent in migraine and acute meningitis or subarachnoid hemorrhage. Myalgias often accompany tension headaches, viral syndromes, and giant cell arteritis. Ipsilateral rhinorrhea and lacrimation during attacks typify cluster headache. Transient loss of consciousness may be a concomitant of both migraine and glossopharyngeal neuralgia.
Characteristics of Pain Headache or facial pain is most often described as throbbing; a dull, steady ache; or a jabbing, lancinating pain. Pulsating, throbbing pain is frequently ascribed to migraine, but it is equally common in patients with tension headache. A steady sensation of tightness or pressure is also commonly seen with tension headache. The pain produced by intracranial mass lesions is typically dull and steady. Sharp, lancinating pain suggests a neuritic cause such as trigeminal neuralgia. Ice picklike pain may be described by patients with migraine, cluster headache, or giant cell arteritis. Headache of virtually any description can occur in patients with migraine or brain tumors, however, so that the character of the pain alone does not provide a reliable etiologic guide.
Location of Pain Unilateral headache is an invariable feature of cluster headache and occurs in the majority of migraine attacks; most patients with tension headache report bilateral pain. Ocular or retroocular pain suggests a primary ophthalmologic disorder such as acute iritis or glaucoma, optic (II) nerve disease (eg, optic neuritis), or retroorbital inflammation (eg, Tolosa-Hunt syndrome). It is also common in migraine or cluster headache. Paranasal pain localized to one or several of the sinuses, often associated with tenderness in the overlying periosteum and skin, occurs with acute infection or outlet obstruction of these structures. Headache from intracranial mass lesions may be focal (“it hurts right here”), but even in such cases it is replaced by bioccipital and bifrontal pain when the intracranial pressure becomes elevated. Bandlike or occipital discomfort is commonly associated with tension headaches. Occipital localization can also occur with meningeal irritation from infection or hemorrhage and with disorders of the joints, muscles, or ligaments of the upper cervical spine. Pain within the first division of the trigeminal nerve (Figure 2–1B), characteristically described as burning in quality, is a common feature of postherpetic neuralgia. Lancinating pain localized to the second or third division of the trigeminal nerve (Figure 2–1B) suggests tic douloureux. The pharynx and external auditory meatus are the most frequent sites of pain caused by glossopharyngeal neuralgia.
Other Features of Headache A. TEMPORAL PATTERN OF HEADACHE Headaches from mass lesions are commonly maximal on awakening, as are sinus headaches. Headaches from mass lesions, however, increase in severity over time. Cluster headaches frequently awaken patients from sleep; they often recur at the same time each day or night. Tension headaches can develop whenever stressful situations occur and are often maximal at the end of a workday. Migraine headaches are episodic and may be worse during menses (Figure 2–2). B. CONDITIONS RELIEVING HEADACHE Migraine headaches are frequently relieved by darkness, sleep, vomiting, or pressing on the ipsilateral temporal artery, and their frequency is often diminished during pregnancy. Postlumbar-puncture and low-pressure headaches are typically relieved by recumbency, whereas headaches caused by intracranial mass lesions may be less severe with the patient standing. C. CONDITIONS EXACERBATING HEADACHE Discomfort exacerbated by rapid changes in head position or by events that transiently raise intracranial pressure, such as coughing and sneezing, is often associated with an intracranial mass but can occur in migraine. Anger, excitement, or irritation can precipitate or
HEADACHE & FACIAL PAIN / 73 B. PULSE Tachycardia can occur in a